Platform technology for treatment of antisynthetase syndrome

Abstract

The invention relates to an immunomodulatory substance(s) and / or a skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises a step (A) selected from one or more of: generating an accumulation of PBMCs within the skin, generating a vasodilation of the capillaries within the skin, generating an increased blood volume within the skin, generating an increased sO2 within the skin, generating an increased rHb within the skin, generating an increased temperature on the skin, generating a redness on the skin, administering conditioning energy to the skin, administering a skin-conditioning agent to the skin or administering PBMCs to the skin of the subject; and the method further comprises step (B) administering a first immunomodulatory substance(s) to the skin of the subject and / or step (C) administering a second immunomodulatory substance(s) to the skin of the subject.

Description

[0001]Platform technology for treatment of antisynthetase syndrome The present invention relates to immunomodulatory substance(s) and / or a skin-conditioning agent for use in a method for treating and / or preventing diseases in a subject, such as an antisynthetase syndrome. The invention further relates to pharmaceutical compositions, topical dosage forms, injectable dosage forms and kits of parts comprising an immunomodulatory substance(s) and / or skin-conditioning agent which may be used in the method for treating and / or preventing of the diseases in a subject. Moreover, the present invention relates to medical devices and kits of parts which may be used in the method for treating and / or preventing of the disease in a subject. Antisynthetase syndrome is an orphan disease with an incidence of 1 to 9 per 100,000. The syndrome is an inflammatory disease and autoimmune disease, particularly an idiopathic inflammatory myopathy with the main features of muscle and joint pain, paroxysmal pallor of the fingers, increased callus formation on the hands, interstitial lung disease and autoantibodies in the blood serum against aminoacyl-transfer RNA synthetases (e.g. anti-Jo1 antibodies) and / or rheumatoid-like polyarthritis. Examples of other inflammatory diseases, immunological diseases and / or autoimmune diseases are for instance arthritis or rheumatoid arthritis. Inflammatory diseases, immunological diseases and / or autoimmunological diseases like antisynthease syndrome cause damaging and painful inflammatory reactions with severe impact on life quality are widespread diseases. In particular, a chronic course of such diseases can cause extreme suffering over long periods of time for the concerned subjects and may frequently be life-shortening. The methods and substances known for treatment and prevention of such diseases are still unsatisfactory to a large degree. For example, glucocorticoids are used for the treatment of these diseases, however, besides their beneficial effects in reducing inflammation, they have considerable negative side effects, especially in long-term use. In case of using for instance biologics and biosimilars like monoclonal antibodies the methods are additionally highly expensive, poorly tolerated by many patients, do not work in a significant proportion of patients and often lose their effect after a certain time. On the other hand, immunotherapies may be available which, however, require immense personal und material resources and can only be provided in specialized health care centers. Hence, they are associated with a journey of the patients to the health care centers or are not accessible to them at all. Hence, such therapies are unsuitable for a broad public application, are time-consuming and cannot be sold as an off-the shelf therapy. It is therefore highly desirable to provide alternative agents, articles and methods for the treatment and / or prevention of inflammatory diseases, immunological diseases and / or autoimmunological diseases, which, accordingly, is the object of the present invention. Highly surprisingly, it was found that this object can be solved by use of an immunomodulatory substance(s) in a method where it is brought in close vicinity and / or contact of Langerhans cells (LHs), peripheral regulatory T cells (peripheral Tregs) and / or peripheral blood mononuclear cells (PBMCs) and incubated in vivo in a subject’s body part such as the skin. The present invention is based on entirely new principles found for the treatment and / or prevention of an inflammatory disease, immunological disease and / or autoimmunological disease like antisynthetase syndrome, and has a multitude of advantages for the subject’s treated. Hence, the present invention provides a novel platform technology generally applicable for the treatment of inflammatory, immunological and / or autoimmunological diseases. The following definitions and preferred embodiments relate generally to any of the embodiments as described herein, even if not explicitly mentioned and even if stated under different topics or outline notes, unless described otherwise. The present invention is based on the surprising finding that the creation of a vasodilation (blood vessel dilation, particularly a capillary dilation), increasing the blood volume, increasing the sO2(oxygen saturation of haemoglobin), increasing the rHb (relative haemoglobin amount), increasing the temperature, generating a redness, administering conditioning energy, administering a skin- conditioning agent within / on / to e.g. the skin needs to be combined with the administration of an immunomodulatory substance(s). Thereby, without wishing to be bound to theory, it is believed that the PBMCs accumulate e.g. within the skin and the PBMCs are brought in close vicinity and / or contact with immunomodulatory substance(s) administered. Further without wishing to be bound to theory, it is believed that the LHs residing within the skin are brought in contact with immunomodulatory substance(s) administered. Further without wishing to be bound to theory, it is believed that peripheral Tregs like skin-resident Foxp3, CD25, CD4 regulatory T cells which reside within the skin are brought in contact with immunomodulatory substance(s) administered. The skin can these ways be used as an in-vivo incubator for the PBMC, LHs and / or peripheral Tregs, thereby it is believed to provide affected PBMCs, LHs and / or peripheral Tregs for effecting a modulated immune system activity. The general concept of the present invention relates to a method comprising the steps of: (A-0) generating an accumulation of PBMCs (peripheral blood mononuclear cells) within a body part, preferably the skin of a subject; (A-1) generating a vasodilation of the capillaries within a body part, preferably the skin of a subject; (A-2) generating an increased blood volume within a body part, preferably the skin of a subject; (A-3) generating an increased sO2 (oxygen saturation of haemoglobin) a body part, preferably the skin, and / or an increased rHb (relative haemoglobin amount) within a body part, preferably the skin of a subject; (A-4) generating an increased temperature on a body part, preferably the skin of a subject; (A-5) generating a redness on a body part, preferably the skin of a subject; (A-6) administering conditioning energy to a body part, preferably the skin of a subject; (A-7) administering a skin-conditioning agent to a body part, preferably the skin of a subject; and / or (A-8) administering PBMCs into a body part, preferably the skin of a subject, and further comprising any or both of steps: (B) administering the immunomodulatory substance(s) to this body part of the subject; and / or (C) administering the immunomodulatory substance(s) to this body part of the subject, wherein the immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B). Hence, the present invention relates to an immunomodulatory substance(s) and / or a skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2 within the skin and / or an increased rHb within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises the step(s) of: (B) administering the immunomodulatory substance(s) to the skin of the subject; and / or (C) administering the immunomodulatory substance(s) to the skin of the subject, wherein the immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B), and to said method as such. The present invention also relates to pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and kits of parts according to the independent claims and as mentioned in further detail below. The present invention is very effective in the treatment and / or prevention of an antisynthetase syndrome. The present invention aims, amoungst others, at the control of joint inflammation and hence, the prevention or delay of future joint degeneration caused thereby. Advanced joint degeneration often necessitates joint replacement in the long term, which may be delayed or possibly never be required at all. Furthermore, present invention has no adverse side effects. Thus, the present invention may also contribute to mental and / or physical wellbeing of the treated subjects, may be life-lengthening while at the same time maintaining an improved quality of life. Furthermore, the present invention is easy and quick to perform, for example, because steps (A) and (B) and / or (C) are performed on and / or within the skin. The skin has the advantage to be easily accessible for treatment and administration. Furthermore advantageous is that treatments on the skin, like balms, crèmes or plasters, or into the skin, like injections, are generally of lower health risk for a subject like for instance intravenous injections. The present invention provides a ready to use immunotherapeutic on a prescription basis without the requirement of specialized health care centers. This keeps the costs low by at the same time ensuring a high patient compliance. The subjects or owner of an animal may in several embodiments of the present invention self-apply the method steps, which allows for an on-site application of the therapy for immobile humans or non-transportable or transport-unwilling animals. Therefore, a therapy is provided by the present invention which is also accessible to patients which live remotely out of the reach of health care centers. Further, the present invention may get along without administering subject’s own body extracts like body fluids, blood, cells, tissue, PBMCs, substance(s) etc. (except for the case of administering PBMCs). Such extracts may be swapped or contaminated, e.g. during storage, freezing or body-external incubation for instance during cell-culturing. Conventional immunotherapies frequently use cell- culturing, wherein the cell-culturing is performed body-external. The present invention moves the cell-culturing into the subject’s body where the incubation takes place thereby using the subject’s body, particularly the skin, as an in-vivo incubator. Hence, with the present invention there is no risk of contamination or swapping such extracts or the risk is at least minimized. Further advantageous, the PBMCs, LHs and / or peripheral Tregs remain in their natural habitat under optimal conditions and in an optimal micro-milieu as it may be for instance provided within the skin. Thereby, the PBMCs, LHs and / or peripheral Tregs are not exposed to any stress due to extraction, freezing, fluctuations in temperature, CO2-environmental content, nutrient supply and media composition, all of which can result in altered expression patterns or even death of a part of the cell population. Furthermore, expensive staff and sophisticated equipment necessary for convention cell-culturing are dispensable. Still further advantages are that the therapy can be offered in forms which do not require training of the user or which compensate inadequate training of the user in performing the method. The handling and execution of the method can be designed very simple and straightforward and a correct execution of the method can be ensured. This may be particularly relevant for very young or elderly patients or for users having impaired manual skills as it is for instance frequently the case with rheumatological diseases. Furthermore, fear of self-application errors can be taken away and a lack of treatment adherence can be mitigated or even overcome due to the simple application and uncomplicated availability of the method without a frequent visit to a doctor. The percentage of patients who respond to therapy of the present invention, is very high. The present invention does not provide any adverse side effects or intolerances as known to date. To the contrary, patients even feel stronger and more energetic. Such adverse side effects or intolerances are also not expected even in long-term use. Moreover, a loss of efficacy in long-term use, as is often the case with e.g. biologics, is also not to be expected with the therapeutic approach of the present invention. Hence, the method is highly suitable to find a broad and sustainable public application. Moreover, the therapy according to the present invention is compatible with conventional preparations, pharmaceuticals and drugs, including biologics, biosimilars, glucocorticoids, Disease modifying antirheumatic drugs (DMARDs) like methotrexate (MTX), hydroxychloroquin (HCQ) and heflunomide (LEF) and confers an effect on top and in addition to these preparations. It may even replace or displace these preparations completely, and that, as stated before, without any side effects, intolerances or long-term damages. Without wishing to be bound to theory, it is believed that the effect of the present invention is mainly conferred by regulatory T-cells and / or helper T-cells or a subset thereof which may be presumably generated when applying the method of the present invention. The present invention is believed to be based, whithout whishing to be bound thereto, on the following principles: the skin tissue provides a tight and firm structure. Thereby, it is believed that skin tissue may trap, immobilize, anchor, entangle and / or hold PBMCs that are believed to be accumulated without being flushed away. Furthermore, it is believed that the skin tissue may trap, immobilize, anchor, entangle and / or hold the administered immunomodulatory substance(s) and the immunomodulatory substance(s) may not beflushed away. Thereby a sufficiently long contact of the PBMCs, LHs and / or peripheral Tregs with the immunomodulatory substance(s) is provided while using the subject’s body as an in-vivo incubator leading directly or indirectly to the development of regulatory T-cells and / or helper T-cells or a subset thereof The principles, again without whishing to be bound thereto, are be belived to be in detail as follows: - The blood supply of the sub-topical skin layers and particularly the dermis essentially provided by capillary vessels. In contrast to veins and arteries, capillaries have in their normal state a very narrow cross section. Solely erythrocytes and thrombocytes, which are deprived of a nucleus, are compressible and flexible enough to enter and stream through non-dilated capillaries thereby ensuring the skin’s oxygen supply and skin integrity. PBMCs are nucleated cells, that is, they contain a nucleus. Therefore, it is believed that PBMCs are too bulky to squeeze through non-dilated capillaries. As a consequence, it is believed that PBMCs, particularly naïve lymphocytes like naïve T-cells, are not present or at least not present in effective amounts within the skin capillaries and hence, within the skin. In other words, it is believed that the skin tissue is normally free or essentially free of blood-derived PBMCs and does not contain blood-derived PBMCs in an effective amount. Hence, it is believed that the skin, that is skin as a whole including capillaries and tissue, normally contains only a very limited amount of PBMCs compared to e.g. the vascular system or the lymph nodes. Therefore, in order to generate an accumulation of PBMCs within the skin, particularly within the skin tissue, beside others, PBMCs might be, for instance, injected directly into the skin tissue as for instance in step (A-8). - Another possibility, again whithout whishing to be bound to that therory, which is believed to generate an accumulation of PBMCs within the skin comprises two things. First, the PBMCs must be given access to the capillaries to bring them in the vicinity of the adjacent skin tissue (effected by e.g. any of steps (A-1) to (A-7)). Thereby an accumulation of PBMCs within the skin of the subject is believed to be generated, particularly within the lumen of the capillaries of the skin. Secondly, the PBMCs require to be caused to leave the capillaries, cross the capillary wall and migrate into the adjacent skin tissue. This migration mechanism is known to naturally occur and does not require further action or affectation. In brief, for crossing the vascular endothelial of the capillaries, PBMCs, e.g. lymphocytes, start tethering and rolling to a complete stop inside along the capillary walls and subsequently cross through the capillary wall thereby migrating from the capillary lumen into the adjacent skin tissue. Hence, according to the theory, but again whithout whishing to be bound thereto, apart from administering PBMCs e.g. by injection, also e.g. any of below steps (A-1) to (A-7) may generate an accumulation of PBMCs within the skin, particularly within the lumen of the skin capillaries and finally the skin tissue due to the natural migration of the PBMCs out of the capillaries into the skin tissue. After accumulation, i.e. migration and / or administration into the skin tissue, the PBMCs are, unlike in blood, believed to be trapped and hold by the skin tissue and cannot be flushed away. - Similarly, the immunomodulatory substance(s) administered to the skin (e.g. steps (B) and / or (C)) are not flushed away and diluted by the blood and stay in place, at least for a certain time limited by their diffusion rates. - The trapping and holding of at the same time the immunomodulatory substance(s) and PBMCs allows to incubate the PBMCs, e.g. lymphocytes, more particularly naïve lymphocytes like naïve T-cells, for a time sufficient with the immunomodulatory substance(s). Thereby, the PBMCs are incubated in vivo for (further) affecting the PBMCs, like for instance regulating, inducing, pre-activating, activating, suppressing, maturing, differentiating, modulating and / or proliferating PBMCs. The administered immunomodulatory substance(s) may be capable to effect the desired affectation of the PBMCs. Moreover, within the skin tissue dendritic cells like LHs inherently reside, particularly within the basal part of the epidermis, but they are not present within the blood. It is believed that such dendritic cells, further again without wishing to be bound to theory, are also capable of affecting the PBMCs. Such affectation by dendritic cells may be in addition to, in combination with, in an enhancing manner and / or synergistically with the immunomodulatory substance(s). Hence, beside other, LHs may provide an optimal or advantageous micro-milieu supporting PBMCs affection, however LHs cannot replace or compensate for the administration of immunomodulatory substance(s). After affecting the PBMCs (e.g. the naïve PBMCs), affected PBMCs, particularly regulatory T-cells, which are no longer naïve, naturally leave the skin, enter the blood stream and migrate to their place of action in the subject’s body without any further action or affectation. The place of action may be for instance an inflamed joint in the subject’s body. It is believed that the effect of the present invention is mainly conferred by affected PBMCs, particularly regulatory T-cells and / or helper T-cells or a subset thereof. It may be noted that in addition to affecting the PBMCs, the immunomodulatory substance(s) like e.g. INF-y may, but not necessarily, functions as an attractor creating a micro-milieu which facilitates the naturally occurring process of migration of the PBMCs from the capillary lumen across the capillary wall into the surrounding tissue. Nevertheless, this does not replace the fact that prior to crossing the capillary walls the PBMCs need to be accumulated within the skin capillaries or skin capillary lumen. This requires other means than administering the immunomodulatory substance(s) and can be effected by e.g. any of steps (A-1) to (A-7). As already mentioned above, the skin capillaries are in their non-dilated ground state too narrow for PBMCs to squeeze into and through them. The immunomodulatory substance(s) administered in the present invention do not provide for the presence of PBMCs within the capillaries of the skin. - As already mentioned above, LHs and peripheral Tregs are cells inherently residing within the skin, particularly within the basal part of the epidermis. Without wishing to be bound to theory, it is believed that in the blood of patients suffering from an antisynthetase syndrome like for instance rheumatoid arthritis, low amounts of autoantigens like RA- autoantigen / autoantibody immune complexes are present. It is believed that in case LHs get in contact with such low amounts of autoantigens immune suppression, self-tolerance and the reduction of the immune response is initiated and finally activation of CD4 regulatory T cells (Tregs) can occur in the lymph nodes. Without wishing to be bound to theory, it is believed that these autoantigens are delivered and accumulated within the skin by for instance creating a vasodilation, particularly a capillary dilation whithin the skin, increasing the blood volume, sO2 or rHb whithin the skin, increasing the temperature on the skin, generating a redness on the skin or by administering conditioning energy or administering a skin-conditioning agent to the skin. It is believed that these autoantigens are efficiently cross- presented to the peripheral Tregs (like Foxp3, CD25, CD4 T cells) which may, in antigen specific manner, support development of the immuno-suppressive phenotype of the LHs finally leading to activation of regulatory CD4 suppressor T cells (Tregs) within the lymph nodes. The intrinsic capability of LHs to sense self versus foreign antigens drives in the case of acquisition of autoantigen their differentiation toward the development of immuno-suppressive phenotype. The immunolatory substance(s), like e.g. INF-y or IL-2, particularly in ultra-low dosages, may affect the LHs and / or peripheral Tregs thereby promoting activation and maturation of the immunosuppressive phenotype of the LHs. Again without wishing to be bound to theory, it is in particular believed that via their Fc-receptors LHs internalize the autoantigen / autoantibody-complexes present in low amounts in the patient’s blood and process the autoantigen for surface presentation (MHCII-antigen complex). In case of generating an increased temperature on the skin, it is believed that such warming may have a further effect of causing the LHs to generate heat shock proteins (chaperones) which may stabilize the MHC-autoantigen complex, thereby promoting effective antigen presentation. The resulting LHs which carry the autoantigen as MHCII-autoantigen-complex are believed to move to the lymph nodes and present the autoantigen to CD4 T helper cells. CD4 T helper cells recognize the autoantigen as self and finally activate the already pre-activated LHs carrying autoantigen towards immunosuppression and tolerance for this autoantigen. The final distinction between self versus foreign antigens is believed to be made here. Without wishing to be bound thereto, it is believed that based in that theory immunosuppressive and tolerogenically activated LHs are generated within the lymphe nodes. These immunosuppressive and tolerogenically activated LHs presumably then activate regulatory CD4 suppressor T cells (Tregs) by autoantigen cross presentation within the lymph nodes. As already mentioned above, it is believed that also the PBMCs that are beliefed to be accumulated within skin and brought in contact with the immunomodulatory substance(s) finally lead to the generation of Tregs. Both theories, that is, via the PBMCs or via the LHs and the peripheral Tregs, have in common that finally Tregs may be generated. These Tregs are then believed to spread, whereby the tolerogenic and immunosuppressive effect is expanded and globalized within the subject’s body. The production of pro-inflammatory cytokines is lowered, pro-inflammatory cytotoxic T-cells is counteracted in an immunosuppressive manner, self-tolerance is developed and inflammatory responses, immune responses or autoimmune responses are downregulated. The antisynthetase syndrome is controlled. As a consequence, the treatment is local while the effect is systemic. For the above reasons, the skin is highly suitable to be used as an in-vivo incubator for PBMCs, LHs and / or peripheral Tregs in order to generate helper T-cells, or a subset thereof, and / or regulatory T-cells. The present invention relates to an immunomodulatory substance(s) and / or a skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises, preferably consists of, a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2 within the skin and / or an increased rHb within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises, preferably further consists of, a step (B): (B) administering the immunomodulatory substance(s) to the skin of said subject, or wherein the method comprises, preferably consists of, a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2 within the skin and / or an increased rHb within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises, preferably further consists of, a step (C); (C) administering the immunomodulatory substance(s) to the skin of said subject, or wherein the method comprises, preferably consists of, a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2 within the skin and / or an increased rHb within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises, preferably further consists of, the steps; (B) administering the immunomodulatory substance(s) to the skin of said subject; and (C) administering the immunomodulatory substance(s) to the skin of the subject, wherein the immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B), and to any of said methods as such. In a preferred aspect of all embodiments of the present invention described herein, the present invention relates toimmunomodulatory substance(s) and / or a skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises, preferably consists of, a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2within the skin and / or an increased rHb within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises, preferably further consists of, a step (B): (B) administering the immunomodulatory substance(s) to the skin of said subject, or wherein the method comprises, preferably consists of, a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2 within the skin and / or an increased rHb within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises, preferably further consists of, the steps; (B) administering the immunomodulatory substance(s) to the skin of said subject; and (C) administering the immunomodulatory substance(s) to the skin of the subject, wherein the immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B), and to any of said methods as such. In a more preferred aspect of all embodiments of the present invention described herein, the present invention relates to immunomodulatory substances and / or a skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises, preferably consists of, a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2within the skin and / or an increased rHb within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises, preferably further consists of, the steps; (B) administering the immunomodulatory substance(s) to the skin of said subject; and (C) administering the immunomodulatory substance(s) to the skin of the subject, wherein the immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B), and to any of said methods as such. For the sake of simplicity and clarity, several of the following embodiments refer to step (A) in general. However, if not mentioned otherwise, it is to be understood that any of these embodiments refers independently to any of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8). The immunomodulatory substance(s) administered in step (B) is or may also be denoted as first immunomodulatory substance(s), the immunomodulatory substance(s) administered in step (C) is or may also be denoted as second immunomodulatory substance(s) and the immunomodulatory substance(s) administered in step (B1) (see below) is or may also be denoted as third immunomodulatory substance(s). If not mentioned otherwise, it is to be understood that any embodiment or definition described herein in terms of the immunomodulatory substance(s) is independently and mutatis mutandis applicable to the first immunomodulatory substance(s), the second immunomodulatory substance(s) and the third immunomodulatory substance(s) in any of the embodiments described herein, particular to any of the embodiments of the medical device described herein. It is to be understood that the expressions “first”, ”second” and “third” as mentioned in any of the embodiments described herein in respect of the immunomodulatory substance(s) do not intent or suggest any order, hierarchy or prioritization of any of the first immunomodulatory substance(s), the second immunomodulatory substance(s) and the third immunomodulatory substance(s) (also denoted as immunomodulatory substance(s)). These expressions only serve to unambiguously assign, designate and refer to the corresponding immunomodulatory substance(s). Similarly, it is to be understood that in any of the embodiments described herein the immunomodulatory substance(s) of step (B), step (C) and step (B1) may also be regarded as “first immunomodulatory substance(s)” (step (B)), ”second immunomodulatory substance(s)” step (C) and “third immunomodulatory substance(s)” step (B1) as mentioned in any of the embodiments described herein. It is to be understood that the “immunomodulatory substance(s) for use in a method for treating and / or preventing an antisynthetase syndrome in a subject” as mentioned in any of the embodiments described herein is the immunolatory substance(s) of step (B), step (B1) and step (C), respectively, depending on what is applicable. It is further to be understood in any of the embodiments described herein that in case the immunomodulatory substance(s) of step (B) is a “first immunomodulatory substance(s)”, the immunomodulatory substance(s) of step (C) is a “second immunomodulatory substance(s)” and / or the immunomodulatory substance(s) of step (B1) is a “third immunomodulatory substance(s)”, the “immunomodulatory substance(s) for use in a method for treating and / or preventing an antisynthetase syndrome in a subject” as mentioned in any of the embodiments described herein is a first immunomodulatory substance(s), a second immunomodulatory substance(s) and a third immunomodulatory substance(s), respectively, for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, depending on what is applicable. The inflammatory disease, immunological disease and / or autoimmunological disease, particularly the antisynthetase syndrome that may be treated and / or prevented in any of the embodiments described herein requires for treating and / or preventing a modulation of the subject’s immune system, wherein the modulation of the immune system may be a downregulation of the immune system. The downregulation may be for instance an anti-inflammatory regulation and / or a less aggressive regulation in recognizing antigen, autoantigen or antigen presenting cells, thereby providing e.g. a reduction in inflammatory activity and swelling. It is preferred that the inflammatory disease, immunological disease and / or autoimmunological disease particularly the antisynthetase syndrome that may be treated and / or prevented as mentioned in any of the embodiments described herein: - requires for treating and / or preventing a downregulation of the immune system, more preferably of the subject’s immune system; and / or - is characterized by a symptomatic caused by a too aggressive and / or hyperactive immunoreaction of the subject’s body; and / or - involves an overrepresentation and / or hyperactivity of cytotoxic T-cells; and / or - has an immunological background and / or an autoimmunological background. More preferably, the inflammatory disease, immunological disease and / or autoimmunological disease to be treated and / or prevented is an immunological disease, autoimmunological disease and / or an organ rejection reaction after organ transplantation, even more preferably an immunological disease and / or autoimmunological disease. It may be pointed out that an inflammatory disease may have an immunological background or an autoimmunological background, while an immunological disease or autoimmunological disease must not necessarily be associated with an inflammation; and / or - is associated with an inflammation. If not mentioned otherweise, the inflammatory disease, immunological disease and / or autoimmunological disease in any of the embodiments described herein is an antisynthtease syndrome. Examples of other inflammatory diseases, immunological diseases and / or autoimmune diseases include for instance arthritis or rheumatoid arthritis. More preferably, the antisynthetase syndrome is in accordance with code M35.8 of the standard ICD-10-GM 2021. The expression “standard ICD-10-GM 2021” as mentioned in any of the embodiments described herein refers to the “ICD-10-GM 2021 Systematisches Verzeichnis: Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 10. Revision - German Modification”, Deutscher Ärzteverlag, ISBN-13: 978-3-7691-3722-4. The antisynthetase syndrome to be treated and / or prevented and any of the preferred embodiments thereof may be, preferably, are defined and / or determined by any method(s) and / or parameter(s) commonly used in the art and known to the person skilled in the art. Preferably, the definition and / or determination is in accordance with the standard ICD-10-GM 2021, preferably in accordance with the code M35.8 of the standard ICD-10-GM 2021. The subject as mentioned in any of the embodiments described herein may be, preferably, is any subject in need of the treatment and / or prevention. The subject may be, preferably, is as mentioned in any of the embodiments described herein any subject having an immune system capable of rising an adaptive immune response, preferably, capable of rising a T-cell immune response. Preferably, the subject is a vertebrate, more preferably a mammal, even more preferably any of the genus and / or species human or a mammal animal which is selected from cow, buffalo, horse, donkey, elephant, sheep, goat, pig, rabbit, mouse, rat, camel, dromedary, lama, alpaca, dog and / or cat. Still more preferably the subject is a human. The subject may be, preferably, is as mentioned in any of the embodiments described herein a newborn, suckling, infant, child, adolescent and / or adult of the subject, preferably a suckling, infant, child, adolescent and / or adult, still more preferably an infant, child, adolescent or adult, still more preferably a child, adolescent and / or adult, still even more preferably an adolescent and / or adult and further preferably an adult. In case the subject is a human, a newborn is until 28thday of life, a suckling from the beginning of the 29thday of life until the end of the 12thmonth of life, an infant from the beginning of the 13thmonth to the completed 3rdyear of life, a child from the beginning of the 4thyear to the completed 12thyear of life, an adolescent from the beginning of the 13thyear to the completed 18thyear of life and an adult from the beginning of the 19thyear of life. Preferably, the subject is a subject being diagnosed with the antisynthetase syndrome and / or a subject for which it is indicative to be at risk to develop the antisynthetase syndrome. Usually, in a subject being diagnosed with the antisynthetase syndrome, the symptoms of the antisynthetase syndrome are already apparent and the subject suffers from the symptoms of the antisynthetase syndrome. In other words, the antisynthetase syndrome has already been broken out in the subject. Usually, in a subject for which it is indicative to be at risk to develop the antisynthetase syndrome, the symptoms of the antisynthetase syndrome are not yet apparent and the subject does not suffer from the symptoms of the antisynthetase syndrome. In other words, the antisynthetase syndrome has not yet been broken out in the subject. To be at risk is to be understood in the sense that the subject will develop and / or will develop with a high chance the antisynthetase syndrome. This may for instance be the case for subjects carrying a HLA-B*27 allel, which may be indicative to be at risk to develop, for instance, Morbus Bechterew, rheumatoid arthritis, Morbus Crohn, reactive arthritis or juvenile arthritis or in case in the subject’s family history for instance rheumatoid arthritis has frequently occured. The diagnosis of the subject being diagnosed with the inflammatory disease, immunological disease and / or autoimmunological disease, particulalrly the antisynthetase syndrome as mentioned in any of the embodiments described herein may be, preferably, is established by any method(s) and / or parameter(s) commonly used in the art and known to the person skilled in the art. Preferably, the diagnosis established in accordance with the standard ICD-10-GM 2021, preferably in accordance with the code of the standard ICD-10-GM 2021 indicated as preferred for the embodiment of the inflammatory disease, immunological disease and / or autoimmunological disease and the preferred embodiments thereof. More preferably, the diagnosis of the subject being diagnosed with antisynthetase syndrome is established in accordance with the standard ICD-10-GM 2021, preferably M35.-, more preferably in accordance with code M35.8 of the standard ICD-10-GM 2021. The indication of the subject for which it is indicative to be at risk to develop the antisynthetase syndrome as mentioned in any of the embodiments described herein may be, preferably, is established by any method(s) and / or parameter(s) commonly used in the art and known to the person skilled in the art. More preferably, the indication is established in accordance with the ICD-10-GM 2021. The indication of the subject for which it is indicative to be at risk to develop the antisynthetase syndrome may be, preferably, is established by any method(s) and / or parameter(s) commonly used in the art and known to the person skilled in the art, for instance family history and / or genetic association like HLA-B*27 in case of Bechterew’s disease, rheumatoid arthritis, Morbus Crohn, reactive arthritis or juvenile arthritis. Preferably, the subject for which it is indicative to be at risk to develop the antisynthetase syndrome, is a subject for which it is indicative to develop the antisynthetase syndrome. Preferably, the expression “treating” as mentioned in any of the embodiments described herein refers to a subject being diagnosed with the antisynthetase syndrome and the subject’s condition is improved e.g. pain and / or inflammation are relieved or disappear; organ, tissue and / or joint destruction is prevented; blood parameters are improved or normalized; further progress of organ, tissue and / or joint destruction is slowed down, stopped and / or regeneration has occurred; organ, tissue and / or joint functional ability is preserved or improved; swelling of joints and / or pressure sensitivity is reduced; the subject’s normal lifestyle maintained; and / or the subject’s quality of life and / or mental and / or physical wellbeing are maintained or improved. Preferably, the expression “preventing” as mentioned in any of the embodiments described herein refers to a subject being diagnosed to be at risk to develop the antisynthetase syndrome and the subject’s healthy condition is maintained and the onset of the symptoms of the antisynthetase syndrome in the subject is prevented and / or delayed; organ, tissue and / or joint destruction is prevented; organ, tissue and / or joint functional ability is preserved; the subject’s normal lifestyle is maintained; and / or the subject’s quality of life and / or mental and / or physical wellbeing are maintained or improved. The expression “PBMCs” (“peripheral blood mononuclear cells”) as used in any of the embodiments described herein typically refers to a sub-population of cells of the cellular blood components, particularly of the leucocytes. Preferably, leucocytes comprise, more preferably consist of as cellular components, lymphocytes and monocytes. Preferably, PBMCs comprise, preferably consist of as cellular components, lymphocytes and monocytes, whereas erythrocytes and platelets (which do not possess a nucleus) and granulocytes (which possess multi-lobed nuclei) are not present in effective amounts, essentially absent or absent, more preferably absent. More preferably, the PBMCs as mentioned in any of the embodiments described herein are lymphocytes, such as natural killer cells, B-cells and / or T-cells, more preferably B-cells and / or T-cells, even more preferably are naïve PBMCs, still more preferably naïve lymphocytes, still even more preferably naïve B-cells and / or naïve T-cells, and still even more preferably are naïve T-cells. Preferably, the PBMCs as mentioned in any of the embodiments described herein are blood-derived PBMCs. This applies equally to PBMCs, which are administered e.g. injected (as it may be the case in step (A-8)), as well as to any accumulated PBMCs or PBMCs that may be accumulated. Hence, the expression “PBMCs” preferably does not refer to PBMCs inherently reside within tissues, preferably within the skin. Hence, PBMCs inherently residing within the skin, particularly the skin tissue, are preferably not encompassed in the accumulated PBMCs, in the accumulation of PBMCs or the PBMCs to be accumulated. PBMCs may be extracted from the blood, preferably whole blood, and may then be present in an isolated, preferably purified, form, in the following termed “isolated PBMCs”, or they may be present as a sub-population of cells of the cellular blood components within the blood, preferably whole blood, in the following termed “blood PBMCs”. In isolated PBMCs, blood components and cellular blood components other than PBMCs are preferably not present in effective amounts, essentially absent or absent, more preferably absent. Isolated PBMCs may be obtained by any method known to the person skilled in the art, preferably by ficoll-extraction in combination with gradient centrifugation or by apheresis, more preferably by apheresis, using whole blood, preferably as described in the Materials and Methods’ section ‘Preparation of PBMCs’. The expression “lymphocytes” as mentioned in any of the embodiments described herein typically refers to a sub-population of cells of the PBMCs. Lymphocytes again may comprise sub-populations of cells, including B-cells, T-cells and / or natural killer cells. Preferably lymphocytes may comprise, preferably consist of as cellular components, B-cells including naïve and affected B-cells, like mature B-cells; natural killer cells; and / or T-cells including naïve and affected T-cells, like mature T-cells. More preferably, lymphocytes as mentioned in any of the embodiments described herein comprise, more preferably consist of as cellular components, naïve lymphocytes, affected lymphocytes and / or natural killer cells, even more preferably naïve lymphocytes, still even more preferably naïve B-cells and / or naïve T-cell, further preferably naïve T-cells. Preferably, as mentioned in any of the embodiments described herein, the lymphocytes are naïve lymphocytes, more preferably comprising, even more preferably consisting of as cellular components, naïve B-cells and / or naïve T-cells. Still even more preferably, the lymphocytes are naïve T-cells. The expression “naïve” or “naïve cells” as mentioned in any of the embodiments described herein in respect to any type of cells like naïve PBMCs, naïve lymphocytes, naïve B-cells and / or naïve T-cells, typically have not been exposed to their corresponding antigen. Preferably, such naïve cells are not activated and / or they have a potential to be affected by the immunomodulatory substance(s) and possibly dendritic cells, more preferably both. Upon affectation, naïve cells become affected cells. Even more preferably, naïve cells are not activated, have a potential to be affected and have not been exposed to their corresponding antigen. Typically, the expression “naïve” does not exclude that the naïve cells have already gained a certain degree of regulation, induction, pre-activation, activation, suppression, maturation, differentiation, modulation, proliferation, migration, survival, changed gene expression, preferably as long as such cells still have a potential to be affected by the immunomodulatory substance(s) and possibly dendritic cells, by at least one member of the list of possible affectations, like attraction, migration, survival, changed gene expression, cell-cell interaction, regulation, induction, suppression, maturation, differentiation, modulation and / or proliferation. The expression “the potential to be affected” as mentioned in any of the embodiments described herein in respect to any type of cells like LHs, peripheral Tregs, naïve PBMCs, naïve lymphocytes, naïve B-cells and / or naïve T-cells typically means that such LHs, peripheral Tregs or naïve cells are upon affectation caused by the immunomodulatory substance(s) attracted, regulated, induced, pre- activated, activated, suppressed, matured, differentiated, modulated,proliferated, migrate, survive, have changed gene expression, process antigen and / or undergo cell-cell interaction, more preferably attracted, matured, pre-activated, activated, differentiated, proliferated, migrate, survive, have changed gene expression, process antigen and / or undergo cell-cell interaction. The expression “affected” or “affected cells” as mentioned in any of the embodiments described herein in respect to any type of cells like affected LHs, affected peripheral Tregs or affected PBMCs, affected lymphocytes, affected B-cells and / or affected T-cells typically means that such affected cells have, due to the affectation caused by the immunomodulatory substance(s) undergone attraction, migration, survival, changed gene expression, processing of antigen, cell-cell interaction, regulation, induction, pre-activation, activation, suppression, maturation, differentiation, modulation and / or proliferation, more preferably undergone attraction, migration, survival, changed gene expression, processing of antigen, cell-cell interaction, maturation, pre-activation, activation, differentiation and / or proliferation, even more preferably undergone migration, survival, changed gene expression, processing of antigen, cell-cell interaction, maturation, pre-activation, activation, differentiation and / or proliferation. Preferably, “affected” excludes that such affected cells have undergone activation due to the affectation caused by the immunomodulatory substance(s) and possibly dendritic cells, i.e. such affected cells do not provide an increased aggression against antigen, autoantigen and / or antigen presenting cells. The expression “attract”, “attracting”, “attracted” and / or “attraction” as mentioned in any of the embodiments described herein in respect to any type of cells like LHs, peripheral Tregs, PBMCs, lymphocytes, B-cells and / or T-cells, particularly naïve PBMCs, naïve lymphocytes, naïve B-cells and / or naïve T-cells typically means that such cells are caused to directionally migrate towards an attractor. Such attractor may be, but is not necessarily, e.g. the immunomodulatory substance(s). The expression for instance means that e.g. PBMCs may be caused to leave the lumen of the skin capillaries by crossing the vascular endothelial and enter into the surrounding skin tissue towards the site where the immunomodulatory substance(s) is present. As already stated in further detail above, this migration mechanism is known to naturally occur and does not require further action or affectation. Nevertheless, such an attractor may facilitate or contribute to such migration by providing a beneficial micro milieu. Therefore, the affectation may, but not necessarily, be amongst others an attraction. This could be advantageous in case of e.g. steps (A-0) to (A-7), where the accumulation of PBMCs is believed to be generated particularly within the lumen of the capillaries of the skin. The crossing of the PBMCs of the capillary wall then relies on the naturally occurring process and is believed to lead to an accumulation within the skin, particularly within the skin tissue. Contrary, in case of e.g. step (A-8), the PBMCs may be administered by injection and the accumulation of PBMCs is directly generated within the skin, particularly within the skin tissue. A migration into the skin tissue is then not required. In any case, such accumulated PBMCs are believed to be trapped and hold within the skin. The LHs and peripheral Tregs already reside within the skin. Furthermore, the immunomodulatory substance(s) administered are also believed to be trapped and hold within the skin. Thereby an in-vivo incubation of the LHs, peripheral Tregs and / or PBMCs with the immunomodulatory substance(s) is provided so that the LHs, peripheral Tregs and / or PBMCs may become affected LHs, affected peripheral Tregs and / or affected PBMCs. These affected LHs, affected peripheral Tregs and / or affected PBMCsare preferably attracted, regulated, induced, pre-activated, activated, suppressed, matured, differentiated, modulated, proliferated and / or migrate, survive, have changed gene expression, process antigen and / or undergo cell-cell interaction. The expressions “proliferate”, “proliferating”, “proliferated” and / or “proliferation” as mentioned in any of the embodiments described herein in respect to any type of cells typically means that the amounts of such cells, relative to the amounts of such cells prior to affectation caused by the immunomodulatory substance(s), increase / are increased or decrease / are decreased, preferably increase / are increased (it may be noted that in dependency of the type of cell, a certain amount of such cells may already be present prior to affectation due to immune processes naturally occurring in the subject’s body). For instance, in case regulatory T-cells and / or helper T-cells, or a subset thereof, are proliferated, this means that the amounts of such cells are increased relative to the amounts prior to affectation, preferably within the blood of the subject (it may be noted that a certain amount of such cells may already be present prior to affectation due to immune processes naturally occurring in the subject’s body). The expressions “differentiate”, “differentiating”, “differentiated” and / or “differentiation” as mentioned in any of the embodiments described herein in respect to any type of cells typically means that such cells may already be differentiated to a certain degree and they do have the potential to further differentiate and / or mature. The expressions “mature”, “maturing”, “matured” and / or “maturation” as mentioned in any of the embodiments described herein in respect to any type of cells typically means that such cells do not have the potential to further differentiate and / or mature. Differentiated cells may for instance be helper T-cells, or subsets thereof, having the potential to mature to for instance regulatory T-cells. Mature cells may for instance be regulatory T-cells which have no longer the potential for a further differentiation and / or maturation. The expression “affected LHs” as mentioned in any of the embodiments described herein typically refers to LHs that have, without wishing to be bound to theory, due to the affectation caused by the immunomodulatory substance(s), undergone attraction, migration, survival, changed gene expression, processing of antigen, cell-cell interaction, regulation, induction, pre-activation, activation, maturation, differentiation, modulation and / or proliferation, more preferably undergone migration, changed gene expression, processing of antigen, cell-cell interaction, regulation, induction, pre-activation, activation, maturation, differentiation and / or modulation. The expression “affected peripheral Tregs” as mentioned in any of the embodiments described herein typically refers to peripheral Tregs that have, without wishing to be bound to theory, due to the affectation caused by the immunomodulatory substance(s), undergone attraction, migration, survival, changed gene expression, processing of antigen, cell-cell interaction, regulation, induction, pre- activation, activation, maturation, differentiation, modulation and / or proliferation, more preferably undergone attraction, migration, survival, changed gene expression, cell-cell interaction, regulation, induction, modulation and / or proliferation. The expression “naïve PBMCs” as mentioned in any of the embodiments described herein typically refers to PBMCs that have differentiated, at least to a certain degree. Preferably, naïve PBMCs as mentioned in any of the embodiments described herein have not been exposed to their corresponding antigen. Preferably, naïve PBMCs are not activated and / or they have a potential to be affected by the immunomodulatory substance(s) and possibly dendritic cells, more preferably both. Upon affectation naïve PBMCs become affected PBMCs. Even more preferably, naïve PBMCs are not activated, have a potential to be affected and have not been exposed to their corresponding antigen. Preferably, all PBMCs, more preferably all lymphocytes, that leave the pivotal (central) lymphoid organs like the thymus or bone marrow are considered naïve PBMCs. More preferably, those leaving the bone marrow are naïve B-lymphocytes, also called naïve B-cells, and / or those leaving the thymus are naïve T-lymphocytes, also called naïve T-cells. Naïve PBMCs as mentioned in any of the embodiments described herein more preferably comprise, even more preferably consist of as cellular components, naïve lymphocytes, even more preferably naïve T-cells and / or naïve B-cell, still more preferably naïve T-cells. The expression “affected PBMCs” as mentioned in any of the embodiments described herein typically refers to naïve PBMCs upon affectation caused by the immunomodulatory substance(s) and possibly dendritic cells. Without wishing to be bound to theory, it is believed that affected PBMCs preferably comprise, more preferably consist of as cellular components, affected lymphocytes, even more preferably affected B-cells and / or affected T-cells, still more preferably affected T-cells, regulatory B-cells, helper T-cells or a subset thereof, and / or regulatory T-cells; even more preferably regulatory B-cells, helper T-cells or a subset thereof, and / or regulatory T-cells; still more preferably helper T-cells, or a subset thereof, and / or regulatory T-cells. Further, without wishing to be bound to theory, preferably, affected PBMCs have, due to the affectation caused by the immunomodulatory substance(s) and possibly dendritic cells, undergone attraction, migration, survival, changed gene expression, cell-cell interaction, regulation, induction, suppression, maturation, differentiation, modulation and / or proliferation, more preferably undergone attraction, migration, survival, changed gene expression, cell-cell interaction, maturation, differentiation, and / or proliferation, even more preferably undergone maturation, differentiation, and / or proliferation. Preferably, the expression “affected PBMCs” excludes that affected PBMCs have undergone activation due to the affectation caused by the immunomodulatory substance(s) and possibly dendritic cells. Hence, preferably, affected PBMCs do not provide an increased aggression against antigen, autoantigen and / or antigen presenting cells. The expression “naïve lymphocytes” as mentioned in any of the embodiments described herein typically refers to lymphocytes that have differentiated, at least to a certain degree. Preferably, naïve lymphocytes as mentioned in any of the embodiments described herein have not been exposed to their corresponding antigen. Preferably, naïve lymphocytes are not activated and / or they have a potential to be affected by the immunomodulatory substance(s) and possibly dendritic cells, more preferably both. Upon affectation naïve lymphocytes become affected lymphocytes. Even more preferably, naïve lymphocytes are not activated, have a potential to be affected and have not been exposed to their corresponding antigen. Preferably, all lymphocytes that leave the pivotal (central) lymphoid organs like the thymus or bone marrow are considered naïve lymphocytes. More preferably, those leaving the bone marrow are naïve B-lymphocytes, also called naïve B-cells, and / or those leaving the thymus are naïve T-lymphocytes, also called naïve T-cells. Naïve lymphocytes as mentioned in any of the embodiments described herein more preferably comprise, even more preferably consist of as cellular components, naïve T-cells and / or naïve B-cell, still more preferably naïve T-cells. The expression “affected lymphocytes” as mentioned in any of the embodiments described herein typically refers to naïve lymphocytes upon affectation caused by the immunomodulatory substance(s) and possibly dendritic cells. Without wishing to be bound to theory, it is believed that affected lymphocytes, preferably comprise, more preferably consist of as cellular components, memory B-cells, plasma cells, regulatory B-cells, helper T-cells or a subset thereof, and / or regulatory T-cells; more preferably regulatory B-cells, helper T-cells or a subset thereof, and / or regulatory T-cells; even more preferably helper T-cells or a subset thereof, and / or regulatory T-cells. Further, without wishing to be bound to theory, preferably, affected lymphocytes have, due to the affectation caused by the immunomodulatory substance(s) and possibly dendritic cells, undergone attraction, migration, survival, changed gene expression, cell-cell interaction, regulation, induction, suppression, maturation, differentiation, modulation and / or proliferation, more preferably undergone attraction, migration, survival, changed gene expression, cell-cell interaction, maturation, differentiation, and / or proliferation, even more preferably undergone maturation, differentiation, and / or proliferation. Preferably, the expression “affected lymphocytes” excludes that affected lymphocytes have undergone activation due to the affectation caused by the immunomodulatory substance(s) and possibly dendritic cells. Hence, preferably, affected lymphocytes do not provide an increased aggression against antigen, autoantigen and / or antigen presenting cells. The expression “naïve T-cells” as mentioned in any of the embodiments described herein typically refers to T-cells that have differentiated, preferably at least to a certain degree, in the thymus, and successfully undergone the positive and negative processes of central selection in the thymus. Furthermore, they may have or have been released by the thymus. Preferably, naïve T-cells as mentioned in any of the embodiments described herein have not been exposed to their corresponding antigen. Preferably, naïve T-cells are not activated and / or they have a potential to be affected by the immunomodulatory substance(s) and possibly dendritic cells, more preferably both. Upon affectation, naïve T-cells become affected T-cells. Even more preferably, naïve T-cells are not activated, have a potential to be affected and have not been exposed to their corresponding antigen. The expression “affected T-cells” as mentioned in any of the embodiments described herein typically refers to naïve T-cells upon affectation caused by the immunomodulatory substance(s) and possibly dendritic cells. Without wishing to be bound to theory, it is believed that affected T-cells preferably comprise, more preferably consist of as cellular components, helper T-cells and / or regulatory T-cells, more preferably helper T-cells and / or regulatory T-cells. Further, without wishing to be bound to theory, preferably, affected T-cells have, due to the affectation caused by the immunomodulatory substance(s) and possibly dendritic cells, undergone attraction, migration, survival, changed gene expression, cell-cell interaction, regulation, induction, suppression, maturation, differentiation, modulation and / or proliferation, more preferably undergone attraction, migration, survival, changed gene expression, cell-cell interaction, maturation, differentiation, and / or proliferation, even more preferably undergone maturation, differentiation, and / or proliferation. Preferably, the expression “affected T-cells” excludes that affected T-cells have undergone activation, particularly not due to the affectation caused by the immunomodulatory substance(s) and possibly dendritic cells. Hence, preferably, affected T-cells do not provide an increased aggression against antigen, autoantigen and / or antigen presenting cells. It may be pointed out that according to the above definitions of naïve T-cells and affected T-cells, the helper T-cells can be considered as naïve T-cells and / or as affected T-cell. The expression “naïve B-cells” as mentioned in any of the embodiments described herein typically refers to B-cells that have differentiated, at least to a certain degree, in the bone marrow. Preferably, naïve B-cells as mentioned in any of the embodiments described herein have not been exposed to their corresponding antigen. Preferably, naïve B-cells are not activated and / or they have a potential to be affected by the immunomodulatory substance(s) and possibly dendritic cells, more preferably both. Upon affectation, naïve B-cells become affected B-cells. Even more preferably, naïve B-cells are not activated, have a potential to be affected and have not been exposed to their corresponding antigen. The expression “affected B-cells” as mentioned in any of the embodiments described herein typically refers to naïve B-cells upon affectation caused by the immunomodulatory substance(s) and possibly dendritic cells. Without wishing to be bound to theory, it is believed that affected B-cells preferably comprise, more preferably consist of as cellular components, memory B-cells, plasma cells and / or regulatory B-cells, even more preferably regulatory B-cells. Preferably, affected B-cells have, due to the affectation caused by the immunomodulatory substance(s) and possibly dendritic cells, undergone attraction, migration, survival, changed gene expression, cell-cell interaction, regulation, induction, suppression, maturation, differentiation, modulation and / or proliferation, more preferably undergone attraction, migration, survival, changed gene expression, cell-cell interaction, maturation, differentiation, and / or proliferation, even more preferably undergone maturation, differentiation, and / or proliferation. Preferably, the expression “affected B-cells” excludes that affected B-cells have undergone activation due to the affectation caused by the immunomodulatory substance(s) and possibly dendritic cells. Hence, preferably, affected B-cells do not provide an increased aggression against antigen, autoantigen and / or antigen presenting cells. If not mentioned otherwise, the definitions of LHs, peripheral Tregs, affected LHs, affected peripheral Tregs, PBMCs, naïve PBMCs, affected PBMCs, lymphocytes, naïve lymphocytes, affected lymphocytes, T-cells, naïve T-cells, affected T-cells, helper T-cells or a subset thereof, B-cells, naïve B-cells, affected B-cells and the preferred embodiments thereof apply generally to any of the embodiments as described herein in which PBMCs, naïve PBMCs, affected PBMCs, lymphocytes, naïve lymphocytes, affected lymphocytes, T-cells, naïve T-cells, affected T-cells, helper T-cells or a subset thereof, B-cells, naïve B-cells and / or affected B-cells are mentioned. If not mentioned otherwise, it is to be understood that any embodiment or definition of the immunomodulatory substance(s) as described herein is independently and mutatis mutandis applicable to the immunomodulatory substance(s) as mentioned in any of the embodiments described herein, particularly the immunomodulatory substance(s) for use according to the present invention, the immunomodulatory substance(s) of steps (B), (B1) and / or step (C), the pharmaceutical composition, injectable dosage form, topical dosage forms, medical devices and / or kits of parts. The expression “immunomodulatory substance” or “immunomodulatory substance(s)” as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be, preferably is, any type of substance(s) capable of affecting and / or which affect(s), preferably directly and / or indirectly, the LHs, peripheral Tregs and / or PBMCs. The expression “to affect” or “affecting” as mentioned in any of the embodiments described herein in respect to the immunomodulatory substance(s) and in any of the preferred embodiments thereof typically means that the immunomodulatory substance(s) attracts, regulates, induces, pre-activates, activates, suppresses, matures, differentiates, modulates, proliferates, promotes migration, survival, changed gene expression, processing of antigen, cell-cell interaction LHs, peripheral Tregs and / or PBMCs. Preferably, the immunomodulatory substance(s) regulates, induces, pre-activates, activates, matures, differentiates, modulates, proliferates, causes migration, survival, changed gene expression, processing of antigen and / or cell-cell interaction, more preferably regulates, induces, pre-activates, activates, matures, differentiates, modulates, promotes migration, changed gene expression, processing of antigen and / or cell-cell interaction the LHs. Preferably the immunomodulatory substance(s) attracts, regulates, induces, pre-activates, activates, matures, differentiates, modulates, proliferates, migrates, causes survival, changed gene expression, cell-cell interaction, more preferably attracts, regulates, induces, modulates, proliferates, promotes migration, survival, changed gene expression and / or cell-cell interaction the peripheral Tregs. Preferably, the immunomodulatory substance(s) attracts, matures, differentiates and / or proliferates PBMCs, even more preferably matures, differentiates and / or proliferates PBMCs. In other words the immunomodulatory substance(s) may attracts, regulates, induces, modulates and / or suppresses the PBMCs and / or causes the PBMCs to mature, differentiate and / or to proliferate. Preferably, “to affect” or “affecting” in respect of PBMCs excludes that the immunomodulatory substance(s) activates PBMCs. Hence, preferably, upon affectation, affected PBMCs do not provide an increased aggression against antigen, autoantigen and / or antigen presenting cells. More preferably, the PBMCs are naïve PBMCs, even more preferably lymphocytes, still more preferably T-cells and / or B-cells, still even more preferably naïve lymphocytes, further preferably naïve B-cells and / or naïve T-cells, further preferably naïve T-cells. The expression “capable of affecting” as mentioned in any of the embodiments described herein in respect to the immunomodulatory substance(s) and in any of the preferred embodiments thereof typically means that the immunomodulatory substance(s) is capable of attracting, regulating, inducing, pre-activating, activating, suppressing, maturing, differentiating, modulating, proliferating, promoting migration, survival, changed gene expression, processing of antigen and / or cell-cell interaction of LHs, peripheral Tregs and / or PBMCs. Hence, the immunomodulatory substance(s) may be capable of affecting and / or affects the LHs, peripheral Tregs and / or PBMCs by attracting, regulating, inducing, pre-activating, activating, suppressing, maturing, differentiating, modulating, proliferating, promoting migration, survival, changed gene expression, processing of antigen and / or cell-cell interaction. Preferably the immunomodulatory substance(s) is capable of regulating, inducing, pre-activating, activates, maturing, differentiating, modulating, proliferating, causing migration, survival, changed gene expression, processing of antigen and / or cell-cell interaction, more preferably regulating, inducing, pre-activating, activating, maturing, differentiating, modulating, promoting migration, changed gene expression, processing of antigen and / or cell-cell interaction the LHs. Hence, in other words the immunomodulatory substance(s) may more preferably be capable of affecting and / or affects the LHs by regulating, inducing, pre-activating, activates, maturing, differentiating, modulating, proliferating, causing migration, survival, changed gene expression, processing of antigen and / or cell-cell interaction, more preferably regulating, inducing, pre-activating, activating, maturing, differentiating, modulating, promoting migration, changed gene expression, processing of antigen and / or cell-cell interaction. Preferably the immunomodulatory substance(s) is capable of attracting, regulating, inducing, pre-activating, activating, maturing, differentiating, modulating, proliferating, migrating, causing survival, changed gene expression, cell-cell interaction, more preferably attracts, regulating, inducing, modulating, proliferating, promoting migration, survival, changed gene expression and / or cell-cell interaction the peripheral Tregs. Hence, in other words the immunomodulatory substance(s) may more preferably be capable of affecting and / or affects the peripheral Tregs attracting, regulating, inducing, pre-activating, activating, maturing, differentiating, modulating, proliferating, migrating, causing survival, changed gene expression, cell-cell interaction, more preferably attracts, regulating, inducing, modulating, proliferating, promoting migration, survival, changed gene expression and / or cell-cell interaction. Preferably the immunomodulatory substance(s) is capable of attracting, maturing, differentiating and / or proliferating PBMCs, even more preferably maturing, differentiating and / or proliferating PBMCs. Preferably, “capable of affecting” in respect of PBMCs excludes that the immunomodulatory substance(s) is capable of activating PBMCs. Hence, preferably, upon a potential affectation, affected PBMCs do not provide an increased aggression against antigen, autoantigen and / or antigen presenting cells. More preferably, the PBMCs are naïve PBMCs, even more preferably lymphocytes, still more preferably T-cells and / or B-cells, still even more preferably naïve lymphocytes, further preferably naïve B-cells and / or naïve T-cells, further preferably naïve T-cells. Hence, more preferably, the immunomodulatory substance(s) is capable of affecting and / or affects the LHs, peripheral Tregs or PBMCs by attracting, proliferating, differentiating and / or maturing, even more preferably by proliferating, differentiating and / or maturing, even more preferably differentiating and / or maturing. Hence, more preferably, the immunomodulatory substance(s) is capable of attracting, proliferating, differentiating and / or maturing the PBMCs and / or attracts, proliferates, differentiates and / or matures the PBMCs. Even more preferably, the immunomodulatory substance(s) is capable of proliferating, differentiating and / or maturing the PBMCs and / or proliferates, differentiates and / or matures the PBMCs. Still even more preferably, the immunomodulatory substance(s) is capable of differentiating and / or maturing the PBMCs and / or differentiates and / or matures the PBMCs. More preferably, the PBMCs are naïve PBMCs, even more preferably lymphocytes, still more preferably T-cells and / or B-cells, still even more preferably naïve lymphocytes, further preferably naïve B-cells and / or naïve T-cells, even further preferably naïve T-cells. The expression “directly” as mentioned in any of the embodiments described herein typically means in the context of ‘affecting’ or ‘capable of affecting’ LHs, peripheral Tregs and / or PBMCs that the immunomodulatory substance(s) acts or is capable of acting by itself as the effector causing a desired affectation of the LHs, peripheral Tregs and / or PBMCs. For instance it may activate of may be capable of activating the respective receptor of the immunomodulatory substance(s) of a cell. The receptor of the immunomodulatory substance(s) may for be for instance one of the LHs, peripheral Tregs and / or PBMCs. For instance in case the immunomodulatory substance(s) is a cytokine(s), the cytokine(s) may be capable of activating the respective cytokine-receptor(s). More preferably, the PBMCs are naïve PBMCs, even more preferably lymphocytes, still more preferably T-cells and / or B-cells, still even more preferably naïve lymphocytes, further preferably naïve B-cells and / or naïve T-cells, further preferably naïve T-cells. The expression “indirectly” as mentioned in any of the embodiments described herein typically means in the context of ‘affecting’ or ‘capable of affecting’ LHs, peripheral Tregs and / or PBMCs that the immunomodulatory substance(s) is any substance(s) that results in or causes or is capable of resulting in or causing the generation of the immunomodulatory substance(s), such as in particular a precursor, propeptide or prodrug. In other words, the immunomodulatory substance(s) may encompass substances which are usually not active as such, i.e. have no immunomodulatory activity like the affectation or capability of affectation, but which, upon use in accordance with the present invention, are converted into the actually active immunomodulatory substance. Thereby the desired affectation of the LHs, peripheral Tregs and / or PBMCs is indirectly effected. This may for instance be the case if the immunomodulatory substance(s) is any substance(s) like: - an inductor inducing cells to produce and / or secrete the immunomodulatory substance(s), wherein such cells may be any cells capable of producing and / or secreting the immunomodulatory substance(s).; - a precursor of the immunomodulatory substance(s) which e.g. is metabolized by the subject’s body to generate the immunomodulatory substance(s). The precursor of the immunomodulatory substance(s) includes, beside others, for instance peptide(s), protein(s), protein-analogue(s), protein-variant(s), propeptide(s), derivative(s) thereof, RNA, DNA, salts, capped immunomodulatory substance(s), etc.; - an inhibitor for a substance, enzyme or factor preventing the expression, interaction, production, secretion and / or aktivity of the immunomodulatory substance(s), like for instance particles or nanoparticles or a cap-structure. The immunomodulatory substance(s) may for instance be packed in particles for delivery. These particles may sterically prevent and protect the substance from interacting with its target, e.g. the receptor, and the substance may for instance exert its action only after the release from the particles in the patient's body; - a prodrug of the immunomodulatory substance(s); - and / or - a co-drug of the immunomodulatory substance(s). More preferably, the PBMCs to be affected are naïve PBMCs, even more preferably lymphocytes, still more preferably T-cells and / or B-cells, still even more preferably naïve lymphocytes, further preferably naïve B-cells and / or naïve T-cells, further preferably naïve T-cells; etc. The expression “biopharmaceutical” encompasses biologics, biosimilars, biomimics, biobetters and / or biosuperiors. More preferably, the immunomodulatory substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts: - is capable of affecting and / or affects, preferably directly and / or indirectly, the LHs, peripheral Tregs and / or PBMCs in the subject, more preferably within the skin of the subject; - is capable of affecting and / or affects, preferably directly and / or indirectly, the LHs, peripheral Tregs and / or PBMCs in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention, more preferably within the skin of a vertebrate, even more preferably within the skin of a mammal, still more preferably within the skin of a human or a mammal animal as defined above, further preferably within the skin of the subject; - is capable of affecting and / or affects, preferably directly and / or indirectly, the LHs, peripheral Tregs and / or PBMCs within the skin of the subject; - even more preferably is capable of directly affecting and / or directly affects the LHs, peripheral Tregs and / or PBMCs in the subject, more preferably within the skin of the subject. Preferably, the PBMCs are naïve PBMCs, more preferably lymphocytes, even more preferably T-cells and / or B-cells, still more preferably naïve lymphocytes, still even more preferably naïve B-cells and / or naïve T-cells, further preferably naïve T-cells. The immunomodulatory substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts may encompass precursors, prodrugs and propetides of such immunomodulatory substance(s) which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active immunomodulatory substance. Hence, the immunomodulatory substance(s) may be any substance, molecule, peptide, protein, protein-analogue, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide(s) and / or any derivative, fragment, subunit, pharmaceutically acceptable salt of any of these. More preferably it is any peptide, protein, protein-analogue, protein-variant, inductor, precursor, prodrug, mutein, co-drug and / or any derivative, fragment, subunit, pharmaceutically acceptable salt of any of these. The immunomodulatory substance(s) in any of the embodiments described herein may be any naturally occurring or artificial immunomodulatory substance(s), as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective interferon-receptor(s). The immunomodulatory substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts is any peptide(s), protein(s) and / or any derivative(s) or fragment(s) of these, may be, preferably is similar or identical, more preferably identical, to any peptide, protein or any fragment of these naturally occurring in a vertebrate, preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. The immunomodulatory substance(s) may comprise, preferably consists of an amino acid sequence which has an amino acid sequence identity to any peptide, protein or any fragment of these naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, even more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the amino acid sequence identity is 70 % or more, still more preferably of 85 % or more, still even more preferably 90 % or more, further preferably 95 % or more, even further preferably 97 % or more, still further preferably 98 % or more, still even further preferably 99 % or more and 100 % or less. Preferably, the amino acid sequence identity includes substitutions, insertions and / or deletions of amino acid residues in respect to the naturally occurring peptide, protein or any fragment of these. Preferably, the total number of substitutions, insertions and / or deletions or the total number combined of substitutions, insertions and / or deletions of amino acid residues is 60 or less, more preferably 40 or less, even more preferably 20 or less, still more preferably 12 or less, still even more preferably 8 or less, further preferably 4 or less, even further preferably 2 or less and zero or more, still further preferably zero. The immunomodulatory substance(s) may be identical to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to or the amino acid sequence identity refers to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to. The expression “is identical” typically means in this particular context that the immunomodulatory substance(s) is in respect to its primary, secondary, tertiary and quaternary protein structure identical to an / the immunomodulatory substance(s) of the same genus and / or species the subject belongs to, more preferably, also in view of the modification pattern, particularly glycosylations. The immunomodulatory substance(s) the immunomodulatory substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts may be derived from an individual belonging to the same genus and / or species as the subject, or which is identical to an / the immunomodulatory substance(s) of the same genus and / or species the subject belongs to. For instance, in case the subject is: a human the immunomodulatory substance(s) is a human immunomodulatory substance(s); in case the subject is a cow the immunomodulatory substance(s) is a bovine immunomodulatory substance(s); in case the subject is a horse the immunomodulatory substance(s) is an equine immunomodulatory substance(s); in case the subject is a donkey the immunomodulatory substance(s) is a donkey immunomodulatory substance(s); in case the subject is an elephant the immunomodulatory substance(s) is an elephant immunomodulatory substance(s); in case the subject is a sheep the immunomodulatory substance(s) is a sheep immunomodulatory substance(s); in case the subject is a goat the immunomodulatory substance(s) is a goat immunomodulatory substance(s); in case the subject is a pig the immunomodulatory substance(s) is a porcine immunomodulatory substance(s); in case the subject is a rabbit the immunomodulatory substance(s) is a rabbit immunomodulatory substance(s); in case the subject is a mouse the immunomodulatory substance(s) is a mouse immunomodulatory substance(s); in case the subject is a rat the immunomodulatory substance(s) is a rat immunomodulatory substance(s); in case the subject is a camel the immunomodulatory substance(s) is a camel immunomodulatory substance(s); in case the subject is a dromedary the immunomodulatory substance(s) is a dromedary immunomodulatory substance(s); in case the subject is a lama the immunomodulatory substance(s) is a lama immunomodulatory substance(s); in case the subject is an alpaca the immunomodulatory substance(s) is an alpaca immunomodulatory substance(s); in case the subject is a dog the immunomodulatory substance(s) is a dog immunomodulatory substance(s); and / or in case the subject is a cat the immunomodulatory substance(s) is a cat immunomodulatory substance(s). Preferably, the immunomodulatory substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is not the subject’s endogenous immunomodulatory substance(s). In other words, preferably the immunomodulatory substance(s) is not an immunomodulatory substance(s) isolated from the subject’s body, i.e. from the individual subject to be treated or prevented. Preferably, the immunomodulatory substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be, preferably, is a recombinant immunomodulatory substance(s) which may be which may be generated by any recombinant expression techniques known to the person skilled in the art, a chemically synthesized immunomodulatory substance(s) synthesized by any production techniques known to the person skilled in the art, an artificially produced immunomodulatory substance(s) produced by any production techniques known to the person skilled in the art, a naturally occurring immunomodulatory substance(s) obtained from natural sources like an animal or human, or any combination thereof. More preferably, the immunomodulatory substance(s) is a recombinant immunomodulatory substance(s), chemically synthesized immunomodulatory substance(s), artificially produced immunomodulatory substance(s) or any combination thereof, even more preferably a recombinant immunomodulatory substance(s). Furthermore, the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts may or may not be derivatized, stabilized, fused with other proteins or peptides, conjugated with polymers, contain amino acid analogue(s) or artificial amino acids, modified, covalently or non-covalently, for instance glycosylated or methylated by e.g. posttranslational modification, and / or oligomerized, e.g. dimerized or trimerized, an protein- analogue, protein-variant as long as it is capable of affecting and / or affects LHs, peripheral Tregs and / or PBMCs. More preferably, the modification pattern and / or oligomerization status is similar or identical to the peptide, protein or any fragment of these naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, even more preferably the subject as defined in any of the embodiments according to the present invention. An advantage of such similarity or identity to immunomodulatory substance(s) naturally occurring in the subject’s body, particularly in case of an identity, is that the raise of an immune response against such substances and elimination thereof by the subject’s immune system cannot be expected (e.g. generation of antibodies). This appears particularly true in case the immunomodulatory substance(s) is vital for the subject. This for instance is the case if the immunomodulatory substance(s) is a cytokine(s), particularly IFN-γ (interferon gamma), IL-2 (interleukin 2), IL-4 (interleukin 4) or BDNF (brain-derived neurotropic factor). An immune system’s attack on such immunomodulatory substance(s) would be most likely life-threatening or even fatal and is hence, not expected. In case of e.g. biologics and biosimilars, like TNF-α inhibitors (tumor necrosis factor alpha inhibitors) or IL-6 inhibitors (interleukin-6 inhibitors) monoclonal antibodies, the situation is different. They are artificial substances which do not naturally occur in the subject’s body. Sooner or later they are usually recognized by the subject’s immune systems as foreign and will be neutralized. This possible, because an elimination thereof by the subject’s immune systems has no life-threatening consequences on the homeostasis of the immune system. Precisely, as soon as suitable antibodies are formed, such antibodies will eliminate or neutralize e.g. the biologic or biosimilar. It consequently loses its effect, at least to some extent, and clinical resistance for a treatment with the biologic or biosimilar is observed in the subject. The biologic or biosimilar consequently becomes ineffective. Moreover, this loss of effect is typically permanent and last a subject’s lifetime. Memory B-cells usually remain as a remnant of the immune response in the body for the rest of the subject’s life. Thereby they repeatedly ensure elimination of the biologic or biosimilar for the rest of the subject’s lifetime. Moreover, this can also not be reversed and a substitution is difficult. Hence, in this event, this biologic or biosimilar cannot be effectively applied again in this particular individual once such antibodies were generated. Contrary to e.g. biologics or biosimilars, such loss off effectiveness is not expected for the immunomodulatory substance(s) preferably used in the present invention due to the reasons explained above. An additional advantage of such similarity or identity to immunomodulatory substance(s) naturally occurring in the subject’s body, particularly in case of an identity, is that less or no adverse side effects, like malaise and drug intolerance, are observed and are not to be expected. However, this frequently the case for e.g. biologics and biosimilars. The patients treated according to the present invention even feel stronger and more energetic, presumably because the inflammation draining the subject’s body is repressed (e.g. indicated by decreasing values of the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index), the HAQ (Health Assessment Questionnaire), in assessments on numeric scales [PhGA (Physician's global assessment of disease activity), IRS (Impairment Rating Scale), NPS (Numeric pain scale) and PtGA (Patient's global assessment of disease activity)] and increasing values of the SF-36v1,0 (36-Item Short Form Survey Version 1.0)). The therapy of the present invention does not add any adverse side effects or incompatibilities, even in long term use over more than a year. Furthermore, in the treatment of inflammatory diseases glucocorticoids are frequently used. Since glucocorticoids have also a high similarity or are even identical with substances naturally occurring in the subject’s body, the following shall be mentioned. In conventional therapies glucocorticoids need to be administered in high concentrations to be effective. Due to that fact, in long-term use they develop severe adverse effects, in adults and even more in children. It is a general interest in medicine to administer drugs and pharmaceuticals in the lowest concentration still effective. However, with a lowering of the dosage of e.g. glucocorticoids it is not possible that they can confer their beneficial effects. Hence, in conventional therapies an unpleasant weighing between side effects and curative effects must be made. Similarly, also the immunomodulatory substance(s), particularly e.g. IFN-γ and IL-2, are employed in conventional therapies or therapy attempts solely in very high dosages of immunomodulatory substance(s). Furthermore, it has been reported previously, that administering high concentrations of e.g. IFN-γ (50,000 ng recombinant IFN-γ) proved even to be no more effective than placebo in patients with rheumatoid arthritis (“A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-γ versus placebo in the treatment of rheumatoid arthritis”, Eric M. Veys MD, PhD, Charles-Joël Menkes MD, PhD, Paul Emery FRCP, First published: January 1997, https: / / doi.org / 10.1002 / art.1780400110). In the present invention the highest preferred concentration of e.g. IFN-γ is 1,500 ng, which is 33-times less than used by Eric et al. In the Examples of the present invention an amount of even 5 ng IFN-γ has been effectively used, which is as much as 10,000-times less than the amount used by Eric et al. Hence, the present invention is based on the further surprising finding that the immunomodulatory substance(s) can be administered in extremely low concentrations while still being effective. Such low concentrations typically do not lead to a systemic increase of the immunomodulatory substance(s) in the subject’s body, presumably at least not to a systemic increase which is effective (systemic effective increase). In other words, when scaling the administered doses of the immunomodulatory substance(s) to the entire body of the subject, the resulting systemic concentrations is assumed to remain in the magnitude of the endogenous levels.The systemic homeostasis of the immune system is unlikely to be altered. The low amounts locally administered can easy be handled by the subject’s metabolism. From these points of view adverse side effects are not to be expected even in long-term use and a weighing between side effects and curative effects is not be necessary. Moreover, by administering low amounts of immunomodulatory substance(s), the effectiveness of the treatment, the reliability of the treatment success and the repeatability in a greater proportion of patients is even improved. Without wishing to be bound to theory, it is believed that the tolerogenic phenotype of LHs finally leading to the generation of regulatory T-cells may only be promoted and fully executed by administering ultra-low amounts of immunomodulatory substance(s) like e.g. IFN-γ and IL-2. Further, without wishing to be bound to theory, it is believed that by administering extremely low amounts of immunomodulatory substance(s), the end phase of an inflammatory reaction can be locally resembled e.g. within the skin. The generation of immunosuppressive T-cells like helper T-cells, or a subset thereof, and particularly regulatory T-cells is thereby promoted with at the same time avoiding the generation of highly aggressive pro-inflammatory cytotoxic T-cells. Thereby, the desired and therapeutic anti- inflammatory effects are promoted while the non-wanted and adverse pro-inflammatory effects are prevented. It is noted that cytotoxic T-cells are, in a sense, the pro-inflammatory counteractors of anti-inflammatory helper T-cells, or a subset thereof, and particularly regulatory T-cells. However, when administering high amounts of immunomodulatory substance(s) it is believed that the desired anti-inflammatory effects may be cancelled out, not be achieved or even exceeded by the non-wanted pro-inflammatory effects. This could possibly be an explanation for why the high concentrations administered in Eric et al. do not show any significant beneficial effects beyond the placebo. Precisely, in order to neutralize harmful antigen a healthy immune system produces during an inflammatory reaction large quantities of cytotoxic T-cells. As mentioned above, these cells are highly aggressive. The presence of high amounts of autoantigen in combination with immunomodulatory substance(s) such as IFN-γ is believed to cause naïve T-cells to develop into cytotoxic T-cells. At the end of an inflammatory reaction all antigen is neutralized and there is an excess of cytotoxic T-cells, which are relieved of their task. To prevent these cells with their high aggression potential from causing damage elsewhere in the body, the immune system provides for e.g. regulatory T-cells. As stated before, such regulatory T-cells may act as immunosuppressive counterparts of cytotoxic T-cells. They ensure that the extent of an immune activation is limited. At the end of an inflammatory response all antigen is neutralized, but immunomodulatory substance(s) like e.g. IFN-γ are still present. Consequently, at the end of an inflammatory response the milieu has turned towards the favour of regulatory T-cells and / or helper T-cells, or a subset thereof, respectively. Without the presence of high amounts of autoantigen in the simultaneous presence of immunomodulatory substance(s) such as IFN-γ, trailing or subsequent naïve T-cells no longer develop into cytotoxic T-cells – they will mature or develop into regulatory T-cells. Consequently, whithout whishing to be bound to theory, the formation of regulatory T-cells is believed to be promoted by administering low amount of the immunomodulatory substance(s), either based on the theory relating to PBMCs or the the theory relating to LHs and peripheral Tregs. Without wishing to be bound to theory, it is believed that in the present invention in the skin, which is free from high amounts of antigen / autoantigen / allergen or essentially free of antigen / autoantigen / allergen, that is only low amounts of antigen / autoantigen / allergen may be present, formation of immunosuppressive T-cells like regulatory and / or helper T-cells is initiated. It is further believed that by accumulating PBMCs e.g. within the skin, and contacting them with immunomodulatory substance(s) by at the same time avoiding antigen, autoantigen or allergen contact in large amounts, immunosuppressive T-cells like regulatory T-cells and helper T-cells, or a subset thereof, are generated. It is further believed that by accumulating low amounts of autoantigen within the skin at the site where LHs and peripheral Tregs reside at concomitant providance of immunomodulatory substance(s) by at the same time avoiding antigen, autoantigen or allergen contact in large amounts, immunosuppressive T-cells like regulatory T-cells and helper T-cells, or a subset thereof, are generated. However, if high amounts of immunomodulatory substance(s) are administered, it is believed, whithout whishing to be bound thereto, that the LHs will develop to an immunogenic phenotyp instead of the tolerogenic, immunosuppressive phenotype. Furthermore, if high amounts of immunomodulatory substance(s) are administered, it is believed, again whithout whishing to be bound thereto, that a systemic increase of the concentration of immunomodulatory substance(s) is generated to an extent which is effective, i.e. a systemic effective increase is generated. Thereby, also e.g. rheumatically inflamed joints are flushed with immunomodulatory substance(s) such as IFN-γ in effective amounts while at the same time a large amount of autoantigen, i.e. joint tissue, is present. Consequently, cytotoxic T-cells may be generated within the joints. The autoagression within the joints may be even be increased. Without wishing to be bound to theory, the beneficial suppressive effects of e.g. the regulatory T-cells believed to the generated by the method of the present invention are cancelled or even exceeded to the worse. In short, without wishing to be bound to theory, it is believed that naïve PBMCs, particularly naïve T-cells, are the targets of the present invention. By using e.g. the skin as an in-vivo incubator for the naïve T-cells, specifically and locally helper T-cells, or subsets thereof, and regulatory T-cells, may be produced. The latter are then considered to be the effectors which spread and exert their beneficial anti- inflammatory effect at locations of need. At the same time the generation of pro-inflammatory cytotoxic T-cells is elsewhere preferably in the subject’s body avoided. Hence, preferably, in any of the embodiments described herein it is intended to administer the immunomodulatory substance(s) in an amount low enough to avoid a systemic increase, particularly an effective systemic increase, of the concentration of the immunomodulatory substance(s) in the subject’s body. Hence, the immunomodulatory substance(s) may be administered in an amount that, when scaled to the entire body of the subject, the resulting systemic concentrations remain in the magnitude of the endogenous levels. Thereby, without wishing to be bound to theory, it is believed that the generation of an increased concentration of the immunomodulatory substance(s) for instance at sites of inflammation like inflamed joint shall be avoided. As already stated above, for instance naïve T-cells can mature in the presence of antigen / autoantigen / allergen towards cytotoxic T-cells. These T-cells act pro- inflammatory thereby decreasing, cancelling or even reversing the beneficial anti-inflammatory effects conferred by the regulatory T-cells and / or helper T-cells, or a subset thereof. Hence, by administering the immunomodulatory substance(s) in sufficiently low amounts, it is believed to solely promote the generation of regulatory T-cells and / or helper T-cells, or a subset thereof, locally within the skin while the generation of cytotoxic T-cells elsewhere in the subject’s body is prevented. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the immunomodulatory substance(s) is administered in an amount that does not cause a systemic increase, more preferably an effective systemic increase, of the concentration of immunomodulatory substance(s) in the subject, preferably the blood of the subject, and / or that causes a systemic increase of the concentration of the immunomodulatory substance(s). Preferably, immunomodulatory substance(s) is administered in an amount low enough that the systemic increase is non-effective. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the immunomodulatory substance(s) is administered in an amount that causes a local increase, preferably an effective local increase, of the concentration of the immunomodulatory substance(s) in the subject, preferably in the skin tissue of the subject. The skin tissue is preferred, because unlike administration into the blood, no or less flushing away and dilution of the immunomodulatory substance(s) takes place. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the generated increased concentration, preferably the generated effective increased concentration of the immunomodulatory substance(s) administered is only local but not systemic in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the immunomodulatory substance(s) is administered in an amount that does not cause a systemic activation, preferably an effective systemic activation, of the respective receptor of the immunomodulatory substance(s) of a cell, and / or that does not cause a systemic generation, preferably an effective systemic generation, of the immunomodulatory substance(s), preferably in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the immunomodulatory substance(s) is administered in an amount that causes a local activation, preferably an effective local activation of the respective receptor of the immunomodulatory substance(s) of a cell, and / or causes a local generation, preferably an effective local generation of the immunomodulatory substance(s), preferably in the subject. Preferably, the activation and / or generation, more preferably the effective generation and / or effective activation is only local but not systemic in the subject. Preferably, the immunomodulatory substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is a cytokine-like acting substance(s), preferably a cytokine(s), or any peptide, protein, protein-analogue, peptide, protein-variant,derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug thereof and / or pharmaceutically acceptable salt of any of these.. In the present invention, the expression “cytokine-like acting substance”, “interferon-like acting substance”, “interleukin-like acting substance”, “neutrophin-like acting substance”, or any similar expression, designates substances which directly or indirectly, e.g. after being metabolized, exert an effect similar or identical to the effect exerted by the substance itself in the body of the subject, and encompasses in each case also the substance itself, i.e. the “cytokine-like acting substance” encompasses the cytokine, the “interferon- like acting substance” encompasses the interferon, the “interleukin-like acting substance” encompasses the interleukin, and the “neutrophin-like acting substance” encompasses the neutrophin, and so on. This applies also where herein in the following terms like “cytokine and / or cytokine-like acting substance” or “cytokine or cytokine- like acting substance” or similar terms are used, i.e. also in these terms the expression “cytokine-like acting substance” designates the cytokine itself and any substances which directly or indirectly, e.g. after being metabolized, exert an effect similar or identical to the effect exerted by the cytokine itself in the body of the subject. The expression “cytokine-like acting substance” or “cytokine-like acting substance(s)” as mentioned in any of the embodiments described herein can be, preferably is, any substance that exerts a similar or identical effect to a cytokine in the body of the subject when administered thereto. The cytokine-like acting substance(s) may encompass precursors, prodrugs and propetides of such substances which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active cytokine-like acting substance(s). Hence, it may be any substance, molecule, peptide, protein protein-analogue, protein-variant, derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or any derivative, fragment and / or pharmaceutically acceptable salt of any of these. Therefore cytokine-like acting substance(s) may: - activates or is / are capable of activating a respective cytokine-receptor(s) of a cell. The cytokine-receptor(s) may for instance be the receptor of the LHs, peripheral Tregs or PBMCs; and / or - results in or causes or is capable of resulting in or causing the generation of a cytokine(s) and / or a cytokine-like acting substance(s). Preferably, the cytokine-like acting substance(s) activates or is capable of activating the respective cytokine-receptor(s). The activating or the capability of activating the respective cytokine-receptor(s) may be directly and / or it may be indirectly. Preferably, the cytokine-like acting substance(s) activates or is / are capable of activating a respective cytokine-receptor(s) within the skin of the subject. The cytokine-like acting substance(s) may be any naturally occurring or artificial cytokine-like acting substance(s) as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective cytokine-receptor(s). Preferably, the cytokine-like acting substance(s) is known to the person skilled in the art at the effective date of filing of the present invention. Preferably, the cytokine-like acting substance is any peptide, protein, protein-analogue, protein-variant) or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. In a preferred embodiment, the cytokine-like acting substance(s) may be as detailed below amongst others a cytokine(s) and / or any peptide, protein, protein-analogue, peptide, protein-variant, derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug thereof and / or pharmaceutically acceptable salt of any of these. More preferably, the cytokine-like acting substance(s) is a cytokine(s) and / or any peptide, protein, protein-analogue, peptide, protein- variant, derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug thereof and / or pharmaceutically acceptable salt of any of these. The expression “cytokine” or “cytokine(s)” as mentioned in any of the embodiments described herein preferably has to be interpreted broad. Typically, the cytokine(s) activates or is are capable of activating a respective cytokine-receptor(s) of a cell. The cytokine- receptor(s) may for instance be the receptor of the LHs, peripheral Tregs and / or PBMCs. Preferably, the activating or capability of activating is within the skin of the subject, more preferably locally in effective amounts within the skin of the subject, even more preferably not in amounts systemically effective within the subject’s body. Preferably the cytokine may be any type of cytokine known to the person skilled in the art. Furthermore, the present invention encompass the use or medical use of precursors, prodrugs and propetides of such cytokine(s) which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active cytokine. Hence, these may be used in the method or medical use as described herein or in preparation of the pharmaceutical compositions, injectable dosage form, topical dosage forms, medical devices and / or kit of parts as described herein. The cytokine(s) may be any peptide, protein, protein-analogue, protein-variant or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. The cytokine(s) does not necessarily be derived from or be identical to the cytokine(s) of the same genus and / or species the subject belongs to, it may be any naturally occurring or an artificial cytokine(s), as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective cytokine-receptor(s). Preferably, the biologic activity of the cytokine(s) and / or cytokine-like acting substance(s) is sufficient to achieve the treating and / or preventing of the antisynthetase syndrome, preferably in the subject. A cytokine and / or a cytokine-like acting substance typically affects cells by binding and activating the respective cytokine(s)-receptor on the cells. Hence, the activating of the respective receptor typically leads to the affectation of the cell as described above for the immunomodulatory substance. Hence, any embodiment mentioned herein for the immunomodulatory substance relating to the affecting cells like LHs, peripheral Tregs and / or PBMCs is independently and mutatis mutandis applicable to the cytokine(s) and the cytokine- like acting substance. The activating or the capability of activating the respective cytokine-receptor(s) by the cytokine(s) and / or cytokine-like acting substance(s) may be directly and / or it may be indirectly. The expression “directly” as mentioned in any of the embodiments described herein typically means in the context of ‘activating’ and / or ‘capable of activating’ the respective receptor that the cytokine(s) or the cytokine-like acting substance(s) acts or is capable of acting by itself as the activator of the respective receptor of the cytokine(s) or the cytokine-like acting substance(s) of a cell like. The expression “indirectly” as mentioned in any of the embodiments described herein typically means in the context of ‘activating’ and / or ‘capable of activating’ the respective receptor that the cytokine(s) or cytokine-like acting substance(s) is any substance(s) that results in or causes or is capable of resulting in or causing the generation of the cytokine(s) or cytokine-like acting substance(s), such as in particular a precursor, propeptide or prodrug. In other words, the cytokine(s) or cytokine-like acting substance(s) may encompass substances which are usually not active as such, i.e. have no immunomodulatory activity like the activation or capability of activation of a receptor, but which, upon use in accordance with the present invention, are converted into the actually cytokine(s) or cytokine-like acting substance(s). Thereby the desired activation of the respective cytokine(s)-receptor is indirectly effected. This may for instance be the case if the cytokine(s) or the cytokine-like acting substance(s) is any substance(s) like: - an inductor inducing cells to produce and / or secrete the cytokine(s) or the cytokine-like acting substance(s), wherein such cells may be any cells capable of producing and / or secreting the cytokine(s) or the cytokine-like acting substance(s).; - a precursor of the cytokine(s) or the cytokine-like acting substance(s) which e.g. is metabolized by the subject’s body to generate the cytokine(s) or the cytokine-like acting substance(s). The precursor of the immunomodulatory substance(s) includes, beside others, for instance peptide(s), protein(s), protein-analogue(s), protein-variant(s), propeptide(s), derivative(s) thereof, RNA, DNA, salts, capped immunomodulatory substance(s) etc.; - an inhibitor for a substance, enzyme or factor preventing the expression, interaction, production, secretion and / or aktivity of the cytokine(s) or the cytokine-like acting substance(s), like for instance particles or nanoparticles or a cap-structure. The cytokine(s) or the cytokine-like acting substance(s) may for instance be packed in particles for delivery. These particles may sterically prevent and protect the substance from interacting with its target, e.g. the receptor, and the substance may for instance exert its action only after the release from the particles in the patient's body; - a prodrug of the cytokine(s) or the cytokine-like acting substance(s); and / or - a co-drug of the cytokine(s) or the cytokine-like acting substance(s). Preferably, the cytokine(s) and / or cytokine-like acting substance(s) for use according to the present invention and / or the cytokine(s) and / or cytokine-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is capable of affecting and / or affects the LHs, peripheral Tregs and / or PBMCs. Preferably, the PBMCs are naïve PBMCs, more preferably lymphocytes, even more preferably T-cells and / or B-cells, still more preferably naïve lymphocytes, still even more preferably naïve B-cells and / or naïve T-cells, further preferably naïve T-cells. More preferably, the cytokine(s) and / or cytokine-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs and / or PBMCs. More preferably, the cytokine(s) and / or cytokine-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs and / or PBMCs in the subject as defined in any of the embodiments according to the present invention, further preferably within the skin of the subject. If not mentioned otherwise, the description and definition of the immunomodulatory substance(s) stated above is independently and mutatis mutandis applicable to the cytokine(s) and / or cytokine-like acting substance(s). Particualry, if not mentioned otherwise, the description and definition of the immunomodulatory substance(s) in respect of “directly” and “indirectly” affecting or capable of affecting the PBMCs is independently and mutatis mutandis applicable to the cytokine(s) and / or cytokine-like acting substance(s). The cytokine(s) and / or cytokine-like acting substance(s) for use according to the present invention and / or the cytokine(s) and / or cytokine-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be similar or identical, preferably identical, to any cytokine(s) and / or cytokine-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the cytokine(s) and / or cytokine-like acting substance(s) may be similar or identical, preferably identical, to any peptide, protein or any fragment of these of a cytokine(s) and / or cytokine-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. The cytokine(s) and / or cytokine-like acting substance(s) may comprise, preferably consist of an amino acid sequence which has an amino acid sequence identity to any peptide, protein or any fragment of a cytokine(s) and / or cytokine-like acting substance(s) naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the amino acid sequence identity is 70 % or more, even more preferably 85 % or more, still more preferably 90 % or more, still even more preferably 95 % or more, further preferably 97 % or more, even further preferably 98 % or more, still further preferably 99 % or more and 100 % or less. Preferably, the amino acid sequence identity includes substitutions, insertions and / or deletions of amino acid residues in respect to the naturally occurring peptide, protein or any fragment of these. Preferably, the total number of substitutions, insertions and / or deletions or the total number combined of substitutions, insertions and / or deletions of amino acid residues is 60 or less, more preferably 40 or less, even more preferably 20 or less, still more preferably 12 or less, still even more preferably 8 or less, further preferably 4 or less, even further preferably 2 or less and zero or more, still further preferably zero. The cytokine(s) and / or cytokine-like acting substance(s) may be identical to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to or the amino acid sequence identity refers to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to. The expression “is identical” typically means in this particular context that the cytokine(s) and / or cytokine-like acting substance(s) is in respect to its primary, secondary, tertiary and quaternary protein structure identical to an / the cytokine(s) and / or cytokine-like acting substance(s) of the same genus and / or species the subject belongs to, more preferably, also in view of the modification pattern, particularly glycosylations. The cytokine(s) and / or cytokine-like acting substance(s) for use according to the present invention and / or the cytokine(s) and / or cytokine-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be derived from an individual belonging to the same genus and / or species as the subject, or which is identical to an / the cytokine(s) and / or cytokine-like acting substance(s) of the same genus and / or species the subject belongs to. For instance, in case the subject is: a human the cytokine(s) and / or cytokine-like acting substance(s) is human cytokine(s) and / or cytokine-like acting substance(s); a cow the cytokine(s) and / or cytokine-like acting substance(s) is bovine cytokine(s) and / or cytokine-like acting substance(s); a horse the cytokine(s) and / or cytokine-like acting substance(s) is equine cytokine(s) and / or cytokine-like acting substance(s); a donkey the cytokine(s) and / or cytokine-like acting substance(s) is donkey cytokine(s) and / or cytokine-like acting substance(s); an elephant the cytokine(s) and / or cytokine-like acting substance(s) is elephant cytokine(s) and / or cytokine-like acting substance(s); a sheep the cytokine(s) and / or cytokine-like acting substance(s) is sheep cytokine(s) and / or cytokine-like acting substance(s); a goat the cytokine(s) and / or cytokine-like acting substance(s) is goat cytokine(s) and / or cytokine-like acting substance(s); a pig the cytokine(s) and / or cytokine-like acting substance(s) is porcine cytokine(s) and / or cytokine-like acting substance(s); a rabbit the cytokine(s) and / or cytokine-like acting substance(s) is rabbit cytokine(s) and / or cytokine- like acting substance(s); a mouse the cytokine(s) and / or cytokine-like acting substance(s) is mouse cytokine(s) and / or cytokine-like acting substance(s); a rat the cytokine(s) and / or cytokine-like acting substance(s) is rat cytokine(s) and / or cytokine-like acting substance(s); a camel the cytokine(s) and / or cytokine-like acting substance(s) is camel cytokine(s) and / or cytokine-like acting substance(s); a dromedary the cytokine(s) and / or cytokine-like acting substance(s) is dromedary cytokine(s) and / or cytokine-like acting substance(s); a lama the cytokine(s) and / or cytokine-like acting substance(s) is lama cytokine(s) and / or cytokine-like acting substance(s); an alpaca the cytokine(s) and / or cytokine-like acting substance(s) is alpaca cytokine(s) and / or cytokine-like acting substance(s); a dog the cytokine(s) and / or cytokine-like acting substance(s) is dog cytokine(s) and / or cytokine-like acting substance(s); and / or a cat the cytokine(s) and / or cytokine-like acting substance(s) is cat cytokine(s) and / or cytokine-like acting substance(s). Preferably, the cytokine(s) and / or cytokine-like acting substance(s) for use according to the present invention and / or the cytokine(s) and / or cytokine-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is not the subject’s endogenous cytokine(s) and / or cytokine-like acting substance(s). In other words, preferably the cytokine(s) and / or cytokine-like acting substance(s) is not an cytokine(s) and / or cytokine-like acting substance(s) isolated from the subject’s body, i.e. from the individual subject to be treated or prevented. Preferably, the cytokine(s) and / or cytokine-like acting substance(s) for use according to the present invention and / or the cytokine(s) and / or cytokine-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be, preferably, is a recombinant cytokine(s) and / or cytokine- like acting substance(s) which may be which may be generated by any recombinant expression techniques known to the person skilled in the art, a chemically synthesized cytokine(s) and / or cytokine-like acting substance(s) synthesized by any production techniques known to the person skilled in the art, an artificially produced cytokine(s) and / or cytokine-like acting substance(s) produced by any production techniques known to the person skilled in the art, a naturally occurring cytokine(s) and / or cytokine-like acting substance(s) obtained from natural sources like an animal or human, or any combination thereof. More preferably, the cytokine(s) and / or cytokine- like acting substance(s) is a recombinant cytokine(s) and / or cytokine-like acting substance(s), chemically synthesized cytokine(s) and / or cytokine-like acting substance(s), artificially produced cytokine(s) and / or cytokine-like acting substance(s) or any combination thereof, even more preferably a recombinant cytokine(s) and / or cytokine-like acting substance(s). Furthermore, the cytokine(s) and / or cytokine-like acting substance(s) for use according to the present invention and / or the cytokine(s) and / or cytokine-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may or may not be derivatized, stabilized, fused with other proteins or peptides, conjugated with polymers, contain amino acid analogue(s) or artificial amino acids, modified, covalently or non-covalently, for instance glycosylated or methylated by e.g. posttranslational modification and / or oligomerized, e.g. dimerized or trimerized as long as it is capable of affecting and / or affects LHs, peripheral Tregs and / or PBMCs. More preferably, the modification pattern and / or oligomerization status is similar or identical to the peptide, protein or any fragment of these naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, in any of the embodiments described herein it is intended to administer the cytokine(s) and / or cytokine-like acting substance(s) in an amount low enough to avoid a systemic increase of the cytokine(s) and / or cytokine-like acting substance(s)-concentration in the subject’s body. Hence, the cytokine(s) and / or cytokine-like acting substance(s) may be administered in an amount that, when scaled to the entire body of the subject, the resulting systemic concentrations remain in the magnitude of the endogenous levels. Thereby, without wishing to be bound to theory, it is believed that the generation of an increased cytokine(s) and / or cytokine-like acting substance(s)-concentration for instance at sites of inflammation, like inflamed joint. As already stated above, for instance naïve T-cells can mature in the presence of antigen / autoantigen / allergen towards cytotoxic, which may act pro- inflammatory. Thereby decreasing, cancelling or even reversing the beneficial effects achieved by the present invention, particularly, the anti-inflammatory effect of the regulatory T-cells and / or helper T-cells, or of a subset thereof, which are presumably generated. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the cytokine(s) and / or cytokine-like acting substance(s) is administered in an amount that does not cause a systemic increase, more preferably an effective systemic increase, of the concentration of cytokine(s) and / or cytokine-like acting substance(s) in the subject, preferably the blood of the subject, and / or that causes a systemic increase of the concentration of the cytokine(s) and / or cytokine-like acting substance(s). Preferably, cytokine(s) and / or cytokine-like acting substance(s) is administered in an amount low enough that the systemic increase is non-effective. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the cytokine(s) and / or cytokine-like acting substance(s) is administered in an amount that causes a local increase, preferably an effective local increase, of the concentration of the cytokine(s) and / or cytokine-like acting substance(s) in the subject, preferably in the skin tissue of the subject. The skin tissue is preferred, because unlike administration into the blood, no or less flushing away and dilution of the cytokine(s) and / or cytokine-like acting substance(s) takes place. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the generated increased concentration, preferably the generated effective increased concentration of the cytokine(s) and / or cytokine-like acting substance(s) administered is only local but not systemic in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the cytokine(s) and / or cytokine-like acting substance(s) is administered in an amount that does not cause a systemic activation, preferably an effective systemic activation, of the respective receptor of the cytokine(s) and / or cytokine-like acting substance(s) of a cell, and / or that does not cause a systemic generation, preferably an effective systemic generation, of the cytokine(s) and / or cytokine-like acting substance(s), preferably in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the cytokine(s) and / or cytokine-like acting substance(s) is administered in an amount that causes a local activation, preferably an effective local activation of the respective receptor of the cytokine(s) and / or cytokine-like acting substance(s) of a cell, and / or causes a local generation, preferably an effective local generation of the cytokine(s) and / or cytokine-like acting substance(s), preferably in the subject. Preferably, the activation and / or generation, more preferably the effective generation and / or effective activation is only local but not systemic in the subject. Preferably, the cytokine-like acting substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is an cytokine-like acting substance(s), more preferably an interferon-like acting substance(s), interleukin- like acting substance(s) and / or neurotrophin-like acting substance(s). Preferably, the cytokine(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is an cytokine(s), more preferably an interferons, interleukins, neurotrophins, colony-stimulating factors, tumour necrosis factors and / or chemokines, even more preferably an interferon(s), interleukin(s) and / or neurotrophin(s), still more preferably an interferon(s) and / or interleukin(s). The expression “interferon-like acting substance” or “interferon-like acting substance(s)” as mentioned in any of the embodiments described herein can be, preferably is, any substance that exerts a similar or identical effect to an interferon in the body of the subject when administered thereto. The interferon-like acting substance(s) may encompass precursors, prodrugs and propetides of such substances which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active interferon-like acting substance(s). Hence, it may be any substance, molecule, peptide, protein, protein-analogue, protein-variant, derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or any derivative, fragment and / or pharmaceutically acceptable salt of any of these. Therefore interferon-like acting substance(s) may: - activates or is / are capable of activating a respective interferon-receptor(s) of a cell. The interferon-receptor(s) may for instance be the receptor of the LHs, peripheral Tregs or PBMCs; and / or - results in or causes or is capable of resulting in or causing the generation of a interferon(s) and / or a interferon-like acting substance(s). Preferably, the interferon-like acting substance(s) activates or is capable of activating the respective interferon-receptor(s). The activating or the capability of activating the respective interferon-receptor(s) may be directly and / or it may be indirectly. Preferably, the interferon-like acting substance(s) activates or is / are capable of activating a respective interferon-receptor(s) within the skin of the subject. The interferon-like acting substance(s) may be any naturally occurring or artificial interferon-like acting substance(s) as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective interferon-receptor(s). Preferably, the interferon-like acting substance(s) is known to the person skilled in the art at the effective date of filing of the present invention. Preferably, the interferon-like acting substance is any peptide, protein, protein-analogue, protein-variant or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. In a preferred embodiment, the interferon-like acting substance(s) may be as detailed below amongst others an interferon(s) and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co- drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. More preferably, the interferon-like acting substance(s) is a interferon(s) and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. The expression “interferon” or “interferon(s)” as mentioned in any of the embodiments described herein preferably has to be interpreted broad. Typically, the interferon(s) activates or is are capable of activating a respective interferon-receptor(s) of a cell. The interferon- receptor(s) may for instance be the receptor of the LHs, peripheral Tregs or PBMCs. Preferably, the activating or capability of activating is within the skin of the subject, more preferably locally in effective amounts within the skin of the subject, even more preferably not in amounts systemically effective within the subject’s body. Preferably the interferon may be any type of interferon known to the person skilled in the art. Furthermore, the present invention encompass the use or medical use of precursors, prodrugs and propetides of such interferon(s) which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active interferon. Hence, these may be used in the method or the medical use as described herein or in preparation of the pharmaceutical compositions, injectable dosage form, topical dosage forms, medical devices and / or kit of parts as described herein. The interferon(s) may be any peptide, protein, protein-analogue, protein-variant or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. The interferon(s) does not necessarily be derived from or be identical to the interferon(s) of the same genus and / or species the subject belongs to, it may be any naturally occurring or an artificial interferon(s), as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective interferon-receptor(s). Preferably, the biologic activity of the interferon(s) and / or interferon-like acting substance(s) is sufficient to achieve the treating and / or preventing of the antisynthetase syndrome, preferably in the subject. An interferon and / or an interferon-like acting substance typically affects cells by binding and activating the respective interferon(s)- receptor on the cells. Hence, the activating of the respective receptor typically leads to the affectation of the cell as described above for the immunomodulatory substance. Hence, any embodiment mentioned herein for the immunomodulatory substance relating to the affecting cells like LHs, peripheral Tregs or PBMCs is independently and mutatis mutandis applicable to the interferon(s) and the interferon-like acting substance. The activating or the capability of activating the respective interferon-receptor(s) by the interferon(s) and / or interferon-like acting substance(s) may be directly and / or it may be indirectly. If not mentioned otherwise, the description and definition of the cytokine(s) or the cytokine-like acting substance stated above is independently and mutatis mutandis applicable to the interferon(s) and / or interferon-like acting substance(s). Particualry, if not mentioned otherwise, the description and definition of the cytokine(s) or the cytokine-like acting substance in respect of “directly” and “indirectly” activating or capable of activating the respective interferon-receptor(s), is independently and mutatis mutandis applicable to the interferon(s) and / or interferon-like acting substance(s). Preferably, the interferon(s) and / or interferon-like acting substance(s) for use according to the present invention and / or the interferon(s) and / or interferon-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is capable of affecting and / or affects the LHs, peripheral Tregs or PBMCs. Preferably, the PBMCs are naïve PBMCs, more preferably lymphocytes, even more preferably T-cells and / or B-cells, still more preferably naïve lymphocytes, still even more preferably naïve B-cells and / or naïve T-cells, further preferably naïve T-cells. More preferably, the interferon(s) and / or interferon-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs or PBMCs. More preferably, the interferon(s) and / or interferon-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs or PBMCs in the subject as defined in any of the embodiments according to the present invention, further preferably within the skin of the subject. If not mentioned otherwise, the description and definition of the immunomodulatory substance(s) stated above is independently and mutatis mutandis applicable to the interferon(s) and / or interferon-like acting substance(s). Particualry, if not mentioned otherwise, the description and definition of the immunomodulatory substance(s) in respect of “directly” and “indirectly” affecting or capable of affecting the PBMCs is independently and mutatis mutandis applicable to the interferon(s) and / or interferon-like acting substance(s). The interferon(s) and / or interferon-like acting substance(s) for use according to the present invention and / or the interferon(s) and / or interferon-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be similar or identical, preferably identical, to any interferon(s) and / or interferon-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the interferon(s) and / or interferon-like acting substance(s) may be similar or identical, preferably identical, to any peptide, protein or any fragment of these of a interferon(s) and / or interferon-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. The interferon(s) and / or interferon-like acting substance(s) may comprise, preferably consist of an amino acid sequence which has an amino acid sequence identity to any peptide, protein or any fragment of an interferon(s) and / or interferon-like acting substance(s) naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the amino acid sequence identity is 70 % or more, even more preferably 85 % or more, still more preferably 90 % or more, still even more preferably 95 % or more, further preferably 97 % or more, even further preferably 98 % or more, still further preferably 99 % or more and 100 % or less. Preferably, the amino acid sequence identity includes substitutions, insertions and / or deletions of amino acid residues in respect to the naturally occurring peptide, protein or any fragment of these. Preferably, the total number of substitutions, insertions and / or deletions or the total number combined of substitutions, insertions and / or deletions of amino acid residues is 60 or less, more preferably 40 or less, even more preferably 20 or less, still more preferably 12 or less, still even more preferably 8 or less, further preferably 4 or less, even further preferably 2 or less and zero or more, still further preferably zero. The interferon(s) and / or interferon-like acting substance(s) may be identical to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to or the amino acid sequence identity refers to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to. The expression “is identical” typically means in this particular context that the interferon(s) and / or interferon-like acting substance(s) is in respect to its primary, secondary, tertiary and quaternary protein structure identical to an / the interferon(s) and / or interferon-like acting substance(s) of the same genus and / or species the subject belongs to, more preferably, also in view of the modification pattern, particularly glycosylations. The interferon(s) and / or interferon-like acting substance(s) for use according to the present invention and / or the interferon(s) and / or interferon-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be derived from an individual belonging to the same genus and / or species as the subject, or which is identical to an / the interferon(s) and / or interferon-like acting substance(s) of the same genus and / or species the subject belongs to. For instance, in case the subject is: a human the interferon(s) and / or interferon-like acting substance(s) is human interferon(s) and / or interferon-like acting substance(s); a cow the interferon(s) and / or interferon-like acting substance(s) is bovine interferon(s) and / or interferon-like acting substance(s); a horse the interferon(s) and / or interferon-like acting substance(s) is equine interferon(s) and / or interferon-like acting substance(s); a donkey the interferon(s) and / or interferon-like acting substance(s) is donkey interferon(s) and / or interferon-like acting substance(s); an elephant the interferon(s) and / or interferon-like acting substance(s) is elephant interferon(s) and / or interferon-like acting substance(s); a sheep the interferon(s) and / or interferon-like acting substance(s) is sheep interferon(s) and / or interferon-like acting substance(s); a goat the interferon(s) and / or interferon-like acting substance(s) is goat interferon(s) and / or interferon-like acting substance(s); a pig the interferon(s) and / or interferon-like acting substance(s) is porcine interferon(s) and / or interferon-like acting substance(s); a rabbit the interferon(s) and / or interferon-like acting substance(s) is rabbit interferon(s) and / or interferon-like acting substance(s); a mouse the interferon(s) and / or interferon-like acting substance(s) is mouse interferon(s) and / or interferon-like acting substance(s); a rat the interferon(s) and / or interferon-like acting substance(s) is rat interferon(s) and / or interferon-like acting substance(s); a camel the interferon(s) and / or interferon-like acting substance(s) is camel interferon(s) and / or interferon-like acting substance(s); a dromedary the interferon(s) and / or interferon-like acting substance(s) is dromedary interferon(s) and / or interferon-like acting substance(s); a lama the interferon(s) and / or interferon-like acting substance(s) is lama interferon(s) and / or interferon-like acting substance(s); an alpaca the interferon(s) and / or interferon-like acting substance(s) is alpaca interferon(s) and / or interferon-like acting substance(s); a dog the interferon(s) and / or interferon-like acting substance(s) is dog interferon(s) and / or interferon-like acting substance(s); and / or a cat the interferon(s) and / or interferon-like acting substance(s) is cat interferon(s) and / or interferon-like acting substance(s). Preferably, the interferon(s) and / or interferon-like acting substance(s) for use according to the present invention and / or the interferon(s) and / or interferon-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is not the subject’s endogenous interferon(s) and / or interferon- like acting substance(s). In other words, preferably the interferon(s) and / or interferon-like acting substance(s) is not an interferon(s) and / or interferon-like acting substance(s) isolated from the subject’s body, i.e. from the individual subject to be treated or prevented. Preferably, the interferon(s) and / or interferon-like acting substance(s) for use according to the present invention and / or the interferon(s) and / or interferon-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be, preferably, is a recombinant interferon(s) and / or interferon-like acting substance(s) which may be generated by any recombinant expression techniques known to the person skilled in the art, a chemically synthesized interferon(s) and / or interferon-like acting substance(s) synthesized by any production techniques known to the person skilled in the art, an artificially produced interferon(s) and / or interferon-like acting substance(s) produced by any production techniques known to the person skilled in the art, a naturally occurring interferon(s) and / or interferon-like acting substance(s) obtained from natural sources like an animal or human, or any combination thereof. More preferably, the interferon(s) and / or interferon-like acting substance(s) is a recombinant interferon(s) and / or interferon-like acting substance(s), chemically synthesized interferon(s) and / or interferon-like acting substance(s), artificially produced interferon(s) and / or interferon-like acting substance(s) or any combination thereof, even more preferably a recombinant interferon(s) and / or interferon-like acting substance(s). Furthermore, the interferon(s) and / or interferon-like acting substance(s) for use according to the present invention and / or the interferon(s) and / or interferon-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may or may not be derivatized, stabilized, fused with other proteins or peptides, conjugated with polymers, contain amino acid analogue(s) or artificial amino acids, modified, covalently or non-covalently, for instance glycosylated or methylated by e.g. posttranslational modification and / or oligomerized, e.g. dimerized or trimerized as long as it is capable of affecting and / or affects LHs, peripheral Tregs or PBMCs. More preferably, the modification pattern and / or oligomerization status is similar or identical to the peptide, protein or any fragment of these naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, in any of the embodiments described herein it is intended to administer the interferon(s) and / or interferon-like acting substance(s) in an amount low enough to avoid a systemic increase of the interferon(s) and / or interferon-like acting substance(s)-concentration in the subject’s body. Hence, the interferon(s) and / or interferon-like acting substance(s)may be administered in an amount that, when scaled to the entire body of the subject, the resulting systemic concentrations remain in the magnitude of the endogenous levels. Thereby, without wishing to be bound to theory, it is believed that the generation of increased interferon(s) and / or interferon-like acting substance(s)-concentration for instance at sites of inflammation, like inflamed joint. As already stated above, for instance naïve T-cells can mature in the presence of antigen / autoantigen / allergen towards cytotoxic, which may act pro- inflammatory. Thereby decreasing, cancelling or even reversing the beneficial effects achieved by the present invention, particularly, the anti-inflammatory effect of the regulatory T-cells and / or helper T-cells, or of a subset thereof, which are presumably generated. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the interferon(s) and / or interferon- like acting substance(s) is administered in an amount that does not cause a systemic increase, more preferably an effective systemic increase, of the concentration of interferon(s) and / or interferon-like acting substance(s) in the subject, preferably the blood of the subject, and / or that causes a systemic increase of the concentration of the interferon(s) and / or interferon-like acting substance(s). Preferably, interferon(s) and / or interferon-like acting substance(s) is administered in an amount low enough that the systemic increase is non-effective. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the interferon(s) and / or interferon- like acting substance(s) is administered in an amount that causes a local increase, preferably an effective local increase, of the concentration of the interferon(s) and / or interferon-like acting substance(s) in the subject, preferably in the skin tissue of the subject. The skin tissue is preferred, because unlike administration into the blood, no or less flushing away and dilution of the interferon(s) and / or interferon-like acting substance(s) takes place. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the generated increased concentration, preferably the generated effective increased concentration of the interferon(s) and / or interferon-like acting substance(s) administered is only local but not systemic in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the interferon(s) and / or interferon- like acting substance(s) is administered in an amount that does not cause a systemic activation, preferably an effective systemic activation, of the respective receptor of the interferon(s) and / or interferon-like acting substance(s) of a cell, and / or that does not cause a systemic generation, preferably an effective systemic generation, of the interferon(s) and / or interferon-like acting substance(s), preferably in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the interferon(s) and / or interferon- like acting substance(s) is administered in an amount that causes a local activation, preferably an effective local activation of the respective receptor of the interferon(s) and / or interferon-like acting substance(s) of a cell, and / or causes a local generation, preferably an effective local generation of the interferon(s) and / or interferon-like acting substance(s), preferably in the subject. Preferably, the activation and / or generation, more preferably the effective generation and / or effective activation is only local but not systemic in the subject. Preferably, the interferon-like acting substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is an interferon and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these and / or is an IFN-γ-like acting substance(s). Preferably, the interferon as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is IFN-γ. More preferably, the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these, even more preferably IFN-γ. The expression “interleukin-like acting substance” or “interleukin-like acting substance(s)” as mentioned in any of the embodiments described herein can be, preferably is, any substance that exerts a similar or identical effect to a interleukin in the body of the subject when administered thereto. The interleukin-like acting substance(s) may encompass precursors, prodrugs and propetides of such substances which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active interleukin-like acting substance(s). Hence, it may be any substance, molecule, peptide, protein, protein-analogue, protein-variant, derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or any derivative, fragment and / or pharmaceutically acceptable salt of any of these. Therefore interleukin-like acting substance(s) may: - activates or is / are capable of activating a respective interleukin-receptor(s) of a cell. The interleukin-receptor(s) may for instance be the receptor of the LHs, peripheral Tregs or PBMCs; and / or - results in or causes or is capable of resulting in or causing the generation of a interleukin(s) and / or a interleukin-like acting substance(s). Preferably, the interleukin-like acting substance(s) activates or is capable of activating the respective interleukin-receptor(s). The activating or the capability of activating the respective interleukin-receptor(s) may be directly and / or it may be indirectly. Preferably, the interleukin-like acting substance(s) activates or is / are capable of activating a respective interleukin-receptor(s) within the skin of the subject. The interleukin-like acting substance(s) may be any naturally occurring or artificial interleukin-like acting substance(s) as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective interleukin-receptor(s). Preferably, the interleukin-like acting substance(s) is known to the person skilled in the art at the effective date of filing of the present invention. Preferably, the interleukin-like acting substance is any peptide, protein, protein-analogue, protein-variant or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. In a preferred embodiment, the interleukin-like acting substance(s) may be as detailed below amongst others an interleukin(s) and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. More preferably, the interleukin-like acting substance(s) is an interleukin(s) and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. The expression “interleukin” or “interleukin(s)” as mentioned in any of the embodiments described herein preferably has to be interpreted broad. Typically, the interleukin(s) activates or is are capable of activating a respective interleukin-receptor(s) of a cell. The interleukin-receptor(s) may for instance be the receptor of the LHs, peripheral Tregs or PBMCs. Preferably, the activating or capability of activating is within the skin of the subject, more preferably locally in effective amounts within the skin of the subject, even more preferably not in amounts systemically effective within the subject’s body. Preferably the interleukin may be any type of interleukin known to the person skilled in the art. Furthermore, the present invention encompass the use or medical use of precursors, prodrugs and propetides of such interleukin(s) which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active interleukin. Hence, these may be used in the method or the medical use as described herein or in preparation of the pharmaceutical compositions, injectable dosage form, topical dosage forms, medical devices and / or kit of parts as described herein. Preferably, the interleukin(s) may be any peptide, protein, protein-analogue, protein-variant or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. The interleukin(s) does not necessarily be derived from or be identical to the interleukin(s) of the same genus and / or species the subject belongs to, it may be any naturally occurring or an artificial interleukin(s), as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective interleukin-receptor(s). Preferably, the biologic activity of the interleukin(s) and / or interleukin-like acting substance(s) is sufficient to achieve the treating and / or preventing of the antisynthetase syndrome, preferably in the subject. An interleukin and / or an interleukin-like acting substance typically affects cells by binding and activating the respective interleukin(s)- receptor on the cells. Hence, the activating of the respective receptor typically leads to the affectation of the cell as described above for the immunomodulatory substance. Hence, any embodiment mentioned herein for the immunomodulatory substance relating to the affecting cells like LHs, peripheral Tregs or PBMCs is independently and mutatis mutandis applicable to the interleukin(s) and the interleukin-like acting substance. The activating or the capability of activating the respective interleukin-receptor(s) by the interleukin(s) and / or interleukin-like acting substance(s) may be directly and / or it may be indirectly. If not mentioned otherwise, the description and definition of the cytokine(s) or the cytokine-like acting substance stated above is independently and mutatis mutandis applicable to the interleukin(s) and / or interleukin-like acting substance(s). Particualry, if not mentioned otherwise, the description and definition of the cytokine(s) or the cytokine-like acting substance in respect of “directly” and “indirectly” activating or capable of activating the respective interleukin-receptor(s), is independently and mutatis mutandis applicable to the interleukin(s) and / or interleukin-like acting substance(s). Preferably, the interleukin(s) and / or interleukin-like acting substance(s) for use according to the present invention and / or the interleukin(s) and / or interleukin-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is capable of affecting and / or affects the LHs, peripheral Tregs or PBMCs . Preferably, the PBMCs are naïve PBMCs, more preferably lymphocytes, even more preferably T-cells and / or B-cells, still more preferably naïve lymphocytes, still even more preferably naïve B-cells and / or naïve T-cells, further preferably naïve T-cells. More preferably, the interleukin(s) and / or interleukin-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs or PBMCs. More preferably, the interleukin(s) and / or interleukin-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs or PBMCs in the subject as defined in any of the embodiments according to the present invention, further preferably within the skin of the subject. If not mentioned otherwise, the description and definition of the immunomodulatory substance(s) stated above is independently and mutatis mutandis applicable to the interleukin(s) and / or interleukin-like acting substance(s). Particualry, if not mentioned otherwise, the description and definition of the immunomodulatory substance(s) in respect of “directly” and “indirectly” affecting or capable of affecting the PBMCs is independently and mutatis mutandis applicable to the interleukin(s) and / or interleukin-like acting substance(s). The interleukin(s) and / or interleukin-like acting substance(s) for use according to the present invention and / or the interleukin(s) and / or interleukin-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be similar or identical, preferably identical, to any interleukin(s) and / or interleukin-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the interleukin(s) and / or interleukin-like acting substance(s) may be similar or identical, preferably identical, to any peptide, protein or any fragment of these of a interleukin(s) and / or interleukin-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. The interleukin(s) and / or interleukin-like acting substance(s) may comprise, preferably consist of an amino acid sequence which has an amino acid sequence identity to any peptide, protein or any fragment of an interleukin(s) and / or interleukin-like acting substance(s) naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the amino acid sequence identity is 70 % or more, even more preferably 85 % or more, still more preferably 90 % or more, still even more preferably 95 % or more, further preferably 97 % or more, even further preferably 98 % or more, still further preferably 99 % or more and 100 % or less. Preferably, the amino acid sequence identity includes substitutions, insertions and / or deletions of amino acid residues in respect to the naturally occurring peptide, protein or any fragment of these. Preferably, the total number of substitutions, insertions and / or deletions or the total number combined of substitutions, insertions and / or deletions of amino acid residues is 60 or less, more preferably 40 or less, even more preferably 20 or less, still more preferably 12 or less, still even more preferably 8 or less, further preferably 4 or less, even further preferably 2 or less and zero or more, still further preferably zero. The interleukin(s) and / or interleukin-like acting substance(s) may be identical to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to or the amino acid sequence identity refers to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to. The expression “is identical” typically means in this particular context that the interleukin(s) and / or interleukin-like acting substance(s) is in respect to its primary, secondary, tertiary and quaternary protein structure identical to an / the interleukin(s) and / or interleukin-like acting substance(s) of the same genus and / or species the subject belongs to, more preferably, also in view of the modification pattern, particularly glycosylations. The interleukin(s) and / or interleukin-like acting substance(s) for use according to the present invention and / or the interleukin(s) and / or interleukin-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be derived from an individual belonging to the same genus and / or species as the subject, or which is identical to an / the interleukin(s) and / or interleukin-like acting substance(s) of the same genus and / or species the subject belongs to. For instance, in case the subject is: a human the interleukin(s) and / or interleukin-like acting substance(s) is human interleukin(s) and / or interleukin-like acting substance(s); a cow the interleukin(s) and / or interleukin-like acting substance(s) is bovine interleukin(s) and / or interleukin-like acting substance(s); a horse the interleukin(s) and / or interleukin-like acting substance(s) is equine interleukin(s) and / or interleukin-like acting substance(s); a donkey the interleukin(s) and / or interleukin-like acting substance(s) is donkey interleukin(s) and / or interleukin-like acting substance(s); an elephant the interleukin(s) and / or interleukin-like acting substance(s) is elephant interleukin(s) and / or interleukin-like acting substance(s); a sheep the interleukin(s) and / or interleukin-like acting substance(s) is sheep interleukin(s) and / or interleukin-like acting substance(s); a goat the interleukin(s) and / or interleukin-like acting substance(s) is goat interleukin(s) and / or interleukin-like acting substance(s); a pig the interleukin(s) and / or interleukin-like acting substance(s) is porcine interleukin(s) and / or interleukin-like acting substance(s); a rabbit the interleukin(s) and / or interleukin-like acting substance(s) is rabbit interleukin(s) and / or interleukin-like acting substance(s); a mouse the interleukin(s) and / or interleukin-like acting substance(s) is mouse interleukin(s) and / or interleukin-like acting substance(s); a rat the interleukin(s) and / or interleukin-like acting substance(s) is rat interleukin(s) and / or interleukin-like acting substance(s); a camel the interleukin(s) and / or interleukin-like acting substance(s) is camel interleukin(s) and / or interleukin-like acting substance(s); a dromedary the interleukin(s) and / or interleukin-like acting substance(s) is dromedary interleukin(s) and / or interleukin-like acting substance(s); a lama the interleukin(s) and / or interleukin-like acting substance(s) is lama interleukin(s) and / or interleukin-like acting substance(s); an alpaca the interleukin(s) and / or interleukin-like acting substance(s) is alpaca interleukin(s) and / or interleukin-like acting substance(s); a dog the interleukin(s) and / or interleukin-like acting substance(s) is dog interleukin(s) and / or interleukin-like acting substance(s); and / or a cat the interleukin(s) and / or interleukin-like acting substance(s) is cat interleukin(s) and / or interleukin-like acting substance(s). Preferably, the interleukin(s) and / or interleukin-like acting substance(s) for use according to the present invention and / or the interleukin(s) and / or interleukin-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is not the subject’s endogenous interleukin(s) and / or interleukin-like acting substance(s). In other words, preferably the interleukin(s) and / or interleukin-like acting substance(s) is not an interleukin(s) and / or interleukin-like acting substance(s) isolated from the subject’s body, i.e. from the individual subject to be treated or prevented. Preferably, the interleukin(s) and / or interleukin-like acting substance(s) for use according to the present invention and / or the interleukin(s) and / or interleukin-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be, preferably, is a recombinant interleukin(s) and / or interleukin-like acting substance(s) which may be generated by any recombinant expression techniques known to the person skilled in the art, a chemically synthesized interleukin(s) and / or interleukin-like acting substance(s) synthesized by any production techniques known to the person skilled in the art, an artificially produced interleukin(s) and / or interleukin-like acting substance(s) produced by any production techniques known to the person skilled in the art, a naturally occurring interleukin(s) and / or interleukin- like acting substance(s) obtained from natural sources like an animal or human, or any combination thereof. More preferably, the interleukin(s) and / or interleukin-like acting substance(s) is a recombinant interleukin(s) and / or interleukin-like acting substance(s), chemically synthesized interleukin(s) and / or interleukin-like acting substance(s), artificially produced interleukin(s) and / or interleukin- like acting substance(s) or any combination thereof, even more preferably a recombinant interleukin(s) and / or interleukin-like acting substance(s). Furthermore, the interleukin(s) and / or interleukin-like acting substance(s) for use according to the present invention and / or the interleukin(s) and / or interleukin-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may or may not be derivatized, stabilized, fused with other proteins or peptides, conjugated with polymers, contain amino acid analogue(s) or artificial amino acids, modified, covalently or non-covalently, for instance glycosylated or methylated by e.g. posttranslational modification and / or oligomerized, e.g. dimerized or trimerized as long as it is capable of affecting and / or affects LHs, peripheral Tregs or PBMCs. More preferably, the modification pattern and / or oligomerization status is similar or identical to the peptide, protein or any fragment of these naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, in any of the embodiments described herein it is intended to administer the interleukin(s) and / or interleukin-like acting substance(s) in an amount low enough to avoid a systemic increase of the interleukin(s) and / or interleukin-like acting substance(s)-concentration in the subject’s body. Hence, the interleukin(s) and / or interleukin-like acting substance(s)may be administered in an amount that, when scaled to the entire body of the subject, the resulting systemic concentrations remain in the magnitude of the endogenous levels. Thereby, without wishing to be bound to theory, it is believed that the generation of an increased interleukin(s) and / or interleukin-like acting substance(s)-concentration for instance at sites of inflammation, like inflamed joint. As already stated above, for instance naïve T-cells can mature in the presence of antigen / autoantigen / allergen towards cytotoxic, which may act pro-inflammatory. Thereby decreasing, cancelling or even reversing the beneficial effects achieved by the present invention, particularly, the anti-inflammatory effect of the regulatory T-cells and / or helper T-cells, or of a subset thereof, which are presumably generated. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the interleukin(s) and / or interleukin- like acting substance(s) is administered in an amount that does not cause a systemic increase, more preferably an effective systemic increase, of the concentration of interleukin(s) and / or interleukin-like acting substance(s) in the subject, preferably the blood of the subject, and / or that causes a systemic increase of the concentration of the interleukin(s) and / or interleukin-like acting substance(s). Preferably, interleukin(s) and / or interleukin-like acting substance(s) is administered in an amount low enough that the systemic increase is non-effective. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the interleukin(s) and / or interleukin- like acting substance(s) is administered in an amount that causes a local increase, preferably an effective local increase, of the concentration of the interleukin(s) and / or interleukin-like acting substance(s) in the subject, preferably in the skin tissue of the subject. The skin tissue is preferred, because unlike administration into the blood, no or less flushing away and dilution of the interleukin(s) and / or interleukin-like acting substance(s) takes place. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the generated increased concentration, preferably the generated effective increased concentration of the interleukin(s) and / or interleukin-like acting substance(s) administered is only local but not systemic in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the interleukin(s) and / or interleukin- like acting substance(s) is administered in an amount that does not cause a systemic activation, preferably an effective systemic activation, of the respective receptor of the interleukin(s) and / or interleukin-like acting substance(s) of a cell, and / or that does not cause a systemic generation, preferably an effective systemic generation, of the interleukin(s) and / or interleukin-like acting substance(s), preferably in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the interleukin(s) and / or interleukin- like acting substance(s) is administered in an amount that causes a local activation, preferably an effective local activation of the respective receptor of the interleukin(s) and / or interleukin-like acting substance(s) of a cell, and / or causes a local generation, preferably an effective local generation of the interleukin(s) and / or interleukin-like acting substance(s), preferably in the subject. Preferably, the activation and / or generation, more preferably the effective generation and / or effective activation is only local but not systemic in the subject. Preferably, the interleukin-like acting substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is an interleukin and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these and / or is an IL-2-like acting substance(s) and / or an IL-4-like acting substance(s). Preferably, the interleukin as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is IL-2 and / or IL-4. More preferably, the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is IL-2 and / or IL-4 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these, even more preferably IL-2 and / or IL-4. The expression “neurotrophine-like acting substance” or “neurotrophine-like acting substance(s)” as mentioned in any of the embodiments described herein can be, preferably is, any substance that exerts a similar or identical effect to a neurotrophine in the body of the subject when administered thereto. The neurotrophine-like acting substance(s) may encompass precursors, prodrugs and propetides of such substances which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active neurotrophine-like acting substance(s). Hence, it may be any substance, molecule, peptide, protein, protein-analogue, protein-variant, derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or any derivative, fragment and / or pharmaceutically acceptable salt of any of these. Therefore neurotrophine-like acting substance(s) may: - activates or is / are capable of activating a respective neurotrophine-receptor(s) of a cell. The neurotrophine-receptor(s) may for instance be the receptor of the LHs, peripheral Tregs or PBMCs; and / or - results in or causes or is capable of resulting in or causing the generation of a neurotrophine(s) and / or a neurotrophine-like acting substance(s). Preferably, the neurotrophine-like acting substance(s) activates or is capable of activating the respective neurotrophine-receptor(s). The activating or the capability of activating the respective neurotrophine-receptor(s) may be directly and / or it may be indirectly. Preferably, the neurotrophine-like acting substance(s) activates or is / are capable of activating a respective neurotrophine-receptor(s) within the skin of the subject. The neurotrophine-like acting substance(s) may be any naturally occurring or artificial neurotrophine- like acting substance(s) as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective neurotrophine-receptor(s). Preferably, the neurotrophine-like acting substance(s) is known to the person skilled in the art at the effective date of filing of the present invention. Preferably, the neurotrophine-like acting substance is any peptide, protein, protein-analogue, protein-variant or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. In a preferred embodiment, the neurotrophine-like acting substance(s) may be as detailed below amongst others a neurotrophine(s) and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. More preferably, the neurotrophine-like acting substance(s) is a neurotrophine(s) and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. The expression “neurotrophine” or “neurotrophine(s)” as mentioned in any of the embodiments described herein preferably has to be interpreted broad. Typically, the neurotrophine(s) activates or is are capable of activating a respective neurotrophine-receptor(s) of a cell. The neurotrophine-receptor(s) may for instance be the receptor of the LHs, peripheral Tregs or PBMCs. Preferably, the activating or capability of activating is within the skin of the subject, more preferably locally in effective amounts within the skin of the subject, even more preferably not in amounts systemically effective within the subject’s body. Preferably the neurotrophine may be any type of neurotrophine known to the person skilled in the art. Furthermore, the present invention encompass the use or medical use of precursors, prodrugs and propetides of such neurotrophine(s) which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active neurotrophine. Hence, these may be used in the method or the medical use as described herein or in preparation of the pharmaceutical compositions, injectable dosage form, topical dosage forms, medical devices and / or kit of parts as described herein. The neurotrophine(s) may be any peptide, protein, protein-analogue, protein-variant or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. The neurotrophine(s) does not necessarily be derived from or be identical to the neurotrophine(s) of the same genus and / or species the subject belongs to, it may be any naturally occurring or an artificial neurotrophine(s), as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective neurotrophine-receptor(s). Preferably, the biologic activity of the neurotrophine(s) and / or neurotrophine-like acting substance(s) is sufficient to achieve the treating and / or preventing of the antisynthetase syndrome, preferably in the subject. A neurotrophine and / or an neurotrophine-like acting substance typically affects cells by binding and activating the respective neurotrophine(s)-receptor on the cells. Hence, the activating of the respective receptor typically leads to the affectation of the cell as described above for the immunomodulatory substance. Hence, any embodiment mentioned herein for the immunomodulatory substance relating to the affecting cells like LHs, peripheral Tregs or PBMCs is independently and mutatis mutandis applicable to the neurotrophine(s) and the neurotrophine-like acting substance. The activating or the capability of activating the respective neurotrophine-receptor(s) by the neurotrophine(s) and / or neurotrophine- like acting substance(s) may be directly and / or it may be indirectly. If not mentioned otherwise, the description and definition of the cytokine(s) or the cytokine-like acting substance stated above is independently and mutatis mutandis applicable to the neurotrophine(s) and / or neurotrophine-like acting substance(s). Particulary, if not mentioned otherwise, the description and definition of the cytokine(s) or the cytokine-like acting substance in respect of “directly” and “indirectly” activating or capable of activating the respective neurotrophine-receptor(s), is independently and mutatis mutandis applicable to the neurotrophine(s) and / or neurotrophine-like acting substance(s). Preferably, the neurotrophine(s) and / or neurotrophine-like acting substance(s) for use according to the present invention and / or the neurotrophine(s) and / or neurotrophine-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is capable of affecting and / or affects the LHs, peripheral Tregs or PBMCs. Preferably, the PBMCs are naïve PBMCs, more preferably lymphocytes, even more preferably T-cells and / or B-cells, still more preferably naïve lymphocytes, still even more preferably naïve B-cells and / or naïve T-cells, further preferably naïve T-cells. More preferably, the neurotrophine(s) and / or neurotrophine-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs or PBMCs. More preferably, the neurotrophine(s) and / or neurotrophine-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs or PBMCs in the subject as defined in any of the embodiments according to the present invention, further preferably within the skin of the subject. If not mentioned otherwise, the description and definition of the immunomodulatory substance(s) stated above is independently and mutatis mutandis applicable to the neurotrophine(s) and / or neurotrophine-like acting substance(s). Particualry, if not mentioned otherwise, the description and definition of the immunomodulatory substance(s) in respect of “directly” and “indirectly” affecting or capable of affecting the PBMCs is independently and mutatis mutandis applicable to the neurotrophine(s) and / or neurotrophine-like acting substance(s). The neurotrophin(s) and / or neurotrophin-like acting substance(s) for use according to the present invention and / or the neurotrophin(s) and / or neurotrophin-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be similar or identical, preferably identical, to any neurotrophin(s) and / or neurotrophin-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the neurotrophin(s) and / or neurotrophin-like acting substance(s) may besimilar or identical, preferably identical, to any peptide, protein or any fragment of these of a neurotrophin(s) and / or neurotrophin-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. The neurotrophin(s) and / or neurotrophin-like acting substance(s) may comprise, preferably consist of an amino acid sequence which has an amino acid sequence identity to any peptide, protein or any fragment of an neurotrophin(s) and / or neurotrophin-like acting substance(s) naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the amino acid sequence identity is 70 % or more, even more preferably 85 % or more, still more preferably 90 % or more, still even more preferably 95 % or more, further preferably 97 % or more, even further preferably 98 % or more, still further preferably 99 % or more and 100 % or less. Preferably, the amino acid sequence identity includes substitutions, insertions and / or deletions of amino acid residues in respect to the naturally occurring peptide, protein or any fragment of these. Preferably, the total number of substitutions, insertions and / or deletions or the total number combined of substitutions, insertions and / or deletions of amino acid residues is 60 or less, more preferably 40 or less, even more preferably 20 or less, still more preferably 12 or less, still even more preferably 8 or less, further preferably 4 or less, even further preferably 2 or less and zero or more, still further preferably zero. The neurotrophin(s) and / or neurotrophin-like acting substance(s) may be identical to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to or the amino acid sequence identity refers to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to. The expression “is identical” typically means in this particular context that the neurotrophin(s) and / or neurotrophin-like acting substance(s) is in respect to its primary, secondary, tertiary and quaternary protein structure identical to an / the neurotrophin(s) and / or neurotrophin-like acting substance(s) of the same genus and / or species the subject belongs to, more preferably, also in view of the modification pattern, particularly glycosylations. The neurotrophin(s) and / or neurotrophin-like acting substance(s) for use according to the present invention and / or the neurotrophin(s) and / or neurotrophin-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be derived from an individual belonging to the same genus and / or species as the subject, or which is identical to an / the neurotrophin(s) and / or neurotrophin-like acting substance(s) of the same genus and / or species the subject belongs to. For instance, in case the subject is: a human the neurotrophin(s) and / or neurotrophin- like acting substance(s) is human neurotrophin(s) and / or neurotrophin-like acting substance(s); a cow the neurotrophin(s) and / or neurotrophin-like acting substance(s) is bovine neurotrophin(s) and / or neurotrophin-like acting substance(s); a horse the neurotrophin(s) and / or neurotrophin-like acting substance(s) is equine neurotrophin(s) and / or neurotrophin-like acting substance(s); a donkey the neurotrophin(s) and / or neurotrophin-like acting substance(s) is donkey neurotrophin(s) and / or neurotrophin-like acting substance(s); an elephant the neurotrophin(s) and / or neurotrophin-like acting substance(s) is elephant neurotrophin(s) and / or neurotrophin-like acting substance(s); a sheep the neurotrophin(s) and / or neurotrophin-like acting substance(s) is sheep neurotrophin(s) and / or neurotrophin-like acting substance(s); a goat the neurotrophin(s) and / or neurotrophin-like acting substance(s) is goat neurotrophin(s) and / or neurotrophin-like acting substance(s); a pig the neurotrophin(s) and / or neurotrophin-like acting substance(s) is porcine neurotrophin(s) and / or neurotrophin-like acting substance(s); a rabbit the neurotrophin(s) and / or neurotrophin-like acting substance(s) is rabbit neurotrophin(s) and / or neurotrophin-like acting substance(s); a mouse the neurotrophin(s) and / or neurotrophin- like acting substance(s) is mouse neurotrophin(s) and / or neurotrophin-like acting substance(s); a rat the neurotrophin(s) and / or neurotrophin-like acting substance(s) is rat neurotrophin(s) and / or neurotrophin-like acting substance(s); a camel the neurotrophin(s) and / or neurotrophin-like acting substance(s) is camel neurotrophin(s) and / or neurotrophin-like acting substance(s); a dromedary the neurotrophin(s) and / or neurotrophin-like acting substance(s) is dromedary neurotrophin(s) and / or neurotrophin-like acting substance(s); a lama the neurotrophin(s) and / or neurotrophin-like acting substance(s) is lama neurotrophin(s) and / or neurotrophin-like acting substance(s); an alpaca the neurotrophin(s) and / or neurotrophin-like acting substance(s) is alpaca neurotrophin(s) and / or neurotrophin-like acting substance(s); a dog the neurotrophin(s) and / or neurotrophin-like acting substance(s) is dog neurotrophin(s) and / or neurotrophin-like acting substance(s); and / or a cat the neurotrophin(s) and / or neurotrophin-like acting substance(s) is cat neurotrophin(s) and / or neurotrophin-like acting substance(s). Preferably, the neurotrophin(s) and / or neurotrophin-like acting substance(s) for use according to the present invention and / or the neurotrophin(s) and / or neurotrophin-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is not the subject’s endogenous neurotrophin(s) and / or neurotrophin-like acting substance(s). In other words, preferably the neurotrophin(s) and / or neurotrophin-like acting substance(s) is not an neurotrophin(s) and / or neurotrophin-like acting substance(s) isolated from the subject’s body, i.e. from the individual subject to be treated or prevented. Preferably, the neurotrophin(s) and / or neurotrophin-like acting substance(s) for use according to the present invention and / or the neurotrophin(s) and / or neurotrophin-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be, preferably, is a recombinant neurotrophin(s) and / or neurotrophin-like acting substance(s) which may be generated by any recombinant expression techniques known to the person skilled in the art, a chemically synthesized neurotrophin(s) and / or neurotrophin-like acting substance(s) synthesized by any production techniques known to the person skilled in the art, an artificially produced neurotrophin(s) and / or neurotrophin-like acting substance(s) produced by any production techniques known to the person skilled in the art, a naturally occurring neurotrophin(s) and / or neurotrophin-like acting substance(s) obtained from natural sources like an animal or human, or any combination thereof. More preferably, the neurotrophin(s) and / or neurotrophin-like acting substance(s) is a recombinant neurotrophin(s) and / or neurotrophin-like acting substance(s), chemically synthesized neurotrophin(s) and / or neurotrophin-like acting substance(s), artificially produced neurotrophin(s) and / or neurotrophin-like acting substance(s) or any combination thereof, even more preferably a recombinant neurotrophin(s) and / or neurotrophin-like acting substance(s). Furthermore, the neurotrophin(s) and / or neurotrophin-like acting substance(s) for use according to the present invention and / or the neurotrophin(s) and / or neurotrophin-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may or may not be derivatized, stabilized, fused with other proteins or peptides, conjugated with polymers, contain amino acid analogue(s) or artificial amino acids, modified, covalently or non-covalently, for instance glycosylated or methylated by e.g. posttranslational modification and / or oligomerized, e.g. dimerized or trimerized as long as it is capable of affecting and / or affects LHs, peripheral Tregs or PBMCs. More preferably, the modification pattern and / or oligomerization status is similar or identical to the peptide, protein or any fragment of these naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, in any of the embodiments described herein it is intended to administer the neurotrophin(s) and / or neurotrophin-like acting substance(s) in an amount low enough to avoid a systemic increase of the neurotrophin(s) and / or neurotrophin-like acting substance(s)-concentration in the subject’s body. Hence, the neurotrophin(s) and / or neurotrophin-like acting substance(s) may be administered in an amount that, when scaled to the entire body of the subject, the resulting systemic concentrations remain in the magnitude of the endogenous levels. Thereby, without wishing to be bound to theory, it is believed that the generation of an increased neurotrophin(s) and / or neurotrophin-like acting substance(s)-concentration for instance at sites of inflammation, like inflamed joint. As already stated above, for instance naïve T-cells can mature in the presence of antigen / autoantigen / allergen towards cytotoxic, which may act pro-inflammatory. Thereby decreasing, cancelling or even reversing the beneficial effects achieved by the present invention, particularly, the anti-inflammatory effect of the regulatory T-cells and / or helper T-cells, or of a subset thereof, which are presumably generated. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the neurotrophin(s) and / or neurotrophin-like acting substance(s) is administered in an amount that does not cause a systemic increase, more preferably an effective systemic increase, of the concentration of neurotrophin(s) and / or neurotrophin-like acting substance(s) in the subject, preferably the blood of the subject, and / or that causes a systemic increase of the concentration of the neurotrophin(s) and / or neurotrophin-like acting substance(s). Preferably, neurotrophin(s) and / or neurotrophin-like acting substance(s) is administered in an amount low enough that the systemic increase is non-effective. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the neurotrophin(s) and / or neurotrophin-like acting substance(s) is administered in an amount that causes a local increase, preferably an effective local increase, of the concentration of the neurotrophin(s) and / or neurotrophin-like acting substance(s) in the subject, preferably in the skin tissue of the subject. The skin tissue is preferred, because unlike administration into the blood, no or less flushing away and dilution of the neurotrophin(s) and / or neurotrophin-like acting substance(s) takes place. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the generated increased concentration, preferably the generated effective increased concentration of the neurotrophin(s) and / or neurotrophin-like acting substance(s) administered is only local but not systemic in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the neurotrophin(s) and / or neurotrophin-like acting substance(s) is administered in an amount that does not cause a systemic activation, preferably an effective systemic activation, of the respective receptor of the neurotrophin(s) and / or neurotrophin-like acting substance(s) of a cell, and / or that does not cause a systemic generation, preferably an effective systemic generation, of the neurotrophin(s) and / or neurotrophin-like acting substance(s), preferably in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the neurotrophin(s) and / or neurotrophin-like acting substance(s) is administered in an amount that causes a local activation, preferably an effective local activation of the respective receptor of the neurotrophin(s) and / or neurotrophin-like acting substance(s) of a cell, and / or causes a local generation, preferably an effective local generation of the neurotrophin(s) and / or neurotrophin-like acting substance(s), preferably in the subject. Preferably, the activation and / or generation, more preferably the effective generation and / or effective activation is only local but not systemic in the subject. Preferably, the neurotrophin-like acting substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is a neurotrophin, a BDNF-like acting substance(s) and / or a NGF-like acting substance(s), more preferably a neurotrophin and / or a BDNF-like acting substance(s). Preferably, the neurotrophin as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is BDNF and / or NGF (nerve growth factor), more preferably BDNF. More preferably, the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is BDNF, NGF (nerve growth factor) and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these, even more preferably BDNF. The “skin-conditioning agent” the as mentioned in any of the embodiments described herein, specifically the skin-conditioning agent for use according to the present invention and / or the skin-conditioning agent administered in step (A) may be, preferably is any type or kind of substance(s), composition or formulation suitable for modifying a condition of the skin particularly in respect of the amount of PBMCs, the vasodilation of the capillaries within the skin, the blood volume within the skin, the sO2 within the skin, the rHb within the skin, the temperature on the skin and / or the redness on the skin. More preferably, the skin-conditioning agent preferably is any type or kind of substance(s), composition or formulation suitable to generate and / or generates: - an accumulation of PBMCs within the skin, wherein it is to be understood that preferably any embodiment or definition thereof which is described under the outline note ‘As further regards step (A-0) for any of the embodiments as described herein’ is independently and mutatis mutandis applicable; and / or - a vasodilation of the capillaries within the skin, wherein it is to be understood that preferably any embodiment or definition thereof which is described under the outline note ‘As further regards step (A-1) for any of the embodiments as described herein’ is independently and mutatis mutandis applicable; and / or - an increased blood volume within the skin, wherein it is to be understood that preferably any embodiment or definition thereof which is described under the outline note ‘As further regards step (A-2) for any of the embodiments as described herein’ is independently and mutatis mutandis applicable; and / or - an increased sO2 (oxygen saturation of haemoglobin) and / or an increased rHb (relative haemoglobin amount) within the skin, wherein it is to be understood that preferably any embodiment or definition thereof which is described under the outline note ‘As further regards step (A-3) for any of the embodiments as described herein’ is independently and mutatis mutandis applicable; and / or - an increased temperature on the skin, wherein it is to be understood that preferably any embodiment or definition thereof which is described under the outline note ‘As further regards step (A-4) for any of the embodiments as described herein’ is independently and mutatis mutandis applicable; and / or - a redness on the skin, wherein it is to be understood that preferably any embodiment or definition thereof which is described under the outline note ‘As further regards step (A-5) for any of the embodiments as described herein’ is independently and mutatis mutandis applicable. Even more preferably, the skin-conditioning agent is suitable and / or sufficient to generate and / or generates the vasodilation of the capillaries within the skin, the increased blood volume within the skin, the increased sO2 and / or an increased rHb within the skin and / or the increased temperature on the skin. Still more preferably, the vasodilation of the capillaries within the skin, the increased sO2and / or the increased rHb within the skin, and / or the increased temperature on the skin. Still even more preferably, the increased sO2 and / or the increased rHb within the skin, and / or the increased temperature on the skin. More preferably, the skin-conditioning agent does not cause an allergic reaction in the subject. Preferably, the skin-conditioning agent is any blood-circulation-increasing agent, vasodilating agent, skin-temperature increasing agent, skin-sO2-increasing agent and / or skin-rHb-increasing agent. Examples for the skin-conditioning agent comprise nitrates, alpha blockers, ACE-inhibitors, ginkgo preparations like gingko balm, calcium antagonists, dihydralazine, minoxidil, dihydroergotoxin, nicotinic acid analogues, vasodilators like methylnicotinat, moxa herbs, capsaicine, and / or pentoxifylline, a heat crème, a vasodilator containing crème, a methylnicotinat containing crème, particularly Kytta® heat balm (Kytta® heat balm containing methylnicotinat [“Kytta® heat balm” by P&G Health Germany GmbH, Germany, PZN 12358936]) or any combination thereof. Preferably, the skin- conditioning agent comprises as active ingredient(s), preferably consists of as active ingredient(s) of, nitrates, alpha blockers, ACE-inhibitors, ginkgo preparations like gingko balm, calcium antagonists, dihydralazine, minoxidil, dihydroergotoxin, nicotinic acid analogues, vasodilators like methylnicotinat, moxa herbs, capsaicine, pentoxifylline, vasodilator containing crème, methylnicotinat containing crème, Kytta® heat balm or any combination thereof, more preferably methylnicotinat containing crème and / or methylnicotinat, even more preferably Kytta® heat balm and / or methylnicotinat. Preferably, the skin-conditioning agent is in the form of any of the pharmaceutical compositions, the injectable dosage forms, the topical dosage forms, medical devices and / or the kits of parts according to the present invention or as mentioned in any of the embodiments described herein. Preferably, the blood-circulation-increasing agent is an agent suitable for increasing and / or increasing the blood volume within the skin, i.e. a blood-volume increasing agent. Even more preferably, the blood-circulation-increasing agent is a blood-volume increasing agent. It is to be understood, that the expression: “[…] wherein the method comprises, preferably consists of, the steps of: is equivalent in its meaning and can be used interchangeably with the expression: “[…] wherein the method comprises a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs (peripheral blood mononuclear cells) within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2 (oxygen saturation of haemoglobin) within the skin and / or an increased rHb (relative haemoglobin amount) within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, As already stated above, the present invention relates to an immunomodulatory substance(s) and / or a skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises, preferably consists of, the steps of: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B) administering the immunomodulatory substance(s) to the skin of said subject, or wherein the method comprises, preferably consists of, the steps of: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (C) administering the immunomodulatory substance(s) to the skin of said subject, or wherein the method comprises, preferably consists of, the steps of: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B) administering the immunomodulatory substance(s) to the skin of said subject; and (C) administering the immunomodulatory substance(s) to the skin of the subject, wherein the immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B), and to any of said methods as such. Preferably, the present invention relates to an immunomodulatory substances and / or a skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein step (B) is performed a second time as (B1), wherein the method comprises, preferably consists of, the steps of: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B) administering the immunomodulatory substance(s) to the skin of said subject; and (B1) administering the immunomodulatory substance(s) to the skin of said subject, wherein the immunomodulatory substance(s) administered in step (B1) is different from the immunomodulatory substance(s) administered in step (B). More preferably, the present invention relates to an immunomodulatory substances and / or a skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises, preferably consists of, the steps of: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B) administering the immunomodulatory substance(s) to the skin of said subject; and (B1) administering the immunomodulatory substance(s) to the skin of said subject; and (C) administering the immunomodulatory substance(s) to the skin of said subject, wherein the immunomodulatory substance(s) administered in step (B), step (B1) and step (C) are different from each other. Even more preferably, the present invention relates to an immunomodulatory substances and / or a skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, and the method comprises, preferably consists of: a first set of steps, comprising, preferably, consisting of: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B) administering the immunomodulatory substance(s) to the skin of said subject; and (C) administering the immunomodulatory substance(s) to the skin of the subject, and a second set of steps comprising, preferably consisting of: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B1) administering the immunomodulatory substance(s) to the skin of said subject; and (C) administering the immunomodulatory substance(s) to the skin of the subject, wherein the immunomodulatory substance(s) administered in step (B1) is different from the immunomodulatory substance(s) administered in step (B), and wherein the immunomodulatory substance(s) administered in each of steps (C) is different from the immunomodulatory substance(s) administered in step (B) and step (B1). Preferably, the immunomodulatory substance(s) administered in each of steps (C) are the same or different, more preferably are the same. If not mentioned otherwise, it is to be understood that any embodiment of step (A) described herein is independently applicable to each of steps (A). Hence, step (A) of the first set of steps may or may not be performed the same as step (A) of the second set of steps, for instance in respect to the way of administering a skin-conditioning agent, the used concentration, whether administered by topical application or by injection, the site of the skin area on the patients bod and / or the size of the skin area, etc. More preferably, steps (A) are all performed by topical application or by injection. If not mentioned otherwise, it is to be understood that any embodiment of step (C) described herein is independently applicable to each of steps (C). Hence, step (C) of the first set of steps may or may not be performed the same as step (C) of the second set of steps, for instance in respect to the type of immunomodulatory substance(s), the used concentration, whether administered by topical application or by injection, the size of the skin area etc. More preferably, steps (C) are performed the same. Hence, in step (C) of the first set of steps, for instance, the administration of the immunomodulatory substance(s) may be applied by injection while in step (C) of the second set of steps an administration by topical application may be used. More preferably, the present invention relates to an immunomodulatory substance(s) and / or a skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises, preferably consists of, the steps of: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B) administering the immunomodulatory substance(s) to the skin of said subject, or even more preferably, wherein the method comprises, preferably consists of, the steps of: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B) administering the immunomodulatory substance(s) to the skin of said subject; and (C) administering the immunomodulatory substance(s) to the skin of the subject, wherein the immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B), and to any of said methods as such. Hence, more preferably the immunomodulatory substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is: the cytokine-like acting substance(s); even more preferably the immune-related cytokine-like acting substance(s); still more preferably the interferon-like acting substance(s), interleukin-like acting substance(s) and / or neurotrophin-like acting substance(s); still even more preferably the IFN-γ-like acting substance(s), IL-4-like acting substance(s), BDNF-like acting substance(s) and / or IL-2-like acting substance(s),; further preferably the IFN-γ-like acting substance(s), IL-4-like acting substance(s) and / or BDNF-like acting substance(s); even further the IFN-γ-like acting substance(s), IL-4-like acting substance(s) and / or IL-2-like acting substance(s), or IL-4-like acting substance(s), BDNF-like acting substance(s) and / or IL-2-like acting substance(s); still further preferably the IFN-γ-like acting substance(s) and / or the IL-4-like acting substance(s); or the IL-4-like acting substance(s) and / or the BDNF-like acting substance(s); still even further preferably the IFN-γ-like acting substance(s) and / or the IL-2-like acting substance(s); or the IL-4-like acting substance(s) and / or the BDNF-like acting substance(s); furthermore preferably the IFN-γ-like acting substance(s); or the IL-4-like acting substance(s) and / or BDNF-like acting substance(s); or the IL-2-like acting substance(s). Even more preferably, the immunomodulatory substance(s) as mentioned in any of the embodiments described herein, specifically the immunomodulatory substance(s) for use according to the present invention and / or the immunomodulatory substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is the cytokine(s); still more preferably the immune-related cytokine(s); still even more preferably the interferon(s), interleukin(s) and / or neurotrophin(s); further preferably the IFN-γ, IL-4, BDNF and / or IL-2; even further preferably the IFN-γ, IL-4 and / or BDNF; still further preferably the IFN-γ, IL-4 and / or IL-2; or the IL-4, BDNF and / or IL-2; still even further preferably the IFN-γ and / or IL-4; or the IL-4 and / or BDNF; furthermore preferably the IFN-γ and / or IL-2; or the IL-4 and / or BDNF; even furthermore preferably the IFN-γ; or the IL-4 and / or BDNF; or the IL-2, and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. For the sake of simplicity and clarity, the following embodiments were only written out in full length for the cytokine(s), interferon(s), interleukin(s), neurotrophin(s), IFN-γ, IL-4, BDNF and / or IL-2. If not mentioned otherwise, it is to be understood that any of the embodiments of the present invention stated generally herein for the cytokine(s), interferon(s), interleukin(s), neurotrophin(s), IFN-γ, IL-4, BDNF and / or IL-2 and particularly in the following paragraphs in terms of: - the method comprising steps (A) and (C); steps (A), (B) and (C), steps (A) and (B); steps (A) and (B), wherein step (B) is performed a second time as (B1); or a first set of steps (A), (B) and (C) and a second set of steps (A), (B1) and (C); and / or - the particular antisynthetase syndrome to be treated and / or prevented; and / or - any combination of any of these, is independently and mutatis mutandis applicable to the cytokine-like acting substance(s), interferon-like acting substance(s), interleukin-like acting substance(s), neurotrophin-like acting substance(s), IFN-γ-like acting substance(s), IL-2-like acting substance(s), IL-4-like acting substance(s) and / or BDNF-like acting substance(s), wherein for that reason, where applicable, the term ‘cytokine(s)’ is to be understood ‘cytokine-like acting substance(s)’, ‘interferon(s)’ is to be understood ‘interferon-like acting substance(s)’, ‘interleukin(s)’ is to be understood ‘interleukin-like acting substance(s)’, ‘neurotrophin(s)’ is to be understood ‘neurotrophin-like acting substance(s)’, ‘IFN-γ’ is to be understood ‘IFN-γ-like acting substance(s)’, ‘IL-4’ is to be understood ‘IL-4- like acting substance(s)’, ‘BDNF’ is to be understood ‘BDNF-like acting substance(s)’ and ‘IL-2’ is to be understood ‘IL-2-like acting substance(s)’. Preferably, in one particular embodiment all of such terms are replaced or all of such terms remain unchanged, however, not some replaced and some not. The embodiments referring to cytokine(s), interferon(s), neurotrophin(s), interleukin(s), IFN-γ, IL-4, BDNF, IL-2 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of theseare more preferred. The embodiments referring to cytokine(s), interferon(s), neurotrophin(s), interleukin(s), IFN-γ, IL-4, BDNF and / or IL-2 are even more preferred. Preferably, - the method comprises steps (A) and (C); - the immunomodulatory substance(s) for use according to the present invention is any of the immunomodulatory substance(s) as described herein, that is the immunomodulatory substance(s) including IL-2, preferably a cytokine(s) including IL-2, more preferably an interferon(s), neurotrophin(s) and / or interleukin(s) including IL-2, even more preferably IL-2; and - the immunomodulatory substance(s) in step (C) is IL-2, or - the method comprises steps (A), (B) and (C); - the immunomodulatory substance(s) for use according to the present invention is any of the immunomodulatory substance(s) as described herein, that is the immunomodulatory substance(s) including IL-2, preferably a cytokine(s) including IL-2, more preferably an interferon(s), neurotrophin(s) and / or interleukin(s) including IL-2, even more preferably IL-2; - the immunomodulatory substance(s) in step (B) is any of the immunomodulatory substance(s) as described herein except for IL-2; and - the immunomodulatory substance(s) in step (C) is IL-2, or - the method comprises steps (A) and (B); - the immunomodulatory substance(s) for use according to the present invention is IFN-γ, IL-4 and / or BDNF, preferably IFN-γ and / or IL-4; and - the immunomodulatory substance(s) in step (B) is IFN-γ and / or IL-4, or IL-4 and / or BDNF; preferably is IFN-γ, or is IL-4 and / or BDNF; more preferably is IFN-γ or IL-4, or - the method comprises steps (A), (B) and (C); - the immunomodulatory substance(s) for use according to the present invention is IFN-γ, IL-4, BDNF and / or IL-2; - the immunomodulatory substance(s) in step (B) is IFN-γ and / or IL-4, or IL-4 and / or BDNF; preferably is IFN-γ, or IL-4 and / or BDNF; more preferably is IFN-γ or IL-4; and - the immunomodulatory substance(s) in step (C) is IL-2. Even more preferably, the method comprises steps (A), (B) and (C); - the immunomodulatory substance(s) for use according to the present invention is IFN-γ and / or IL-2; - the immunomodulatory substance(s) in step (B) is IFN-γ; and - the immunomodulatory substance(s) in step (C) is IL-2, or - the immunomodulatory substance(s) for use according to the present invention is IL-4 and / or IL-2; - the immunomodulatory substance(s) in step (B) is IL-4; and - the immunomodulatory substance(s) in step (C) is IL-2, or the method comprises steps (A) and (B), wherein step (B) is performed a second time as (B1); - the immunomodulatory substance(s) for use according to the present invention is IFN-γ and / or IL-4; - the immunomodulatory substance(s) in step (B) is IFN-γ; and - the immunomodulatory substance(s) in step (B1) is IL-4, or - the immunomodulatory substance(s) for use according to the present invention is IL-4 and / or BDNF; - the immunomodulatory substance(s) in step (B) is IL-4; and - the immunomodulatory substance(s) in step (B1) is BDNF. The embodiment, in which the method comprises steps (A), (B) and (C) is still more preferred. If not mentioned otherwise, it is to be understood that any embodiment or definition described herein in terms of step (B) is independently and mutatis mutandis applicable to step (B1) as mentioned in any of the embodiments described herein. Still even more preferably, the method comprises steps (A), (B), (B1) and (C); - the immunomodulatory substance(s) for use according to the present invention is IFN-γ, IL-4 and / or IL-2; - the immunomodulatory substance(s) in step (B) is IFN-γ; - the immunomodulatory substance(s) in step (B1) is IL-4; and - the immunomodulatory substance(s) in step (C) is IL-2, or - the immunomodulatory substance(s) for use according to the present invention is IL-4, BDNF and / or IL-2; - the immunomodulatory substance(s) in step (B) is IL-4; - the immunomodulatory substance(s) in step (B1) is BDNF; and - the immunomodulatory substance(s) in step (C) is IL-2. Further preferably, - the immunomodulatory substance(s) for use according to the present invention is IFN-γ, IL-4 and / or IL-2, and the method comprises: a first set of steps, comprising: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B) administering IFN-γ to the skin of said subject; and (C) administering IL-2 to the skin of the subject, and a second set of steps comprising: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B1) administering IL-4 to the skin of said subject; and (C) administering IL-2 to the skin of the subject, or - the immunomodulatory substance(s) for use according to the present invention is IL-4, BDNF and / or IL-2, and the method comprises a first set of steps, comprising: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B) administering IL-4 to the skin of said subject; and (C) administering IL-2 to the skin of the subject, and a second set of steps comprising: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B1) administering BDNF to the skin of said subject; and (C) administering IL-2 to the skin of the subject. In any of the embodiments described herein comprising steps (A) and (B), still further preferably, - the immunomodulatory substance(s) for use according to the present invention is an interferon(s), neurotrophin(s) and / or interleukin(s); - the immunomodulatory substance(s) in step (B) is the interferon(s), neurotrophin(s) and / or interleukin(s), still even further preferably, - the immunomodulatory substance(s) for use according to the present invention is IFN-γ, IL-4 and / or BDNF; and - the immunomodulatory substance(s) in step (B) is IFN-γ, IL-4 and / or BDNF, furthermore preferably, - the immunomodulatory substance(s) for use according to the present invention is IFN-γ and / or IL-4 or IL-4 and / or BDNF; and - the immunomodulatory substance(s) in step (B) is IFN-γ and / or IL-4 or is IL-4 and / or BDNF, even furthermore preferably, - the immunomodulatory substance(s) for use according to the present invention is IFN-γ, IL-4 and / or BDNF; and - the immunomodulatory substance(s) in step (B) is IFN-γ and / or IL-4 or is IL-4 and / or BDNF, still furthermore preferably, - the immunomodulatory substance(s) for use according to the present invention is IFN-γ or IL-4; and - the immunomodulatory substance(s) in step (B) is IFN-γ or IL-4, still even furthermore preferably, - the immunomodulatory substance(s) for use according to the present invention is IFN-γ; and - the immunomodulatory substance(s) in step (B) is IFN-γ. In any of the embodiments described herein comprising steps (A) and (C), still further preferably, - the immunomodulatory substance(s) for use according to the present invention is a cytokine(s); and - the immunomodulatory substance(s) in step (C) is the cytokine(s), still even further preferably, - the immunomodulatory substance(s) for use according to the present invention is an interleukin(s); and - the immunomodulatory substance(s) in step (C) is the interleukin(s), furthermore preferably, - the immunomodulatory substance(s) for use according to the present invention is IL-2; and - the immunomodulatory substance(s) in step (C) is IL-2. In any of the embodiments described herein comprising steps (A), (B) and (C), still further preferably, - the immunomodulatory substance(s) for use according to the present invention is any of the immunomodulatory substance(s) as described herein including IL-2 as described herein, more preferably a cytokine(s) including IL-2; - the immunomodulatory substance(s) in step (B) is any of the immunomodulatory substance(s) as described herein except for IL-2, more preferably the cytokine(s) except for IL-2; and - the immunomodulatory substance(s) in step (C) is IL-2, still even further preferably, - the immunomodulatory substance(s) for use according to the present invention is an interferon(s), neurotrophin(s) and / or interleukin(s) including IL-2; - the immunomodulatory substance(s) in step (B) is the interferon(s), neurotrophin(s) and / or interleukin(s) except for IL-2; and - the immunomodulatory substance(s) in step (C) is IL-2, furthermore preferably, - the immunomodulatory substance(s) for use according to the present invention is IFN-γ, IL-4, BDNF and / or IL-2; - the immunomodulatory substance(s) in step (B) is IFN-γ, IL-4 and / or BDNF, more preferably IFN-γ and / or IL-4 or IL-4 and / or BDNF; and - the immunomodulatory substance(s) in step (C) is IL-2, even furthermore preferably, - the immunomodulatory substance(s) for use according to the present invention is IFN-γ, IL-4 and / or IL-2, preferably IFN-γ and / or IL-2 or IL-4 and / or IL-2; - the immunomodulatory substance(s) in step (B) is IFN-γ and / or IL-4, preferably IFN-γ or IL-4; and - the immunomodulatory substance(s) in step (C) is IL-2, still even furthermore preferably, - the immunomodulatory substance(s) for use according to the present invention is IFN-γ and / or IL-2; - the immunomodulatory substance(s) in step (B) is IFN-γ; and - the immunomodulatory substance(s) in step (C) is IL-2. Hence, still even more preferably, - the method comprises steps (A) and (C); - the immunomodulatory substance(s) for use according to the present invention is any of the immunomodulatory substance(s) as described herein, that is the immunomodulatory substance(s) including IL-2, preferably a cytokine(s) including IL-2, more preferably an interferon(s), neurotrophin(s) and / or interleukin(s) including IL-2, even more preferably IL-2; and - the immunomodulatory substance(s) in step (C) is IL-2, or - the method comprises steps (A), (B) and (C); - the immunomodulatory substance(s) for use according to the present invention is any of the immunomodulatory substance(s) as described herein, that is the immunomodulatory substance(s) including IL-2, preferably a cytokine(s) including IL-2, more preferably an interferon(s), neurotrophin(s) and / or interleukin(s) including IL-2, even more preferably IL-2; - the immunomodulatory substance(s) in step (B) is any of the immunomodulatory substance(s) as described herein except for IL-2; and - the immunomodulatory substance(s) in step (C) is IL-2, or - the method comprises steps (A) and (B); - the immunomodulatory substance(s) for use according to the present invention is IFN-γ and / or IL-4, preferably IFN-γ; and - the immunomodulatory substance(s) in step (B) is IFN-γ and / or IL-4, preferably is IFN-γ. Furthermore preferably, the method comprises steps (A) and (B); - the immunomodulatory substance(s) for use according to the present invention is IFN-γ; and - the immunomodulatory substance(s) in step (B) is IFN-γ. Still furthermore, preferably, the method comprises steps (A), (B) and (C); - the immunomodulatory substance(s) for use according to the present invention is IFN-γ and / or IL-2; - the immunomodulatory substance(s) in step (B) is IFN-γ; and - the immunomodulatory substance(s) in step (C) is IL-2.. The embodiment, in which the method comprises steps (A), (B) and (C) is still more preferred. Even furthermore preferably, the method comprises steps (A), (B), (B1) and (C); - the immunomodulatory substance(s) for use according to the present invention is IFN-γ, IL-4 and / or IL-2; - the immunomodulatory substance(s) in step (B) is IFN-γ; - the immunomodulatory substance(s) in step (B1) is IL-4; and - the immunomodulatory substance(s) in step (C) is IL-2, or - the immunomodulatory substance(s) for use according to the present invention is IL-4, BDNF and / or IL-2; - the immunomodulatory substance(s) in step (B) is IL-4; - the immunomodulatory substance(s) in step (B1) is BDNF; and - the immunomodulatory substance(s) in step (C) is IL-2. Still furthermore preferably, - the immunomodulatory substance(s) for use according to the present invention is IFN-γ, IL-4 and / or IL-2; and the method comprises: a first set of steps, comprising: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B) administering IFN-γ to the skin of said subject; and (C) administering IL-2 to the skin of the subject, and a second set of steps comprising: (A) which is selected from one or more of steps (A-0), (A-1), (A-2), (A-3), (A-4), (A-5), (A-6), (A-7) and / or (A-8); and (B1) administering IL-4 to the skin of said subject; and (C) administering IL-2 to the skin of the subject. For the sake of simplicity and clarity, the above embodiments were only written out in full length for the cytokine(s), interferon(s), interleukin(s), neurotrophin(s), IFN-γ, IL-4, BDNF and / or IL-2. If not mentioned otherwise, it is to be understood that any of the preferred embodiments of the present invention stated herein for the cytokine(s), interferon(s), interleukin(s), neurotrophin(s), IFN-γ, IL-4, BDNF and / or IL-2 is independently and mutatis mutandis applicable to the cytokine-like acting substance(s), interferon-like acting substance(s), interleukin-like acting substance(s), neurotrophin-like acting substance(s), IFN-γ-like acting substance(s), IL-2- like acting substance(s), IL-4-like acting substance(s) and / or BDNF-like acting substance(s), wherein for that reason, where applicable, the term ‘cytokine(s)’ is to be understood ‘cytokine-like acting substance(s)’, ‘interferon(s)’ is to be understood ‘interferon-like acting substance(s)’, ‘interleukin(s)’ is to be understood ‘interleukin-like acting substance(s)’, ‘neurotrophin(s)’ is to be understood ‘neurotrophin-like acting substance(s)’, ‘IFN-γ’ is to be understood ‘IFN-γ-like acting substance(s)’, ‘IL-4’ is to be understood ‘IL-4- like acting substance(s)’, ‘BDNF’ is to be understood ‘BDNF-like acting substance(s)’ and ‘IL-2’ is to be understood ‘IL-2-like acting substance(s)’. Preferably, in one particular embodiment all of such terms are replaced or all of such terms remain unchanged, however, not some are replaced and some not. Similarly, the embodiments referring to cytokine(s), interferon(s), neurotrophin(s), interleukin(s), IFN-γ, IL-4, BDNF, IL-2 encompass also any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. The embodiments referring to cytokine(s), interferon(s), neurotrophin(s), interleukin(s), IFN-γ, IL-4, BDNF, IL-2 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these are more preferred. The embodiments referring to cytokine(s), interferon(s), neurotrophin(s), interleukin(s), IFN-γ, IL-4, BDNF and / or IL-2 are even more preferred. Hence, still even furthermore preferably, the present invention relates to the following: IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these, and / or skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs (peripheral blood mononuclear cells) within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2(oxygen saturation of haemoglobin) within the skin and / or an increased rHb (relative haemoglobin amount) within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises the step(s) of: (B) administering the IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these to the skin of the subject, wherein immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B). Hence, still even much more preferably, the present invention relates to the following: IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these, IL-2 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these, and / or skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs (peripheral blood mononuclear cells) within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2 (oxygen saturation of haemoglobin) within the skin and / or an increased rHb (relative haemoglobin amount) within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises the step(s) of: (B) administering the IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these to the skin of the subject; and / or (C) administering the IL-2 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these to the skin of the subject, wherein immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B). More particularly, the present invention relates to the following: IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these, and / or skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises a step (A), wherein step (A) is selected from one or more of steps: (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2(oxygen saturation of haemoglobin) within the skin and / or an increased rHb (relative haemoglobin amount) within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; and / or (A-7) administering a skin-conditioning agent to the skin of the subject; and the method further comprises the step(s) of: (B) administering the IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these to the skin of the subject, wherein immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B). Still more particularly, the present invention relates to the following: IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these, IL-2 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these, and / or skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises a step (A), wherein step (A) is selected from one or more of steps: (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2 (oxygen saturation of haemoglobin) within the skin and / or an increased rHb (relative haemoglobin amount) within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; and / or (A-7) administering a skin-conditioning agent to the skin of the subject; and the method further comprises the step(s) of: (B) administering the IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these to the skin of the subject; and / or (C) administering the IL-2 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these to the skin of the subject, wherein immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B). The expression “IFN-γ-like acting substance” or “IFN-γ-like acting substance(s)” as mentioned in any of the embodiments described herein can be, preferably is, any substance that exerts a similar or identical effect to a IFN-γ in the body of the subject when administered thereto. The IFN-γ-like acting substance(s) may encompass precursors, prodrugs and propetides of such substances which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active IFN-γ-like acting substance(s). Hence, it may be any substance, molecule, peptide, protein, protein-analogue, protein-variant, derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or any derivative, fragment and / or pharmaceutically acceptable salt of any of these. Therefore IFN-γ-like acting substance(s) may: - activates or is / are capable of activating a respective IFN-γ-receptor(s) of a cell. The IFN-γ-receptor(s) may for instance be the receptor of the LHs, peripheral Tregs or PBMCs; and / or - results in or causes or is capable of resulting in or causing the generation of a IFN-γ and / or a IFN-γ-like acting substance(s). Preferably, the IFN-γ-like acting substance(s) activates or is capable of activating the respective IFN-γ-receptor(s). The activating or the capability of activating the respective IFN-γ-receptor(s) may be directly and / or it may be indirectly. Preferably, the IFN-γ-like acting substance(s) activates or is / are capable of activating a respective IFN-γ-receptor(s) within the skin of the subject. The IFN-γ-like acting substance(s) may be any naturally occurring or artificial IFN-γ-like acting substance(s) as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective IFN-γ-receptor(s). Preferably, the IFN-γ-like acting substance(s) is known to the person skilled in the art at the effective date of filing of the present invention. Preferably, the IFN-γ-like acting substance is any peptide, protein, protein-analogue, protein-variant or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. In a preferred embodiment, the IFN-γ-like acting substance(s) may be as detailed below amongst others an IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. More preferably, the IFN-γ-like acting substance(s) is an IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. The expression “IFN-γ” as mentioned in any of the embodiments described herein preferably has to be interpreted broad. Typically, the IFN-γ activates or is are capable of activating a respective IFN-γ-receptor(s) of a cell. The IFN-γ-receptor(s) may for instance be the receptor of the LHs, peripheral Tregs or PBMCs. Preferably, the activating or capability of activating is within the skin of the subject, more preferably locally in effective amounts within the skin of the subject, even more preferably not in amounts systemically effective within the subject’s body. Preferably the IFN-γ may be any type of IFN-γ known to the person skilled in the art. Furthermore, the present invention encompass the use or medical use of precursors, prodrugs and propetides of such IFN-γ which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active IFN-γ. Hence, these may be used in the method or the medical use as described herein or in preparation of the pharmaceutical compositions, injectable dosage form, topical dosage forms, medical devices and / or kit of parts as described herein. Preferably, the IFN-γ may be any peptide, protein, protein-analogue, protein-variant or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. The IFN-γ does not necessarily be derived from or be identical to the IFN-γ of the same genus and / or species the subject belongs to, it may be any naturally occurring or an artificial IFN-γ, as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective IFN-γ-receptor(s). Preferably, the biologic activity of the IFN-γ and / or IFN-γ-like acting substance(s) is sufficient to achieve the treating and / or preventing of the antisynthetase syndrome, preferably in the subject. An IFN-γ and / or an IFN-γ-like acting substance typically affects cells by binding and activating the respective IFN-γ-receptor on the cells. Hence, the activating of the respective receptor typically leads to the affectation of the cell as described above for the immunomodulatory substance. Hence, any embodiment mentioned herein for the immunomodulatory substance relating to the affecting cells like LHs, peripheral Tregs or PBMCs is independently and mutatis mutandis applicable to the IFN-γ and the IFN-γ-like acting substance. The activating or the capability of activating the respective IFN-γ-receptor(s) by the IFN-γ and / or IFN-γ-like acting substance(s) may be directly and / or it may be indirectly. If not mentioned otherwise, the description and definition of the cytokine(s) or the cytokine-like acting substance stated above is independently and mutatis mutandis applicable to the IFN-γ and / or IFN-γ-like acting substance(s). Particualry, if not mentioned otherwise, the description and definition of the cytokine(s) or the cytokine-like acting substance in respect of “directly” and “indirectly” activating or capable of activating the respective IFN-γ-receptor(s), is independently and mutatis mutandis applicable to the IFN-γ and / or IFN-γ-like acting substance(s). Preferably, the IFN-γ and / or IFN-γ-like acting substance(s) for use according to the present invention and / or the IFN-γ and / or IFN-γ- like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is capable of affecting and / or affects the LHs, peripheral Tregs or PBMCs. Preferably, the PBMCs are naïve PBMCs, more preferably lymphocytes, even more preferably T-cells and / or B-cells, still more preferably naïve lymphocytes, still even more preferably naïve B-cells and / or naïve T-cells, further preferably naïve T-cells. More preferably, the IFN-γ and / or IFN-γ-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs or PBMCs. More preferably, the IFN-γ and / or IFN-γ-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs or PBMCs in the subject as defined in any of the embodiments according to the present invention, further preferably within the skin of the subject.. If not mentioned otherwise, the description and definition of the immunomodulatory substance(s) stated above is independently and mutatis mutandis applicable to the IFN-γ and / or IFN-γ-like acting substance(s). Particualry, if not mentioned otherwise, the description and definition of the immunomodulatory substance(s) in respect of “directly” and “indirectly” affecting or capable of affecting the PBMCs is independently and mutatis mutandis applicable to the IFN-γ and / or IFN-γ-like acting substance(s). The IFN-γ and / or IFN-γ-like acting substance(s) for use according to the present invention and / or the IFN-γ and / or IFN-γ-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be similar or identical, preferably identical, to any IFN-γ and / or IFN-γ-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the IFN-γ and / or IFN-γ-like acting substance(s) may bes similar or identical, preferably identical, to any peptide, protein or any fragment of these of IFN-γ and / or IFN-γ-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the total number of substitutions, insertions and / or deletions or the total number combined of substitutions, insertions and / or deletions of amino acid residues is 60 or less, more preferably 40 or less, even more preferably 20 or less, still more preferably 12 or less, still even more preferably 8 or less, further preferably 4 or less, even further preferably 2 or less and zero or more, still further preferably zero, preferably with reference to amino acid sequence SEQ ID NO: 1, wherein more preferably the subject is a human. The IFN-γ and / or IFN-γ-like acting substance(s) may be identical to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to or the amino acid sequence identity refers to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to. The expression “is identical” typically means in this particular context that the IFN-γ and / or IFN-γ-like acting substance(s) is in respect to its primary, secondary, tertiary and quaternary protein structure identical to an / the IFN-γ and / or IFN-γ-like acting substance(s) of the same genus and / or species the subject belongs to, more preferably, also in view of the modification pattern, particularly glycosylations. The IFN-γ and / or IFN-γ-like acting substance(s) for use according to the present invention and / or the IFN-γ and / or IFN-γ-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, imay be derived from an individual belonging to the same genus and / or species as the subject, or which is identical to an / the IFN-γ and / or IFN-γ-like acting substance(s) of the same genus and / or species the subject belongs to. For instance, in case the subject is: a human the IFN-γ and / or IFN-γ-like acting substance(s) is human IFN-γ and / or IFN-γ-like acting substance(s), more preferably human IFN-γ and / or IFN-γ-like acting substance(s) comprising, even more preferably consisting of, preferably as effective amino acid sequence, the amino acid sequence SEQ ID NO: 1; a cow the IFN-γ and / or IFN-γ-like acting substance(s) is bovine IFN-γ and / or IFN-γ-like acting substance(s); a horse the IFN-γ and / or IFN-γ-like acting substance(s) is equine IFN-γ and / or IFN-γ-like acting substance(s); a donkey the IFN-γ and / or IFN-γ-like acting substance(s) is donkey IFN-γ and / or IFN-γ- like acting substance(s); an elephant the IFN-γ and / or IFN-γ-like acting substance(s) is elephant IFN-γ and / or IFN-γ-like acting substance(s); a sheep the IFN-γ and / or IFN-γ-like acting substance(s) is sheep IFN-γ and / or IFN-γ-like acting substance(s); a goat the IFN-γ and / or IFN-γ-like acting substance(s) is goat IFN-γ and / or IFN-γ-like acting substance(s); a pig the IFN-γ and / or IFN-γ-like acting substance(s) is porcine IFN-γ and / or IFN-γ-like acting substance(s); a rabbit the IFN-γ and / or IFN-γ-like acting substance(s) is rabbit IFN-γ and / or IFN-γ-like acting substance(s); a mouse the IFN-γ and / or IFN-γ-like acting substance(s) is mouse IFN-γ and / or IFN-γ-like acting substance(s); a rat the IFN-γ and / or IFN-γ-like acting substance(s) is rat IFN-γ and / or IFN-γ-like acting substance(s); a camel the IFN-γ and / or IFN-γ-like acting substance(s) is camel IFN-γ and / or IFN-γ-like acting substance(s); a dromedary the IFN-γ and / or IFN-γ-like acting substance(s) is dromedary IFN-γ and / or IFN-γ-like acting substance(s); a lama the IFN-γ and / or IFN-γ-like acting substance(s) is lama IFN-γ and / or IFN-γ-like acting substance(s); an alpaca the IFN-γ and / or IFN-γ-like acting substance(s) is alpaca IFN-γ and / or IFN-γ-like acting substance(s); a dog the IFN-γ and / or IFN-γ-like acting substance(s) is dog IFN-γ and / or IFN-γ- like acting substance(s); and / or a cat the IFN-γ and / or IFN-γ-like acting substance(s) is cat IFN-γ and / or IFN-γ-like acting substance(s). Preferably, the IFN-γ and / or IFN-γ-like acting substance(s) for use according to the present invention and / or the IFN-γ and / or IFN-γ- like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is not the subject’s endogenous IFN-γ and / or IFN-γ-like acting substance(s). In other words, preferably the IFN-γ and / or IFN-γ-like acting substance(s) is not an IFN-γ and / or IFN-γ-like acting substance(s) isolated from the subject’s body, i.e. from the individual subject to be treated or prevented. Preferably, the IFN-γ and / or IFN-γ-like acting substance(s) for use according to the present invention and / or the IFN-γ and / or IFN-γ- like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be, preferably, is a recombinant IFN-γ and / or IFN-γ-like acting substance(s) which may be generated by any recombinant expression techniques known to the person skilled in the art, a chemically synthesized IFN-γ and / or IFN-γ-like acting substance(s) synthesized by any production techniques known to the person skilled in the art, an artificially produced IFN-γ and / or IFN-γ-like acting substance(s) produced by any production techniques known to the person skilled in the art, a naturally occurring IFN-γ and / or IFN-γ-like acting substance(s) obtained from natural sources like an animal or human, or any combination thereof. More preferably, the IFN-γ and / or IFN-γ-like acting substance(s) is a recombinant IFN-γ and / or IFN-γ-like acting substance(s), chemically synthesized IFN-γ and / or IFN-γ-like acting substance(s), artificially produced IFN-γ and / or IFN-γ-like acting substance(s) or any combination thereof, even more preferably a recombinant IFN-γ and / or IFN-γ-like acting substance(s), still even more preferably recombinant human IFN-γ-1b-protein (IFN-γ gamma-1b) preferably produced in genetically modified Escherichia coli (produced by Boehringer Ingelheim RCV GmbH & Co KG and in Germany commercially available from Boehringer Ingelheim Pharma GmbH & Co. KG under the tradename Imukin®, PZN: 06958744, Lot: M000487). Furthermore, the IFN-γ and / or IFN-γ-like acting substance(s) for use according to the present invention and / or the IFN-γ and / or IFN-γ- like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may or may not be derivatized, stabilized, fused with other proteins or peptides, conjugated with polymers, contain amino acid analogue(s) or artificial amino acids, modified, covalently or non-covalently, for instance glycosylated or methylated by e.g. posttranslational modification and / or oligomerized, e.g. dimerized or trimerized as long as it is capable of affecting and / or affects LHs, peripheral Tregs or PBMCs. More preferably, the modification pattern and / or oligomerization status is similar or identical to the peptide, protein or any fragment of these naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, in any of the embodiments described herein it is intended to administer the IFN-γ and / or IFN-γ-like acting substance(s) in an amount low enough to avoid a systemic increase of the IFN-γ and / or IFN-γ-like acting substance(s)-concentration in the subject’s body. Hence, the IFN-γ and / or IFN-γ-like acting substance(s) may be administered in an amount that, when scaled to the entire body of the subject, the resulting systemic concentrations remain in the magnitude of the endogenous levels. Thereby, without wishing to be bound to theory, it is believed that the generation of an increased IFN-γ and / or IFN-γ-like acting substance(s)-concentration for instance at sites of inflammation, like inflamed joint. As already stated above, for instance naïve T-cells can mature in the presence of antigen / autoantigen / allergen towards cytotoxic, which may act pro-inflammatory. Thereby decreasing, cancelling or even reversing the beneficial effects achieved by the present invention, particularly, the anti-inflammatory effect of the regulatory T-cells and / or helper T-cells, or of a subset thereof, which are presumably generated. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IFN-γ and / or IFN-γ-like acting substance(s) is administered in an amount that does not cause a systemic increase, more preferably an effective systemic increase, of the concentration of IFN-γ and / or IFN-γ-like acting substance(s) in the subject, preferably the blood of the subject, and / or that causes a systemic increase of the concentration of the IFN-γ and / or IFN-γ-like acting substance(s). Preferably, IFN-γ and / or IFN-γ-like acting substance(s) is administered in an amount low enough that the systemic increase is non-effective. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IFN-γ and / or IFN-γ-like acting substance(s) is administered in an amount that causes a local increase, preferably an effective local increase, of the concentration of the IFN-γ and / or IFN-γ-like acting substance(s) in the subject, preferably in the skin tissue of the subject. The skin tissue is preferred, because unlike administration into the blood, no or less flushing away and dilution of the IFN-γ and / or IFN-γ-like acting substance(s) takes place. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the generated increased concentration, preferably the generated effective increased concentration of the IFN-γ and / or IFN-γ-like acting substance(s) administered is only local but not systemic in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IFN-γ and / or IFN-γ-like acting substance(s) is administered in an amount that does not cause a systemic activation, preferably an effective systemic activation, of the respective receptor of the IFN-γ and / or IFN-γ-like acting substance(s) of a cell, and / or that does not cause a systemic generation, preferably an effective systemic generation, of the IFN-γ and / or IFN-γ-like acting substance(s), preferably in the subject. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IFN-γ and / or IFN-γ-like acting substance(s) is administered in an amount that causes a local activation, preferably an effective local activation of the respective receptor of the IFN-γ and / or IFN-γ-like acting substance(s) of a cell, and / or causes a local generation, preferably an effective local generation of the IFN-γ and / or IFN-γ-like acting substance(s), preferably in the subject. Preferably, the activation and / or generation, more preferably the effective generation and / or effective activation is only local but not systemic in the subject. Generally, 1 ng (nanogram(s)) IFN-γ corresponds to approximately 20 IU (international unit(s)) IFN-γ or less. Some of the IFN-γ might be denatured or otherwise defect in that the biological activity of IFN-γ has been lost while the mass remains constant. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IFN-γ-like acting substance(s), preferably the IFN-γ, is administered in an effective amount, preferably an effective total amount. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IFN-γ-like acting IFN-γ substance(s) is administered in an amount, preferably a total amount, equivalent to 600 IU IFN-γ / kg (international unit(s) / kilogram) body mass of the subject or less (‘kg body mass’ is in its meaning IFN-γ equivalent to ‘kg of the body mass’), preferably per administration dose, to the skin of the subject. More preferably, IFN-γ is administered in an amount, preferably a total amount, equivalent to 300 IU IFN-γ / kg or less, even more preferably 200 IU IFN-γ / kg or less, still more preferably 100 IU IFN-γ / kg or less, still even more preferably 50 IU IFN-γ / kg or less, further preferably 30 IU IFN-γ / kg or less, further preferably 20 IU IFN-γ / kg or less, even further preferably 6 IU IFN-γ / kg or less. There is no lower limit for the amount per kg body mass as long IFN-γ as the beneficial effects can be achieved, however, usually, a lower limit is and amount equivalent to 0.04 IU IFN-γ / kg or more, more preferably 0.2 IU IFN-γ / kg or more, even more preferably, 0.5 IU IFN-γ / kg or more, still more preferably 1 IU IFN-γ / kg or more, still even more preferably 1.5 IU IFN-γ / kg or more. More preferably, the IFN-γ-like acting IFN-γ substance(s) is administered in an amount, preferably a total amount, in the rang IFN-γe of equivalent to 0.04 IU IFN-γ / kg or more and 600 IU IFN-γ / kg or less, even more preferably 0.2 IU IFN-γ / kg or more and 300 IU IFN-γ / kg or less, still more preferably 0.5 IU IFN-γ / kg or more and 200 IU IFN-γ / kg or less, still even more preferably 0.5 IU IFN-γ / kg or more and 100 IU IFN-γ / kg or less, further preferably 0.5 IU IFN-γ / kg or more and 50 IU IFN-γ / kg or less, even further preferably 1 IU IFN-γ / kg or more and 30 IU IFN-γ / kg or less, still further preferably 1.5 IU IFN-γ / kg or more and 20 IU IFN-γ / kg or less. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IFN-γ-like acting IFN-γ substance(s) is administered in an amount, preferably a total amount, equivalent in activity to 30 ng IFN-γ / kg body mass of the subject or less, preferably per administration dose, to the skin of the subject. More preferably, IFN-γ-like aktinv substance is administered in an amount, preferably a total amount, equivalent in activity to 15 ng IFN-γ / kg or less, even more preferably 10 ng IFN-γ / kg or less, still more preferably 5 ng IFN-γ / kg or less, still even more preferably 2.5 ng IFN-γ / kg or less, further preferably 1.5 ng IFN-γ / kg or less, still even more preferably 1 ng IFN-γ / kg or less, even further preferably 0.3 ng IFN-γ / kg or less. There is no lower limit for the amount per kg body mass as long IFN-γ as the beneficial effects can be achieved, however, usually, a lower limit is an amount equivalent in activity to 0.002 ng IFN-γ / kg or more, more preferably 0.025 ng IFN-γ / kg or more, even more preferably 0.01 ng IFN-γ / kg or more, still more preferably 0.02 mg / kg or more, still even more preferably 0.05 ng IFN-γ / kg or more, further preferably 0.075 ng IFN-γ / kg or more. More preferably, the IFN-γ-like acting IFN-γ substance(s) is administered in an amount, preferably a total amount, in the rang IFN-γe of equivalent in activity to 30 ng IFN-γ / kg or less and 0.002 ng IFN-γ / kg or more, even more preferably 15 ng IFN-γ / kg or less and 0.025 ng IFN-γ / kg or more, still more preferably 10 ng IFN-γ / kg or less and 0.01 ng IFN-γ / kg or more, still even more preferably 5 ng IFN-γ / kg or less and 0.01 ng IFN-γ / kg or more, further preferably 2.5 ng IFN-γ / kg or less and 0.02 ng IFN-γ / kg or more, even further preferably 1.5 ng IFN-γ / kg or less and 0.02 ng IFN-γ / kg or more, still further preferably 1 ng IFN-γ / kg or less and 0.05 ng IFN-γ / kg or more, still even further preferably 0.3 ng IFN-γ / kg or less and 0.075 ng IFN-γ / kg or more. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IFN-γ-like acting IFN-γ substance(s), is administered, preferably per administration dose, in an amount, preferably a total amount, equivalent to 30,000 IU IFN-γ or less, more preferably 15,000 IU IFN-γ or less, even more preferably 10,000 IU IFN-γ or less, still more preferably 5,000 IU IFN-γ or less, still even more preferably 2,500 IU IFN-γ or less, further preferably 1,500 IU IFN-γ or less, still further preferably 1,000 IU IFN-γ or less, even further preferably 300 IU IFN-γ or less. There is no lower limit for the amount as long IFN-γ as the beneficial effects can be achieved, however, usually, a lower limit is and amount equivalent to 2 IU IFN-γ or more, more preferably 10 IU IFN-γ or more, even more preferably 20 IU IFN-γ or more, still more preferably 30 IU IFN-γ or more and still even more preferably 50 IU IFN-γ or more. More preferably, the IFN-γ-like acting IFN-γ substance(s), is administered, preferably per administration dose, in an amount, preferably a total amount, in the rang IFN-γe of equivalent to 30,000 IU IFN-γ or less and 2 IU IFN-γ or more, even more preferably 15,000 IU IFN-γ or less and 2 IU IFN-γ or more, still more preferably 10,000 IU IFN-γ or less and 10 IU IFN-γ or more, still even more preferably 5,000 IU IFN-γ or less and 10 IU IFN-γ or more, further preferably 2,500 IU IFN-γ or less and 20 IU IFN-γ or more, even further preferably 1,500 IU IFN-γ or less and 30 IU IFN-γ or more, still further preferably 1,000 IU IFN-γ or less and 50 IU IFN-γ or more, still even further preferably 300 IU IFN-γ or less and 50 IU IFN-γ or more. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IFN-γ-like acting IFN-γ substance(s), is administered, preferably per administration dose, in an amount, preferably a total amount, equivalent in activity to 1,500 ng IFN-γ or less, more preferably 750 ng IFN-γ or less, even more preferably 500 ng IFN-γ or less, still more preferably 250 ng IFN-γ or less, still even more preferably 125 ng IFN-γ or less, further preferably 75 ng IFN-γ or less, still further preferably 50 ng IFN-γ or less, even further preferably 15 ng IFN-γ or less. There is no lower limit for the amount, preferably the total amount, as long IFN-γ as the beneficial effects can be achieved, however, usually, a lower limit is an amount equivalent in activity to 0.1 ng IFN-γ or more, more preferably 0.5 ng IFN-γ or more, even more preferably 1 ng IFN-γ or more and still even more preferably 2 ng IFN-γ or more. More preferably, the IFN-γ-like acting IFN-γ substance(s), is administered, preferably per administration dose, in an amount, preferably a total amount, in the rang IFN-γe of equivalent in activity to 1,500 ng IFN-γ or less and 0.1 ng IFN-γ or more, even more preferably 750 ng IFN-γ or less and 0.1 ng IFN-γ or more, still more preferably 500 ng IFN-γ or less and 0.1 ng IFN-γ or more, still even more preferably 250 ng IFN-γ or less and 0.5 ng IFN-γ or more, further preferably 125 ng IFN-γ or less and 0.5 ng IFN-γ or more, even further preferably 75 ng IFN-γ or less and 1 ng IFN-γ or more, still further preferably 50 ng IFN-γ or less and 1 ng IFN-γ or more, still even further preferably 15 ng IFN-γ or less and 2 ng IFN-γ or more. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), IFN-γ is administered in an amount, preferably a total amount, of 600 IU / kg (international unit(s) / kilogram) body mass of the subject or less (‘kg body mass’ is in its meaning equivalent to ‘kg of the body mass’), preferably per administration dose, to the skin of the subject. More preferably, IFN-γ is administered in an amount, preferably a total amount, of 300 IU / kg or less, even more preferably 200 IU / kg or less, still more preferably 100 IU / kg or less, still even more preferably 50 IU / kg or less, further preferably 30 IU / kg or less, further preferably 20 IU / kg or less, even further preferably 6 IU / kg or less. There is no lower limit for the amount per kg body mass as long as the beneficial effects can be achieved, however, usually, a lower limit is 0.04 IU / kg or more, more preferably 0.2 IU / kg or more, even more preferably, 0.5 IU / kg or more, still more preferably 1 IU / kg or more, still even more preferably 1.5 IU / kg or more. More preferably, IFN-γ is administered in an amount, preferably a total amount, in the range of 0.04 IU / kg or more and 600 IU / kg or less, even more preferably 0.2 IU / kg or more and 300 IU / kg or less, still more preferably 0.5 IU / kg or more and 200 IU / kg or less, still even more preferably 0.5 IU / kg or more and 100 IU / kg or less, further preferably 0.5 IU / kg or more and 50 IU / kg or less, even further preferably 1 IU / kg or more and 30 IU / kg or less, still further preferably 1.5 IU / kg or more and 20 IU / kg or less. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), IFN-γ is administered in an amount, preferably a total amount, of 30 ng / kg body mass of the subject or less, preferably per administration dose, to the skin of the subject. More preferably, IFN-γ is administered in an amount, preferably a total amount, of 15 ng / kg or less, even more preferably 10 ng / kg or less, still more preferably 5 ng / kg or less, still even more preferably 2.5 ng / kg or less, further preferably 1.5 ng / kg or less, still even more preferably 1 ng / kg or less, even further preferably 0.3 ng / kg or less. There is no lower limit for the amount per kg body mass as long as the beneficial effects can be achieved, however, usually, a lower limit is 0.002 ng / kg or more, more preferably 0.025 ng / kg or more, even more preferably 0.01 ng / kg or more, still more preferably 0.02 mg / kg or more, still even more preferably 0.05 ng / kg or more, further preferably 0.075 ng / kg or more. More preferably, IFN-γ is administered in an amount, preferably a total amount, in the range of 30 ng / kg or less and 0.002 ng / kg or more, even more preferably 15 ng / kg or less and 0.025 ng / kg or more, still more preferably 10 ng / kg or less and 0.01 ng / kg or more, still even more preferably 5 ng / kg or less and 0.01 ng / kg or more, further preferably 2.5 ng / kg or less and 0.02 ng / kg or more, even further preferably 1.5 ng / kg or less and 0.02 ng / kg or more, still further preferably 1 ng / kg or less and 0.05 ng / kg or more, still even further preferably 0.3 ng / kg or less and 0.075 ng / kg or more. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IFN-γ is administered, preferably per administration dose, in an amount, preferably a total amount, of 30,000 IU or less, more preferably 15,000 IU or less, even more preferably 10,000 IU or less, still more preferably 5,000 IU or less, still even more preferably 2,500 IU or less, further preferably 1,500 IU or less, still further preferably 1,000 IU or less, even further preferably 300 IU or less. There is no lower limit for the amount as long as the beneficial effects can be achieved, however, usually, a lower limit is 2 IU or more, more preferably 10 IU or more, even more preferably 20 IU or more, still more preferably 30 IU or more and still even more preferably 50 IU or more. More preferably, IFN-γ is administered, preferably per administration dose, in an amount, preferably a total amount, in the range of 30,000 IU or less and 2 IU or more, even more preferably 15,000 IU or less and 2 IU or more, still more preferably 10,000 IU or less and 10 IU or more, still even more preferably 5,000 IU or less and 10 IU or more, further preferably 2,500 IU or less and 20 IU or more, even further preferably 1,500 IU or less and 30 IU or more, still further preferably 1,000 IU or less and 50 IU or more, still even further preferably 300 IU or less and 50 IU or more. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IFN-γ, preferably IFN-γ is administered, preferably per administration dose, in an amount, preferably a total amount, of 1,500 ng or less, more preferably 750 ng or less, even more preferably 500 ng or less, still more preferably 250 ng or less, still even more preferably 125 ng or less, further preferably 75 ng or less, still further preferably 50 ng or less, even further preferably 15 ng or less. There is no lower limit for the amount, preferably the total amount, as long as the beneficial effects can be achieved, however, usually, a lower limit is 0.1 ng or more, more preferably 0.5 ng or more, even more preferably 1 ng or more and still even more preferably 2 ng or more. More preferably, IFN-γ is administered, preferably per administration dose, in an amount, preferably a total amount, in the range of 1,500 ng or less and 0.1 ng or more, even more preferably 750 ng or less and 0.1 ng or more, still more preferably 500 ng or less and 0.1 ng or more, still even more preferably 250 ng or less and 0.5 ng or more, further preferably 125 ng or less and 0.5 ng or more, even further preferably 75 ng or less and 1 ng or more, still further preferably 50 ng or less and 1 ng or more, still even further preferably 15 ng or less and 2 ng or more. IFN-γ-like acting substances like IFN-γ may be amongst others capable to effect the desired affectation of the LHs, peripheral Tregs or PBMCs as described above. The expression “IL-2-like acting substance” or “IL-2-like acting substance(s)” as mentioned in any of the embodiments described herein can be, preferably is, any substance that exerts a similar or identical effect to a IL-2 in the body of the subject when administered thereto. The IL-2-like acting substance(s) may encompass precursors, prodrugs and propetides of such substances which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active IL-2-like acting substance(s). Hence, it may be any substance, molecule, peptide, protein, protein-analogue, protein-variant, derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or any derivative, fragment and / or pharmaceutically acceptable salt of any of these. Therefore IL-2-like acting substance(s) may: - activates or is / are capable of activating a respective IL-2-receptor(s) of a cell. The IL-2-receptor(s) may for instance be the receptor of the LHs, peripheral Tregs or PBMCs; and / or - results in or causes or is capable of resulting in or causing the generation of a IL-2 and / or a IL-2-like acting substance(s). Preferably, the IL-2-like acting substance(s) activates or is capable of activating the respective IL-2-receptor(s). The activating or the capability of activating the respective IL-2-receptor(s) may be directly and / or it may be indirectly. Preferably, the IL-2-like acting substance(s) activates or is / are capable of activating a respective IL-2-receptor(s) within the skin of the subject. The IL-2-like acting substance(s) may be any naturally occurring or artificial IL-2-like acting substance(s) as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective IL-2-receptor(s). Preferably, the IL-2-like acting substance(s) is known to the person skilled in the art at the effective date of filing of the present invention. Ppreferably, the IL-2-like acting substance is any peptide, protein, protein-analogue, protein-variant or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. In a preferred embodiment, the IL-2-like acting substance(s) may be as detailed below amongst others an IL-2 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. More preferably, the IL-2-like acting substance(s) is an IL-2 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these. The expression “IL-2” as mentioned in any of the embodiments described herein preferably has to be interpreted broad. Typically, the IL-2 activates or is are capable of activating a respective IL-2-receptor(s) of a cell. The IL-2-receptor(s) may for instance be the receptor of the LHs, peripheral Tregs or PBMCs. Preferably, the activating or capability of activating is within the skin of the subject, more preferably locally in effective amounts within the skin of the subject, even more preferably not in amounts systemically effective within the subject’s body. Preferably the IL-2 may be any type of IL-2 known to the person skilled in the art. Furthermore, the present invention encompass the use or medical use of precursors, prodrugs and propetides of such IL-2 which are usually not active as such, i.e. have no immunomodulatory activity, but which, upon use in accordance with the present invention, are converted into the actually active IL-2. Hence, these may be used in the method or the medical use as described herein or in preparation of the pharmaceutical compositions, injectable dosage form, topical dosage forms, medical devices and / or kit of parts as described herein. The IL-2 may be any peptide, protein, protein-analogue, protein-variant or any derivative, fragment, subunit, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug and / or pharmaceutically acceptable salt of any of these. The IL-2 does not necessarily be derived from or be identical to the IL-2 of the same genus and / or species the subject belongs to, it may be any naturally occurring or an artificial IL-2, as long as it has a sufficient biologic activity, i.e. an effective cross-reactivity in the subject, particularly is capable of activating the respective IL-2-receptor(s). Preferably, the biologic activity of the IL-2 and / or IL-2- like acting substance(s) is sufficient to achieve the treating and / or preventing of the antisynthetase syndrome, preferably in the subject. An IL-2 and / or an IL-2-like acting substance typically affects cells by binding and activating the respective IL-2-receptor on the cells. Hence, the activating of the respective receptor typically leads to the affectation of the cell as described above for the immunomodulatory substance. Hence, any embodiment mentioned herein for the immunomodulatory substance relating to the affecting cells like LHs, peripheral Tregs or PBMCs is independently and mutatis mutandis applicable to the IL-2 and the IL-2-like acting substance. The activating or the capability of activating the respective IL-2-receptor(s) by the IL-2 and / or IL-2-like acting substance(s) may be directly and / or it may be indirectly. If not mentioned otherwise, the description and definition of the cytokine(s) or the cytokine-like acting substance stated above is independently and mutatis mutandis applicable to the IL-2 and / or IL-2-like acting substance(s). Particualry, if not mentioned otherwise, the description and definition of the cytokine(s) or the cytokine-like acting substance in respect of “directly” and “indirectly” activating or capable of activating the respective IL-2-receptor(s), is independently and mutatis mutandis applicable to the IL-2 and / or IL-2-like acting substance(s). Preferably, the IL-2 and / or IL-2-like acting substance(s) for use according to the present invention and / or the IL-2 and / or IL-2-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is capable of affecting and / or affects the LHs, peripheral Tregs or PBMCs. Preferably, the PBMCs are naïve PBMCs, more preferably lymphocytes, even more preferably T-cells and / or B-cells, still more preferably naïve lymphocytes, still even more preferably naïve B-cells and / or naïve T-cells, further preferably naïve T-cells. More preferably, the IL-2 and / or IL-2-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs or PBMCs. More preferably, the IL-2 and / or IL-2-like acting substance(s) is capable of directly and / or indirectly affecting and / or affects the LHs, peripheral Tregs or PBMCs in the subject as defined in any of the embodiments according to the present invention, further preferably within the skin of the subject. If not mentioned otherwise, the description and definition of the immunomodulatory substance(s) stated above is independently and mutatis mutandis applicable to the IL-2 and / or IL-2-like acting substance(s). Particualry, if not mentioned otherwise, the description and definition of the immunomodulatory substance(s) in respect of “directly” and “indirectly” affecting or capable of affecting the PBMCs is independently and mutatis mutandis applicable to the IL-2 and / or IL-2-like acting substance(s). The IL-2 and / or IL-2-like acting substance(s) for use according to the present invention and / or the IL-2 and / or IL-2-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be similar or identical, preferably identical, to any IL-2 and / or IL-2-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, the IL-2 and / or IL-2-like acting substance(s) may be similar or identical, preferably identical, to any peptide, protein or any fragment of these of IL-2 and / or IL-2-like acting substance(s) naturally occurring in a vertebrate, preferably a human or a mammal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. The IL-2 and / or IL-2-like acting substance(s) may comprise, preferably consist of an amino acid sequence which has an amino acid sequence identity to any peptide, protein or any fragment of an IL-2 and / or IL-2-like acting substance(s) naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. More preferably, the amino acid sequence identity is with reference to amino acid sequence SEQ ID NO: 2 or any fragment thereof. Preferably, the amino acid sequence identity is 70 % or more, even more preferably 85 % or more, still more preferably 90 % or more, still even more preferably 95 % or more, further preferably 97 % or more, even further preferably 98 % or more, still further preferably 99 % or more and 100 % or less. Preferably, the amino acid sequence identity includes substitutions, insertions and / or deletions of amino acid residues in respect to the naturally occurring peptide, protein or any fragment of these. Preferably, the total number of substitutions, insertions and / or deletions or the total number combined of substitutions, insertions and / or deletions of amino acid residues is 60 or less, more preferably 40 or less, even more preferably 20 or less, still more preferably 12 or less, still even more preferably 8 or less, further preferably 4 or less, even further preferably 2 or less and zero or more, still further preferably zero, preferably with reference to amino acid sequence SEQ ID NO: 2, wherein more preferably the subject is a human. The IL-2 and / or IL-2-like acting substance(s) is identical or the amino acid sequence identity refers to an endogenous immunomodulatory substance(s) of the same genus and / or species the subject belongs to. The expression “is identical” typically means in this particular context that the IL-2 and / or IL-2-like acting substance(s) is in respect to its primary, secondary, tertiary and quaternary protein structure identical to an / the IL-2 and / or IL-2-like acting substance(s) of the same genus and / or species the subject belongs to, more preferably, also in view of the modification pattern, particularly glycosylations. Preferably, the IL-2 and / or IL-2-like acting substance(s) for use according to the present invention and / or the IL-2 and / or IL-2-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be derived from an individual belonging to the same genus and / or species as the subject, or which is identical to an / the IL-2 and / or IL-2-like acting substance(s) of the same genus and / or species the subject belongs to. For instance, in case the subject is: a human the IL-2 and / or IL-2-like acting substance(s) is human IL-2 and / or IL-2-like acting substance(s), more preferably human IL-2 and / or IL-2-like acting substance(s) comprising, even more preferably consisting of, preferably as effective amino acid sequence, the amino acid sequence SEQ ID NO: 2; a cow the IL-2 and / or IL-2-like acting substance(s) is bovine IL-2 and / or IL-2-like acting substance(s); a horse the IL-2 and / or IL-2-like acting substance(s) is equine IL-2 and / or IL-2-like acting substance(s); a donkey the IL-2 and / or IL-2-like acting substance(s) is donkey IL-2 and / or IL-2-like acting substance(s); an elephant the IL-2 and / or IL-2-like acting substance(s) is elephant IL-2 and / or IL-2-like acting substance(s); a sheep the IL-2 and / or IL-2-like acting substance(s) is sheep IL-2 and / or IL-2-like acting substance(s); a goat the IL-2 and / or IL-2-like acting substance(s) is goat IL-2 and / or IL-2-like acting substance(s); a pig the IL-2 and / or IL-2-like acting substance(s) is porcine IL-2 and / or IL-2-like acting substance(s); a rabbit the IL-2 and / or IL-2-like acting substance(s) is rabbit IL-2 and / or IL-2-like acting substance(s); a mouse the IL-2 and / or IL-2-like acting substance(s) is mouse IL-2 and / or IL-2-like acting substance(s); a rat the IL-2 and / or IL-2- like acting substance(s) is rat IL-2 and / or IL-2-like acting substance(s); a camel the IL-2 and / or IL-2-like acting substance(s) is camel IL-2 and / or IL-2-like acting substance(s); a dromedary the IL-2 and / or IL-2-like acting substance(s) is dromedary IL-2 and / or IL-2- like acting substance(s); a lama the IL-2 and / or IL-2-like acting substance(s) is lama IL-2 and / or IL-2-like acting substance(s); an alpaca the IL-2 and / or IL-2-like acting substance(s) is alpaca IL-2 and / or IL-2-like acting substance(s); a dog the IL-2 and / or IL-2-like acting substance(s) is dog IL-2 and / or IL-2-like acting substance(s); and / or a cat the IL-2 and / or IL-2-like acting substance(s) is cat IL-2 and / or IL-2-like acting substance(s). Preferably, the IL-2 and / or IL-2-like acting substance(s) for use according to the present invention and / or the IL-2 and / or IL-2-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, is not the subject’s endogenous IL-2 and / or IL-2-like acting substance(s). In other words, preferably the IL-2 and / or IL-2-like acting substance(s) is not an IL-2 and / or IL-2-like acting substance(s) isolated from the subject’s body, i.e. from the individual subject to be treated or prevented. Preferably, the IL-2 and / or IL-2-like acting substance(s) for use according to the present invention and / or the IL-2 and / or IL-2-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may be, preferably, is a recombinant IL-2 and / or IL-2-like acting substance(s) which may be generated by any recombinant expression techniques known to the person skilled in the art, a chemically synthesized IL-2 and / or IL-2-like acting substance(s) synthesized by any production techniques known to the person skilled in the art, an artificially produced IL-2 and / or IL-2-like acting substance(s) produced by any production techniques known to the person skilled in the art, a naturally occurring IL-2 and / or IL-2-like acting substance(s) obtained from natural sources like an animal or human, or any combination thereof. More preferably, the IL-2 and / or IL-2-like acting substance(s) is a recombinant IL-2 and / or IL-2-like acting substance(s), chemically synthesized IL-2 and / or IL-2-like acting substance(s), artificially produced IL-2 and / or IL-2-like acting substance(s) or any combination thereof, even more preferably a recombinant IL-2 and / or IL-2-like acting substance(s), still even more preferably recombinant human IL-2, further preferably Aldesleukin, preferably produced in genetically modified Escherichia coli (produced by Novartis Pharmaceuticals UK, Limited and in Germany commercially available from Novartis Pharma GmbH under the tradename Proleukin®S). Furthermore, the IL-2 and / or IL-2-like acting substance(s) for use according to the present invention and / or the IL-2 and / or IL-2-like acting substance(s) of steps (B), (B1) and / or (C) of the method, the pharmaceutical compositions, injectable dosage forms, topical dosage forms, medical devices and / or kits of parts, may or may not be derivatized, stabilized, fused with other proteins or peptides, conjugated with polymers, contain amino acid analogue(s) or artificial amino acids, modified, covalently or non-covalently, for instance glycosylated or methylated by e.g. posttranslational modification and / or oligomerized, e.g. dimerized or trimerized as long as it is capable of affecting and / or affects LHs, peripheral Tregs or PBMCs. More preferably, the modification pattern and / or oligomerization status is similar or identical to the peptide, protein or any fragment of these naturally occurring in a vertebrate, preferably a mammal, more preferably a human or a mammal animal as defined above, more preferably in the subject as defined in any of the embodiments according to the present invention. Preferably, in any of the embodiments described herein it is intended to administer the IL-2 and / or IL-2-like acting substance(s) in an amount low enough to avoid a systemic increase of the IL-2 and / or IL-2-like acting substance(s)-concentration in the subject’s body. Hence, the IL-2 and / or IL-2-like acting substance(s) may be administered in an amount that, when scaled to the entire body of the subject, the resulting systemic concentrations remain in the magnitude of the endogenous levels. Thereby, without wishing to be bound to theory, it is believed that the generation of an increased IL-2 and / or IL-2-like acting substance(s)-concentration for instance at sites of inflammation, like inflamed joint. As already stated above, for instance naïve T-cells can mature in the presence of antigen / autoantigen / allergen towards cytotoxic, which may act pro-inflammatory. Thereby decreasing, cancelling or even reversing the beneficial effects achieved by the present invention, particularly, the anti-inflammatory effect of the regulatory T-cells and / or helper T-cells, or of a subset thereof, which are presumably generated. Preferably, in any of the embodiments described herein, particularly in step (B), (B1) and / or (C), the IL-2 and / or IL-2-like acting substance(s) is administered in an amount that does not cause a systemic increase, more preferably an effective systemic increase, of the concentration of IL-2 and / or IL-2-like acting substance(s) in the subject, preferably the blood of the subject, and / or that causes a systemic increase of the concentration of the IL-2 and / or IL-2-like acting substance(s). Preferably, IL-2 and / or IL-2-like acting substance(s) is administered in ...

Claims

Claims 1. Immunomodulatory substance(s) and / or skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs (peripheral blood mononuclear cells) within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2 (oxygen saturation of haemoglobin) within the skin and / or an increased rHb (relative haemoglobin amount) within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises the step(s) of: (B) administering the immunomodulatory substance(s) to the skin of the subject; and / or (C) administering the immunomodulatory substance(s) to the skin of the subject, wherein immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B).

2. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to claim 1, wherein the skin is of a skin area, wherein preferably the skin of the skin area is immunological inactive and / or unchallenged and / or spatially distanced to any site of immunological activity and / or challenge.

3. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein the immunomodulatory substance(s) is administered in step (B) and / or step (C) in an amount that does not cause a systemic increase of the concentration of the immunomodulatory substance(s) in the subject.

4. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein step (A) is selected from one or more of steps (A-0), (A-1), (A-2), (A-3) and / or (A-4).

5. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein in step (A-1) of the method: - the vasodilation is determined in terms of the sO2 and / or the rHb within the skin.

6. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein in step (A-2) of the method: - the increased blood volume is determined in terms of the sO2 and / or the rHb within the skin.

7. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein in step (A-3) of the method: - the sO2 is increased by 2 % or more and / or the sO2 is increased by 2 %-points or more; and / or the rHb is increased by 2 % or more and / or the rHb is increased by 2 AU (arbitrary units).

8. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein in step (A-4) of the method: - the temperature is increased by 1 % or more and / or the temperature is increased by 0.2 °C or more.

9. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein in step (A-6) of the method the conditioning energy is administered to generate: - a vasodilation of the capillaries within the skin of the subject, wherein the vasodilation is determined in terms of the sO2and / or the rHb; and / or - an increased blood volume within the skin of the subject, wherein the vasodilation is determined in terms of the sO2 and / or the rHb; and / or - an increased sO2 and / or an increased rHb within the skin of the subject, wherein preferably the sO2 is increased by 2 % or more and / or increased by 2 %-points or more; and / or the rHb is increased by 2 % or more and / or by 2 AU (arbitrary units) or more; and / or - an increased temperature on the skin of the subject, wherein preferably the temperature is increased by 1 % or more and / or is increased by 0.2 °C or more; and / or - a redness on the skin of the subject, wherein preferably the conditioning energy is administered by using an energizing means.

10. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein in (A-7) of the method the skin-conditioning agent is administered to generate: - a vasodilation of the capillaries within the skin of the subject, wherein the vasodilation is determined in terms of the sO2 and / or the rHb; and / or - an increased blood volume within the skin of the subject, wherein the vasodilation is determined in terms of the sO2and / or the rHb; and / or - an increased sO2and / or an increased rHb within the skin of the subject, wherein preferably the sO2is increased by 2 % or more and / or increased by 2 %-points or more; and / or the rHb is increased by 2 % or more and / or by 2 AU (arbitrary units) or more; and / or - an increased temperature on the skin of the subject, wherein preferably the temperature is increased by 1 % or more and / or is increased by 0.2 °C or more; and / or - a redness on the skin of the subject.

11. Immunomodulatory substance(s) and / or skin-conditioning agent or use according to any of the preceding claims, wherein in step (A-8) of the method the PBMCs are injected into a sub-topical layer of the skin.

12. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein the immunomodulatory substance(s) for use and the immunomodulatory substance(s) of step (B) and / or (C) is a cytokine-like acting substance(s), preferably an interferon-like acting substance(s), interleukin-like acting substance(s) and / or neurotrophin- like acting substance(s), more preferably an IFN-γ-like acting substance(s), IL-4-like acting substance(s), BDNF-like actingsubstance(s) and / or IL-2 like acting substance(s), even more preferably IFN-γ (interferon-gamma), IL-4 (interleukin 4), BDNF (brain-derived neurotrophic factor) and / or IL-2 (interleukin 2) and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these, still more preferably IFN-γ, IL-4, BDNF and / or IL-2.

13. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein: - the method comprises steps (A) and (B); - the immunomodulatory substance(s) for use is IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these; and - the immunomodulatory substance(s) administered in step (B) is IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these.

14. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein: - the method comprises steps (A), (B) and optionally (C); - the immunomodulatory substance(s) for use is IFN-γ and / or IL-2 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these; - the immunomodulatory substance(s) in step (B) is IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these; and - the immunomodulatory substance(s) in step (C) is IL-2 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or any pharmaceutically acceptable salt of any of these.

15. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to claims 12 to 14, wherein: - the IFN-γ is administered in an amount of 600 IU / kg body mass of the subject or less; in an amount of 30 ng / kg body mass of the subject or less; in a total amount of 30,000 IU or less; and / or in a total amount of 1,500 ng or less; and / or - the IL-2 is administered in an amount of 10 IU / kg body mass of the subject or less; in an amount of 0.6 ng / kg body mass of the subject or less; in a total amount of 500 IU or less; and / or in a total amount of 30.5 ng or less.

16. Immunomodulatory substance(s) and / or skin-conditioning agent for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the skin-conditioning agent for use and the skin-conditioning agent of step (A-7) of the method is a blood-circulation-increasing agent, vasodilating agent, skin-temperature increasing agent, skin-sO2- increasing agent and / or skin-rHb-increasing agent, preferably the skin-conditioning agent comprises nitrates, alpha blockers, ACE-inhibitors, ginkgo preparations like gingko balm, calcium antagonists, dihydralazine, minoxidil, dihydroergotoxin, nicotinic acid analogues, vasodilators like methylnicotinat, moxa herbs, capsaicine, pentoxifylline, vasodilator containing crème, methylnicotinat containing crème, Kytta® heat balm and / or any combination thereof.

17. Immunomodulatory substance(s) and / or skin-conditioning agent for use according to any of the preceding claims, wherein step (A), step (B) and / or step (C) is performed multiple times.

18. Pharmaceutical composition (I) comprising: - a skin-conditioning agent; and - an immunomodulatory substance(s).

19. Pharmaceutical composition (II) comprising: - an IFN-γ-like acting substance(s); and / or - an IL-2-like acting substance(s), wherein the pharmaceutical composition is suitable to deliver: - IFN-γ-like acting substance(s) in an amount equivalent to 600 IU IFN-γ / kg body mass of the subject or less; in an amount equivalent in activity to 30 ng IFN-γ / kg body mass of the subject or less; in a total amount equivalent to 30,000 IU IFN-γ or less; and / or in a total amount equivalent in activity to 1,500 ng IFN-γ or less; and / or - IL-2-like acting substance(s) in an amount equivalent to 10 IU / kg body mass of the subject or less; in an amount of 0.6 ng / kg body mass of the subject or less; in a total amount equivalent in activity to 500 IU IL-2 or less; and / or in a total amount equivalent in activity to 30.5 ng IL-2 or less.

20. Pharmaceutical composition (II) according to claim 19 comprising: - IFN-γ; and / or - IL-2, wherein the pharmaceutical composition is suitable to deliver: - IFN-γ in an amount of 600 IU / kg body mass of the subject or less; in an amount of 30 ng / kg body mass of the subject or less; in a total amount of 30,000 IU or less; and / or in a total amount of 1,500 ng or less; and / or - IL-2 in an amount of 10 IU / kg body mass of the subject or less; in an amount of 0.6 ng / kg body mass of the subject or less; in a total amount of 500 IU or less; and / or in a total amount of 30.5 ng or less.

21. Pharmaceutical composition (III), comprising: - IFN-γ-like acting substance(s) in a concentration equivalent to 100,000 IU IFN-γ / ml or IU IFN-γ / g or less, or in a concentration equivalent in activity to 5,000 ng IFN-γ / ml or ng IFN-γ / g or less; and / or - IL-2-like acting substance(s) in a concentration equivalent to 100,000 IU IL-2 / ml or IU IL-2 / g less, or in a concentration equivalent in activity to 6100 ng IL-2 / ml or ng IL-2 / g or less.

22. Pharmaceutical composition (III) according to claim 21, comprising: - IFN-γ in a concentration of 100,000 IU / ml or IU / g or less, or of 5,000 ng / ml or ng / g or less; and / or - IL-2 in a concentration of 100,000 IU / ml or IU / g less of IL-2, or of 6100 ng / ml or ng / g or less of IL-2.

23. Pharmaceutical composition (IV) comprising: - an IFN-γ-like acting substance; or - an IL-2-like acting substance, and an immunomodulatory substance(s), wherein in case the pharmaceutical composition (IV) comprises: - the IFN-γ-like acting substance, the immunomodulatory substance(s) is different from the IFN-γ-like acting substance; and- the IL-2-like acting substance, the immunomodulatory substance(s) is different from the IL-2-like acting substance.

24. Injectable dosage form (I), comprising: - an IFN-γ-like acting substance; or - an IL-2-like acting substance, and an immunomodulatory substance(s), wherein in case the injectable dosage form (I) comprises: - the IFN-γ-like acting substance, the immunomodulatory substance(s) is different from the IFN-γ-like acting substance; and - the IL-2-like acting substance, the immunomodulatory substance(s) is different from the IL-2-like acting substance.

25. Injectable dosage form (II), comprising: - an IFN-γ-like acting substance(s) in a total amount equivalent to 30,000 IU IFN-γ or less and / or in a total amount equivalent in activity to 1,500 ng IFN-γ or less; or - an IL-2-like acting substance(s) a total amount equivalent to 1,000 IU IL-2 or less and / or in a total amount equivalent in activity to 61 ng IL-2 or less.

26. Injectable dosage form (II) according to claim 25, comprising: - IFN-γ in a total amount of 30,000 IU or less and / or in a total amount of 1,500 ng or less; or - IL-2 a total amount of 1,000 IU or less and / or in a total amount of 61 ng or less.

27. Topical dosage form (I) comprising: - an IFN-γ-like acting substance; or - an IL-2-like acting substance.

28. Topical dosage form (II) comprising: - an immunomodulatory substance(s); - an energizing constituent.

29. Medical device (100) comprising: - a skin-conditioning unit (110); and - an applicator unit (120); wherein the skin-conditioning unit (110) and the applicator unit (120) are configured to cooperatively interact to administer to a skin (102) of a subject an amount of a first therapeutic agent by means of the applicator unit (120) with an amount of conditioning measures by means of the skin-conditioning unit (110); and / or wherein the skin-conditioning unit (110) and the applicator unit (120) are configured to act to a skin (102) of a subject.

30. Kit of parts (I) comprising: i) an immunomodulatory substance(s); and ii) a skin-conditioning agent; and / or iii) an energizing means.

31. Kit of parts (II) comprising: i) an IFN-γ-like acting substance, and / or IL-2-like acting substance; and ii) an immunomodulatory substance(s), wherein in case the Kit of parts (II) comprises: - the IFN-γ-like acting substance, the immunomodulatory substance(s) is different from the IFN-γ-like acting substance; and - the IL-2-like acting substance, the immunomodulatory substance(s) is different from the IL-2-like acting substance.

32. Kit of parts (III) comprising: i) an injectable dosage form according to claim 24 and / or claim 255; and ii) a skin-conditioning agent; and / or iii) an energizing means.

33. Kit of parts (IV) comprising: i) a topical dosage form according to claim 7; and ii) a skin-conditioning agent; and / or iv) an energizing means.

34. Kit of parts (V) comprising: - an applicator unit (120); and - a skin-conditioning unit (110); and - optionally a reservoir (121), comprising a first therapeutic agent like an immunomodulatory substance, wherein the reservoir (121) is configured to be fluidly coupled to the applicator unit (120).

35. Pharmaceutical composition (I) according to claim 18; pharmaceutical composition (II) according to claim 1919; pharmaceutical composition (III) according to claim 21; pharmaceutical composition (IV) according to claim 23; injectable dosage form (I) according to claim 24; injectable dosage form (II) according to claim 25; topical dosage form (I) according to claim 27; topical dosage form (II) according to claim 28; kit of parts (I) according to claim 30; kit of parts (II) according to claim 31; kit of parts (III) according to claim 32; kit of parts (IV) according to claim 33; and / or kit of parts (V) according to claim 34, further comprising a pharmaceutically acceptable vehicle, diluent, adjuvant, excipient, carrier, additive and / or salt.

36. Pharmaceutical composition (I) according to claim 18; pharmaceutical composition (II) according to claim 19; pharmaceutical composition (III) according to claim 21; pharmaceutical composition (IV) according to claim 23; injectable dosage form (I) according to claim 24; injectable dosage form (II) according to claim 25;topical dosage form (I) according to claim 27; topical dosage form (II) according to claim 28; kit of parts (I) according to claim 30; kit of parts (II) according to claim 31; kit of parts (III) according to claim 32; and / or kit of parts (IV) according to claim 33; for use as a medicament, preferably for use in the treatment and / or prevention of an antisynthetase syndrome.

37. Pharmaceutical composition (I) according to claim 18; pharmaceutical composition (II) according to claim 29; pharmaceutical composition (III) according to claim 21; pharmaceutical composition (IV) according to claim 23; injectable dosage form (I) according to claim 24; injectable dosage form (II) according to claim 25; topical dosage form (I) according to claim 27; topical dosage form (II) according to claim 28; medical device (100) accordin to claim 29; kit of parts (I) according to claim 30; kit of parts (II) according to claim 31; kit of parts (III) according to claim 32; kit of parts (IV) according to claim 33; and / or kit of parts (V) according to claim 34, suitable for use and / or for use in a method for treating and / or preventing an antisynthetase syndrome in a subject, wherein the method comprises a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2 within the skin and / or an increased rHb within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises the step(s) of: (B) administering the immunomodulatory substance(s) to the skin of the subject; and / or (C) administering the immunomodulatory substance(s) to the skin of the subject, wherein immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B).

38. Pharmaceutical composition (X), topical dosage form (X), injectable dosage forms (X) and / or kit of parts (X) comprising: - a skin-conditioning agent; or - an immunomodulatory substance(s), for use in a method for treating and / or preventing an antisynthetase syndrome in a subject,wherein the method comprises a step (A), wherein step (A) is selected from one or more of steps: (A-0) generating an accumulation of PBMCs within the skin of the subject; (A-1) generating a vasodilation of the capillaries within the skin of the subject; (A-2) generating an increased blood volume within the skin of the subject; (A-3) generating an increased sO2 within the skin and / or an increased rHb within the skin of the subject; (A-4) generating an increased temperature on the skin of the subject; (A-5) generating a redness on the skin of the subject; (A-6) administering conditioning energy to the skin of the subject; (A-7) administering a skin-conditioning agent to the skin of the subject; and / or (A-8) administering PBMCs into the skin of the subject, and the method further comprises the step(s) of: (B) administering the immunomodulatory substance(s) to the skin of the subject; and / or (C) administering the immunomodulatory substance(s) to the skin of the subject, wherein immunomodulatory substance(s) administered in step (C) is different from the immunomodulatory substance(s) administered in step (B).

39. Pharmaceutical composition (I) according to claim 18; pharmaceutical composition (IV) according to claim 23; injectable dosage form (I) according to claim 24; topical dosage form (II) according to claim 28; kit of parts (I) according to claim 30; kit of parts (II) according to claim 31; kit of parts (V) according to claim 34; and / or pharmaceutical composition (X), topical dosage form (X), injectable dosage forms (X) and / or kit of parts (X) according to claim 38, wherein the immunomodulatory substance(s) is a cytokine-like acting substance(s), preferably an interferon-like acting substance(s), interleukin-like acting substance(s) and / or neurotrophin-like acting substance(s), more preferably an IFN-γ-like acting substance(s) and / or IL-2 like acting substance(s), even more preferably IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or pharmaceutically acceptable salt of any of these, still more preferably IL-2, IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or pharmaceutically acceptable salt of any of these furthermore preferably IFN-γ or IFN-γ and / or IL-2.

40. Pharmaceutical composition (II) according to claim 19; pharmaceutical composition (III) according to claim 21; pharmaceutical composition (IV) according to claim 23; injectable dosage form (I) according to claim 24; injectable dosage form (II) according to claim 25;topical dosage form (I) according to claim 27; and / or kit of parts (II) according to claim 31, wherein the IFN-γ-like acting substance is IFN-γ and / or any derivative, fragment, subunit, protein-analogue, peptide, protein- variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereofand / or pharmaceutically acceptable salt thereof, preferably IFN-γ, and the IL-2-like acting substance is IL-2 and / or any derivative, fragment, subunit, protein-analogue, peptide, protein-variant, biopharmaceutical, inductor, precursor, prodrug, mutein, co-drug, propeptide thereof and / or pharmaceutically acceptable salt thereof, preferably IL-2.

41. Use of the pharmaceutical composition according to any of claims 18, 19, 21 and / or 23 for producing an article, preferably the injectable dosage form according to claims 24 and / or 25, and / or the topical dosage form according to any of claims 27 and / or 28, or use of the pharmaceutical composition according to any of claims 18, 19, 21 and / or 23 and / or the injectable dosage form according to any of claims 24 and / or 25 for producing a medical device, preferably the medical device (100) according to claim 29.

Images